

Supporting Information

Site-Selective Defluorinative sp^3 C–H Alkylation of Secondary Amides

Wen-Jun Yue,^{†‡} Craig S. Day,^{†‡} and Ruben Martin^{†§*}

[†]*Institute of Chemical Research of Catalonia (ICIQ), Av. Països Catalans 16, 43007*

Tarragona, Spain; Fax: (+34) 977-920-222, E-mail: rmartinromo@iciq.es

[‡]*Universitat Rovira i Virgili, Departament de Química Analítica i Química Orgànica,
c/Marcel·lí Domingo, 1, 43007 Tarragona, Spain*

[§]*Catalan Institution for Research and Advanced Studies (ICREA), Passeig Lluís Companys, 23,
08010, Barcelona, Spain*

General Considerations	S2
Optimization of the Reaction Conditions	S4
Synthesis of Starting Materials	S7
Defluorinative α/δ sp^3 C-H Alkylation of Secondary Amides	S15
Derivatization of 3a	S54
Mechanistic Experiments	S55
References	S71
NMR spectra	S72

General Considerations


Analytical methods. ^1H and ^{13}C NMR spectra were recorded on Bruker 300 MHz, Bruker 400 MHz and Bruker 500 MHz at 20 °C. All ^1H NMR spectra are reported in parts per million (ppm) downfield of TMS and were calibrated using the residual solvent peak of CHCl_3 (7.26 ppm), unless otherwise indicated. All ^{13}C NMR spectra are reported in ppm relative to TMS, were calibrated using the signal of residual CHCl_3 (77.16 ppm), ^{19}F NMR was obtained with ^1H decoupling unless otherwise indicated. Coupling constants, J are reported in Hertz. Melting points were measured using open glass capillaries in a Büchi B540 apparatus. Infrared spectra (FT-IR) measurements were carried out on a Bruker Optics FT-IR Alpha spectrometer equipped with a DTGS detector, KBr beamsplitter at 4 cm^{-1} resolution using a one bounce ATR accessory with diamond windows. Mass spectra were recorded on a Waters LCT Premier spectrometer or in a MicroTOF Focus, Bruker Daltonics spectrometer. UV/Vis absorption spectra were recorded using a Agilent Technologies Cary 300 UV/Vis spectrophotometer and UV-1800PC spectrophotometer in quartz cuvettes with a path length of 1.0 cm. Bulk electrolysis was conducted on a PARSTAT 2273 potentiometer using a 3-electrode cell configuration at room temperature, The same electrodes were used as for CV experiments, namely a glassy carbon working electrode, platinum flag counter electrode and Ag/AgCl (KCl sat.) reference electrode. Flash chromatography was performed with EM Science silica gel 60 (230-400 mesh). Thin layer chromatography was used to monitor reaction progress and analysed fractions from column chromatography. To this purpose TLC Silica gel 60 F₂₅₄ aluminium sheets from Merck were used and visualization was achieved using UV irradiation and/or staining with Potassium Permanganate or Cerium Molybdate solution. The yields reported refer to isolated yields and represent an average of at least two independent runs. The procedures described in this section are representative. Thus, the yields may differ slightly from those given in the tables of the manuscript.

Reagents. Commercially available materials were used as received without further purification. $\text{NiBr}_2 \cdot \text{diglyme}$ (97% purity) were purchased from Aldrich. 5,5'-Di-Me-2,2'-bipyridine (97% purity) was purchased from Aldrich. Anhydrous K_3PO_4 was purchased from Aldrich (99% purity). Anhydrous 1,4-dioxane (99.5% purity) and toluene (99.5% purity) was purchased from Across.

The defluorinative α sp^3 C-H alkylation of amides was performed with 451 nm LEDs (OSRAM Oslon® SSL 80 royal- blue LEDs), which were installed at the bottom of a custom-made 8 flat-bottom Schlenk tubes holder, equipped with a cooling system (the temperature was set at 15 °C) and a magnetic stirrer (~ 900 rpm).



The defluorinative δ sp^3 C-H alkylation of amides was performed with 451 nm Kessil light (DiCon Fiberoptics, Inc., 40 W), equipped with a fan cooling system (the thermostat was set at 35-40 °C) and a magnetic stirrer (~ 900 rpm).




Optimization of the Reaction Conditions

Optimization of the reaction conditions for the α sp^3 C-H defluorinative alkylation of secondary amides

General procedure for the reaction of 1a with 2a: An oven-dried 8 mL Schlenk tube containing a stirring bar was charged with **1a** (41.0 mg, 0.20 mmol, 2 equiv), Ir(dFCF₃ppy)₂(dtbbpy)PF₆ (**Ir-1**; 1.1 mg, 0.01 equiv), **L** (0.06 equiv) and the base (0.150 mmol, 1.5 equiv). The tube was then introduced in the nitrogen-filled glovebox where the nickel catalyst (0.05 equiv) was added followed by 0.5 mL of the solvent. Then, the tube was brought outside the glovebox, and **2a** (17.2 mg, 0.10 mmol, 1 equiv) was added to the reaction mixture under N₂ atmosphere. Then, the tube was stirred at 15 °C under blue LED irradiation with a cooling system for 36 hours. At that time, the reaction was quenched by the addition of EtOAc (5 mL). The mixture was filtered through a silica plug, and the solvent was removed under vacuum. Then, nitromethane (5.4 μ L, 0.10 mmol) was added as internal standard, and the mixture was analyzed by ¹H NMR.


Table S1. Optimization of α sp^3 C-H defluorinative alkylation of secondary amides.^a

entry	deviation standard conditions	3a (%) ^b
1	none	90 (87) ^c
2	L2 instead of L1	88
3	L3 instead of L1	12
4	L4 instead of L1	0
5	L5 instead of L1	0
6	using Ni(cod) ₂	11
7	using <i>fac</i> -Ir(ppy) ₃ PF ₆ (4-CzIPN)	0
8	PhMe as solvent	0
9	Cs ₂ CO ₃ instead of K ₃ PO ₄	50
10	no NiBr ₂ ·diglyme, Ir-1 or light	0
11	no L1	43
12	no K ₃ PO ₄	67



^a **1a** (0.20 mmol), **2a** (0.10 mmol), NiBr₂·diglyme (5 mol%), **Ir-1** (1 mol%), **L1** (6 mol%), K₃PO₄ (0.15 mmol), dioxane (0.20 M) at 15 °C for 36 h. ^b ¹H NMR yields using MeNO₂ as internal standard. ^c Isolated yield

Table S2. Screening the metal source for α sp^3 C–H defluorinative alkylation ^a




entry	metal salts	3a (%) ^b
1	FeCl ₂	0
2	CuCl	0
3	Cu(OAc) ₂	0
4	CeCl ₃	0
5	CoCl ₂	0
6	ZnCl ₂	0
7	CrCl ₃	0
8	AlCl ₃	0
9	AgF	0
10	MnBr ₂	7

^a **1a** (0.20 mmol), **2a** (0.10 mmol), metal salts (5 mol%), **Ir-1** (1 mol%), K₃PO₄ (0.15 mmol), dioxane (0.20 M) at 15 °C for 36 h. ^b ¹H NMR yields using MeNO₂ as internal standard.

Optimization of the reaction conditions for the δ sp^3 C-H defluorinative alkylation of secondary amides

General procedure for the reaction of 5a with 2a: To an 8 mL vial equipped with a stirring bar was added **5a** (38.5 mg, 0.20 mmol, 2 equiv) and **Ir-1** (1.1 mg, 0.01 equiv). The vial was then introduced in the nitrogen-filled glovebox where the base (0.30 mmol, 3.0 equiv) was added followed by 0.5 mL of the solvent. Then the tube was brought outside the glovebox, and **2a** (0.10 mmol, 1 equiv) was added to the reaction mixture under N_2 atmosphere. The reaction was stirred and irradiated using 451 nm Kessil light (40 W) equipped with a fan cooling system for 36 h. The reaction was quenched by the addition of EtOAc (5 mL). The mixture was filtered through a silica plug and the solvent was removed under vacuum. Then, nitromethane (5.4 μ L, 0.10 mmol) was added as internal standard and the reaction mixture was analyzed by 1H NMR.


Table S3. Optimization of δ sp^3 C-H defluorinative alkylation of secondary amides.^a



^a **5a** (0.20 mmol), **2a** (0.10 mmol), **Ir-1** (1 mol%), K₃PO₄ (0.30 mmol), toluene (0.2 M) at rt for 36 h. ^b 1H NMR yields using nitromethane as internal standard. ^c Isolated yield.


Synthesis of Starting Materials

General procedure A for the synthesis of secondary amides



Amine (1.0 equiv) and Et₃N (1.5 equiv) were added to a round-bottomed flask containing a stirring bar and dichloromethane (0.5 M). The mixture was then stirred and cooled down using an ice bath. Subsequently, the corresponding acyl chloride (1.0 equiv) was added dropwise by syringe. After the addition, the reaction mixture was allowed to warm up to room temperature and stirred overnight. The reaction was then washed with saturated NaCl solution, 1 M HCl solution and water, and the resulting organic phases were dried over MgSO₄. The mixture was then purified by flash column chromatography, eluting with hexane/EtOAc.¹

General procedure B for the synthesis of secondary amides




To a 100 mL oven-dried round-bottom flask equipped with a Teflon-coated magnetic stir bar was added benzoic acid (5.0 mmol, 1.0 equiv). The flask was backfilled with N₂ three times before adding DCM (25 mL, 0.2 M). The mixture was then cooled down to 0 °C using an ice bath prior to addition of oxalyl chloride (0.55 mL, 6.5 mmol, 1.3 equiv) and DMF (3-5 drops). The reaction was then allowed to warm to room temperature and stirred for 4 hours. The crude was concentrated under reduced pressure, and the residue was then taken up in fresh DCM (25 mL, 0.2 M) and cooled to 0 °C. Et₃N (0.70 mL, 5.0 mmol, 1.0 equiv) was added dropwise followed by addition of the amine (5.0 mmol, 1.0 equiv) and DMAP (12 mg, 0.1 mmol, 0.02 equiv). The reaction was then allowed to warm to room temperature and stirred overnight. The reaction was quenched with 10 mL H₂O and 25 mL DCM. The organic phases were washed with 1M HCl (25 mL × 2), 1M NaOH (25 mL × 2), dried with 25 mL brine, and then over Na₂SO₄. The solvent was removed under vacuum and the crude was purified by silica gel chromatography.¹

General procedure for synthesis of trifluoromethyl amides


To a stirring solution of amine (3 mmol) in dichloromethane (30 mL, 0.1 M), triethylamine (6 mmol, 2.0 equiv) was added dropwise under N₂. The resulting solution was cooled with an ice bath and trifluoroacetic anhydride (3.3 mmol, 1.1 equiv) was added dropwise. Then, the reaction was warmed to room temperature and was allowed to stir for 12 hours. The reaction was quenched with slow addition of 1 M HCl and extracted with dichloromethane (3 x 10 mL). The organic layer was then washed with concentrated NaHCO₃ (30 mL) before being passed through a short silica plug and concentrated to afford the corresponding trifluoroacetamide without the need for further purification.²

General procedure for synthesis of trifluoromethylated alkenes



To a Schlenk tube equipped a magnetic stir bar, boronic acid (5 mmol, 1.0 equiv), and Pd(PPh₃)₂Cl₂ (63.2 mg, 3 mol%) were added sequentially. The vessel was evacuated and filled with argon (three times), and then THF (15 mL, degassed) and aqueous K₂CO₃ (2.0 M, 10 mL, degassed) were added. After the addition of 2-bromo-3,3,3-trifluoropropene (1.04 mL, 10 mmol, 2.0 equiv), the reaction mixture was stirred at 60 °C overnight under argon atmospheres. The resulting mixture was cooled to room temperature, quenched with saturated aqueous NH₄Cl, and extracted with EtOAc (3×15 mL). The combined organic phases were dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel (petroleum ether/ethyl acetate) to give the desired trifluoromethylated alkene.³

Synthesis of 6-hexanamidohexyl acetate (1r)




To a 25 mL oven-dried round-bottom flask equipped with a Teflon-coated magnetic stir bar was added **Int 1** (646 mg, 3.0 mmol, 1.0 equiv). The flask was backfilled with N₂ three times before adding DCM (15 mL, 0.2 M) and cooling to 0 °C in an ice bath. Acetyl chloride (0.23 mL, 3.3 mmol, 1.1 equiv) was then added followed by pyridine (0.36 mL, 4.5 mmol, 1.5 equiv). The reaction was then allowed to warm to room temperature and

stirred overnight. The reaction was quenched with water and extracted with DCM (20 mL \times 3), washed with 80 mL brine. Then, the organics were dried over Na₂SO₄. The solvent was removed by rotary evaporation and the crude reaction mixture was purified by silica gel chromatography hexane/EtOAc 1/1 to 100% EtOAc to give the title compound as a pale yellow oil (625 mg, 2.43 mmol, 81% yield).

¹H NMR (400 MHz, CDCl₃) δ 6.04 (s, 1H), 3.96 (t, *J* = 6.7 Hz, 2H), 3.46 – 2.82 (m, 2H), 2.10 – 2.05 (m, 2H), 1.95 (s, 3H), 1.59 – 1.49 (m, 4H), 1.45 – 1.39 (m, 2H), 1.33 – 1.12 (m, 8H), 0.80 (t, *J* = 6.8 Hz, 3H) ppm. ¹³C NMR (126 MHz, CDCl₃) δ 173.3, 171.2, 64.3, 39.3, 36.7, 31.4, 29.5, 28.5, 26.5, 25.6, 25.5, 22.4, 20.9, 13.9 ppm. HRMS calcd. for (C₁₄H₂₈NO₃) [M+H]⁺: 258.2064, found 258.2056. IR (neat): 3294, 2931, 2860, 1739, 1642, 1234, 1037, 731.


Synthesis of N-(6-((tert-butyldimethylsilyloxy)hexyl)hexanamide (1s)



To a 25 mL oven-dried round-bottom flask equipped with a Teflon-coated magnetic stir bar was added **Int 1** (320 mg, 1.5 mmol, 1.0 equiv). The flask was backfilled with N₂ three times before adding DCM (7.5 mL, 0.2 M). TBDMSCl (320 mg, 2.1 mmol, 1.4 equiv) was then added followed by imidazole (240 mg, 3.6 mmol, 2.4 equiv) and DMAP (9 mg, 0.075 mmol, 0.05 equiv). The reaction was stirred overnight at room temperature. Then the reaction was quenched with water and extracted with Et₂O (20 mL \times 3), washed with 20 mL water and 40 mL brine. Then, the organics were dried over Na₂SO₄. The solvent was removed under vacuum and the crude reaction mixture was purified by silica gel chromatography hexane/EtOAc 2/1 to give the title compound as a colorless oil (461 mg, 1.4 mmol, 91% yield).


¹H NMR (400 MHz, CDCl₃) δ 5.41 (s, 1H), 3.59 (t, *J* = 6.5 Hz, 2H), 3.35 – 3.14 (m, 2H), 2.20 – 2.09 (m, 2H), 1.70 – 1.57 (m, 2H), 1.56 – 1.43 (m, 4H), 1.41 – 1.21 (m, 8H), 0.95 – 0.83 (m, 12H), 0.04 (s, 6H) ppm. ¹³C NMR (126 MHz, CDCl₃) δ 173.3, 63.2, 39.5, 36.8, 32.8, 31.6, 29.8, 26.8, 26.0, 25.8, 25.6, 22.5, 18.4, 14.0, -5.2 ppm. HRMS calcd. for (C₁₈H₄₀NO₂Si) [M+H]⁺: 330.2823, found 330.2816. IR (neat): 3290, 2929, 2857, 1643, 1551, 1253, 1096, 834.

Synthesis of *N*-hexyl-5-oxohexanamide (**1z**)



To a 50 mL oven-dried round-bottom flask equipped with a Teflon-coated magnetic stir bar was added 5-oxohexanoic acid (1.30 g, 10.0 mmol, 1.0 equiv). The flask was backfilled with N₂ three times before adding DCM (20 mL, 0.5 M) and CDI (1.95 g, 12.0 mmol, 1.2 equiv). The mixture was stirred at room temperature for 1 h. ⁿHexamine (1.55 mL, 12.0 mmol, 1.2 equiv) was then added followed by NEt₃ (2.10 mL, 15.0 mmol, 1.5 equiv). The reaction was then stirred overnight. The reaction was quenched with aqueous 2 M HCl and stirred for another 15 minutes. Then the mixture was extracted with DCM (20 mL × 3), washed with 30 mL aqueous 2 M HCl, 30 mL water, 40 mL saturated aqueous NaHCO₃, and 30 mL brine sequentially. Then, the organics were dried over Na₂SO₄. The solvent was removed under vacuum and give the title compound as a pale yellow solid (1.40 g, 6.56 mmol, 66% yield), which can be used directly without further purification. M.P.: 63-64 °C. ¹H NMR (400 MHz, CDCl₃) δ 5.58 (s, 1H), 3.22 (td, *J* = 7.2, 5.7 Hz, 2H), 2.51 (t, *J* = 7.0 Hz, 2H), 2.18 (t, *J* = 7.3 Hz, 2H), 2.13 (s, 3H), 1.95 – 1.81 (m, 2H), 1.52 – 1.40 (m, 2H), 1.35 – 1.21 (m, 6H), 0.91 – 0.83 (m, 3H) ppm. ¹³C NMR (126 MHz, CDCl₃) δ 208.7, 172.4, 42.5, 39.5, 35.4, 31.5, 29.9, 29.6, 26.6, 22.6, 19.8, 14.0 ppm. HRMS calcd. for (C₁₂H₂₄NO₂) [M+H]⁺: 214.1802, found 214.1795. IR (neat): 3284, 2922, 2853, 1703, 1638, 1370, 1157, 713.

Synthesis of 6-(hexylamino)-6-oxohexyl benzoate (**1v**)




To a 25 mL oven-dried round-bottom flask equipped with a Teflon-coated magnetic stir bar was added **Int 3** (650 mg, 3.0 mmol, 1.0 equiv). The flask was backfilled with N₂ three times before adding DCM (15 mL, 0.2 M) and cooling to 0 °C in an ice bath. Benzoyl chloride (630 mg, 4.5 mmol, 1.5 equiv) was then added followed by NEt₃ (460 mg, 4.5 mmol, 1.5 equiv) and DMAP (18 mg, 0.15 mmol, 0.05 equiv). The reaction was then allowed to warm to room temperature and stirred for 1 hour. The reaction was

quenched with water and extracted with DCM (20 mL \times 3), washed with 80 mL brine. Then the organics were dried over Na₂SO₄. The solvent was removed under vacuum and the crude reaction mixture was purified by silica gel chromatography hexane/EtOAc 1/1 to give the title compound as a colorless oil (741 mg, 2.31 mmol, 77% yield).

¹H NMR (400 MHz, CDCl₃) δ 8.01 – 7.94 (m, 2H), 7.54 – 7.47 (m, 1H), 7.43 – 7.34 (m, 2H), 5.92 (t, J = 5.8 Hz, 1H), 4.26 (t, J = 6.6 Hz, 2H), 3.18 (td, J = 7.2, 5.6 Hz, 2H), 2.16 (t, J = 7.5 Hz, 2H), 1.79 – 1.58 (m, 4H), 1.50 – 1.34 (m, 4H), 1.32 – 1.11 (m, 6H), 0.86 – 0.77 (m, 3H) ppm. **¹³C NMR** (126 MHz, CDCl₃) δ 172.8, 166.6, 132.9, 130.3, 129.5, 128.3, 64.8, 39.5, 36.5, 31.5, 29.6, 28.5, 26.6, 25.8, 25.5, 22.5, 14.0 ppm. **HRMS** calcd. for (C₁₉H₃₀NO₃) [M+H]⁺: 320.2220, found 320.2219. **IR (neat)**: 3301, 2929, 2859, 1718, 1641, 1271, 1115, 709.


Synthesis of 6-chloro-*N*-hexylhexanamide (**1w**)



To a stirred solution of **Int 3** (650 mg, 3.0 mmol, 1.0 equiv) and PPh₃ (1.57 g, 6.0 mmol, 2.0 equiv) in dry DCM (10 mL, 0.3 M) was added 2,2,2-trichloroacetamide (970 mg, 6.0 mmol, 2.0 equiv) under Ar. The reaction mixture was stirring at rt for 30 min, then quenched with cold water. The aqueous phase was extracted with DCM (3 \times 10 mL), the combined organic phases were dried over MgSO₄, then concentrated. The residue was purified by flash column chromatography (Hexane/EtOAc = 1:1) to provide **1w** (400 mg, 1.73 mmol, 57%) as a colorless oil.

¹H NMR (400 MHz, CDCl₃) δ 5.40 (s, 1H), 3.53 (t, J = 6.6 Hz, 2H), 3.31 – 3.17 (m, 2H), 2.17 (t, J = 7.4 Hz, 2H), 1.88 – 1.71 (m, 2H), 1.72 – 1.63 (m, 2H), 1.55 – 1.41 (m, 4H), 1.37 – 1.22 (m, 6H), 0.92 – 0.83 (m, 3H) ppm. **¹³C NMR** (126 MHz, CDCl₃) δ 172.8, 77.7, 44.9, 39.6, 36.6, 32.3, 31.5, 29.6, 26.7, 26.6, 25.1, 22.6, 14.1 ppm. **HRMS** calcd. for (C₁₂H₂₅ClNO) [M+H]⁺: 234.1619, found 234.1615. **IR (neat)**: 3293, 2929, 2859, 1640, 1549, 1459, 730.


Synthesis of 2,2,2-trifluoro-*N*-(6-(phenylsulfonyl)hexyl)acetamide (**5d**)



To a 25 mL oven-dried round-bottom flask equipped with a Teflon-coated magnetic stir bar was added **Int 4** (1.37 g, 4.5 mmol, 1.0 equiv) and DCM (45 mL, 0.1 M) and cooling to 0 °C in an ice bath. *m*CPBA (1.71 g 75%, 9.9 mmol, 2.2 equiv) was then added. The reaction mixture was then allowed to warm to room temperature and stirred overnight. The reaction was quenched with water and extracted with DCM (20 mL × 3), washed with 80 mL saturated aqueous NaHCO₃ and 50 mL brine sequentially. Then, the organics were dried over Na₂SO₄. The solvent was removed by rotary evaporation and the crude reaction mixture was purified by silica gel chromatography hexane/EtOAc 3/1 to give the title compound as a colorless oil (1.08 g, 3.20 mmol, 71% yield).

¹H NMR (400 MHz, CDCl₃) δ 7.89 – 7.82 (m, 2H), 7.68 – 7.60 (m, 1H), 7.59 – 7.49 (m, 2H), 6.98 (s, 1H), 3.27 (q, *J* = 6.8 Hz, 2H), 3.09 – 3.00 (m, 2H), 1.74 – 1.60 (m, 2H), 1.56 – 1.45 (m, 2H), 1.41 – 1.31 (m, 2H), 1.31 – 1.21 (m, 2H) ppm. **¹⁹F NMR** (376 MHz, CDCl₃) δ -75.98 ppm. **¹³C NMR** (126 MHz, CDCl₃) δ 157.4 (q, *J* = 36.7 Hz), 139.0, 133.9, 129.4, 128.0, 116.0 (q, *J* = 287.7 Hz), 56.0, 39.6, 28.5, 27.7, 26.0, 22.5 ppm. **HRMS** calcd. for (C₁₄H₁₈F₃NNaO₃S) [M+Na]⁺: 360.0852, found 360.0855. **IR (neat)**: 3326, 2941, 2864, 1708, 1556, 1140, 1085, 721.


Synthesis of *N*-(6-(1,3-dioxoisindolin-2-yl)hexyl)-2,2,2-trifluoroacetamide (**5e**)



To a 25 mL oven-dried round-bottom flask equipped with a Teflon-coated magnetic stir bar was added **Int 5** (735 mg, 2.0 mmol, 1.0 equiv). The flask was backfilled with N₂ three times before adding DMF (5 mL, 0.4 M). Potassium phthalimide (437 mg, 2.4 mmol, 1.2 equiv) was then added. The reaction was then heated to 80 °C and stirred at this temperature overnight. The reaction was quenched with brine and extracted with CHCl₃ (20 mL × 3). The combined organic phase was washed with 80 mL water and 80 mL brine. Then, the organics were dried over Na₂SO₄. The solvent was removed under vacuum and the crude reaction mixture was purified by silica gel chromatography

hexane/EtOAc 3/1 to give the title compound as a white solid (560 mg, 1.64 mmol, 82% yield). M.P.: 117-118 °C. $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.82 – 7.76 (m, 2H), 7.73 – 7.65 (m, 2H), 6.88 (s, 1H), 3.65 (t, $J = 7.1$ Hz, 2H), 3.32 (q, $J = 6.7$ Hz, 2H), 1.72 – 1.60 (m, 2H), 1.61 – 1.51 (m, 2H), 1.44 – 1.28 (m, 4H) ppm. $^{19}\text{F NMR}$ (376 MHz, CDCl_3) δ -76.02 ppm. $^{13}\text{C NMR}$ (126 MHz, CDCl_3) δ 168.6, 157.4 (q, $J = 36.8$ Hz), 134.1, 132.1, 123.3, 116.0 (d, $J = 287.8$ Hz), 39.7, 37.6, 28.7, 28.4, 26.1, 25.9 ppm. **HRMS** calcd. for ($\text{C}_{16}\text{H}_{17}\text{F}_3\text{N}_2\text{NaO}_3$) $[\text{M}+\text{Na}]^+$: 365.1083, found 365.1085. **IR (neat)**: 3304, 2930, 2862, 1692, 1560, 1401, 1162, 720.


Synthesis of (1*R*,2*S*,5*R*)-2-isopropyl-5-methylcyclohexyl 6-hexanamidohexanoate (**1ac**)



To a 50 mL oven-dried round-bottom flask equipped with a Teflon-coated magnetic stir bar was added **Int 6** (690 mg, 3.0 mmol, 1.0 equiv), (*L*)-menthol (750 mg, 4.8 mmol, 1.6 equiv), EDC•HCl (920 mg, 4.8 mmol, 1.6 equiv), and DMAP (110 mg, 0.90 mmol, 0.3 equiv) sequentially. The flask was backfilled with N_2 three times before adding DCM (15 mL, 0.2 M). The reaction was stirred overnight. Then the reaction was quenched with water and extracted with DCM (20 mL \times 3), washed with 80 mL brine. Then, the organics were dried over Na_2SO_4 . The solvent was removed under vacuum and the crude reaction mixture was purified by silica gel chromatography hexane/EtOAc 1/1 to give the title compound as a colorless oil (400 mg, 1.09 mmol, 36% yield).

$^1\text{H NMR}$ (400 MHz, CDCl_3) δ 5.80 (s, 1H), 4.63 (td, $J = 10.9, 4.4$ Hz, 1H), 3.20 (q, $J = 6.5$ Hz, 2H), 2.24 (t, $J = 7.4$ Hz, 2H), 2.11 (t, $J = 7.6$ Hz, 2H), 1.97 – 1.87 (m, 1H), 1.85 – 1.72 (m, 1H), 1.69 – 1.52 (m, 6H), 1.52 – 1.39 (m, 3H), 1.37 – 1.17 (m, 7H), 1.06 – 0.88 (m, 2H), 0.89 – 0.77 (m, 10H), 0.71 (d, $J = 7.0$ Hz, 3H) ppm. $^{13}\text{C NMR}$ (126 MHz, CDCl_3) δ 173.3, 173.2, 74.1, 47.1, 41.0, 39.2, 36.8, 34.5, 34.3, 31.5, 31.4, 29.3, 26.4, 26.3, 25.6, 24.7, 23.5, 22.5, 22.1, 20.8, 16.4, 14.0 ppm. **HRMS** calcd. for ($\text{C}_{22}\text{H}_{42}\text{NO}_3$) $[\text{M}+\text{H}]^+$: 368.3159, found 368.3158. **IR (neat)**: 3294, 2928, 2868, 1730, 1644, 1547, 1456, 1169.

Synthesis of (3*S*,5*S*,8*R*,9*S*,10*S*,13*R*,17*R*)-10,13-dimethyl-17-((*R*)-6-methylheptan-2-yl)hexadecahydro-1*H*-cyclopenta[*a*]phenanthren-3-yl 6-hexanamidohexanoate (1ad)




To a 50 mL oven-dried round-bottom flask equipped with a Teflon-coated magnetic stir bar was added **Int 6** (690 mg, 3.0 mmol, 1.0 equiv), 5 α -Cholestan-3 β -ol (1.87 g, 4.8 mmol, 1.6 equiv), EDC•HCl (920 mg, 4.8 mmol, 1.6 equiv), and DMAP (110 mg, 0.90 mmol, 0.3 equiv) sequentially. The flask was backfilled with N₂ three times before adding DCM (15 mL, 0.2 M) and the reaction was stirred overnight. Then, the reaction was quenched with water and extracted with DCM (20 mL \times 3), washed with 80 mL brine. Then, the organics were dried over Na₂SO₄. The solvent was removed under vacuum and the crude reaction mixture was purified by silica gel chromatography hexane/EtOAc 1/1 to give the title compound as a white solid (1.28 g, 2.13 mmol, 71% yield). M.P.: 104–105 °C. ¹H NMR (400 MHz, CDCl₃) δ 5.50 (s, 1H), 4.68 (tt, J = 11.4, 4.9 Hz, 1H), 3.24 (td, J = 7.1, 5.7 Hz, 2H), 2.26 (t, J = 7.4 Hz, 2H), 2.19 – 2.11 (m, 2H), 1.96 (dt, J = 12.5, 3.4 Hz, 1H), 1.85 – 1.72 (m, 3H), 1.70 (t, J = 3.6 Hz, 1H), 1.68 – 1.59 (m, 5H), 1.58 – 1.43 (m, 7H), 1.39 – 1.20 (m, 16H), 1.18 – 1.04 (m, 7H), 1.02 – 0.94 (m, 3H), 0.91 – 0.88 (m, 6H), 0.87 – 0.86 (m, 3H), 0.85 (d, J = 1.8 Hz, 3H), 0.81 (s, 3H), 0.64 (s, 3H) ppm. ¹³C NMR (126 MHz, CDCl₃) δ 173.4, 173.3, 73.7, 56.5, 56.4, 54.3, 44.8, 42.7, 40.1, 39.6, 39.3, 36.9, 36.8, 36.3, 35.9, 35.6, 34.5, 34.2, 32.1, 31.6, 29.3, 28.7, 28.3, 28.1, 27.6, 26.4, 25.60, 24.7, 24.3, 23.9, 22.9, 22.7, 22.5, 21.3, 18.8, 14.0, 12.3, 12.2 ppm. HRMS calcd. for (C₃₉H₇₀NO₃) [M+H]⁺: 600.5350, found 600.5334. IR (neat): 3328, 2934, 2867, 1738, 1644, 1554, 1231, 1183.

Defluorinative α/δ sp^3 C-H alkylation of secondary amides

General procedure A: An oven-dried 8 mL Schlenk tube containing a stirring bar was charged with **1** (0.40 mmol, 2 equiv), **Ir-1** (2.2 mg, 0.01 equiv), **L1** (2.2 mg, 0.06 equiv), and NiBr₂·diglyme (3.6 mg, 0.05 equiv). The tube was then introduced in the nitrogen-filled glovebox where K₃PO₄ (64 mg, 0.30 mmol, 1.5 equiv) was added followed by 1.0 mL 1,4-dioxane. Then the tube was brought outside the glovebox, and **2** (0.20 mmol, 1 equiv) was added to the reaction mixture under N₂ atmosphere. Then the tube was stirred at 15 °C under irradiation of blue LEDs with a cooling system for 36 hours. The reaction was quenched by the addition of EtOAc (5 mL), and the reaction mixture was concentrated under vacuum prior to purification by flash chromatography column on silica gel.


General procedure B: To an 8 mL vial equipped with a stirring bar was added **5** (0.40 mmol, 2.0 equiv), **Ir-1** (2.2 mg, 0.01 equiv). The vial was then introduced in the nitrogen-filled glovebox where K₃PO₄ (128 mg, 0.60 mmol, 3.0 equiv) was added followed by 1.0 mL toluene. Then the tube was brought outside the glovebox, and **2** (0.20 mmol, 1 equiv) was added to the reaction mixture under N₂ atmosphere. The reaction was stirred and irradiated using 451 nm Kessil light (40 W), equipped with a fan cooling system for 72 hours. The reaction was quenched by addition of EtOAc (5 mL), and the mixture was concentrated under vacuum prior to purification by flash chromatography on silica gel.




N-(1,1-difluoro-2-phenylnon-1-en-4-yl)benzamide (3a) Following General Procedure A, *N*-hexylbenzamide (**1a**) (82.1 mg, 0.40 mmol) and (3,3,3-trifluoroprop-1-en-2-yl)benzene (**2a**) (34.4 mg, 0.20 mmol) were used, affording the title compound as a white solid (63.0 mg, 87% yield) by using Hexane/EtOAc (8:1) as eluent. M.P.: 102-103 °C.

¹H NMR (400 MHz, CDCl₃) δ 7.49 – 7.41 (m, 3H), 7.39 – 7.30 (m, 6H), 7.29 – 7.21 (m, 1H), 5.77 (d, J = 8.9 Hz, 1H), 4.37 – 3.89 (m, 1H), 2.77 – 2.62 (m, 2H), 1.67 – 1.53 (m, 1H), 1.54 – 1.42 (m, 1H), 1.41 – 1.11 (m, 6H), 0.90 – 0.80 (m, 3H) ppm. **¹⁹F NMR** (376 MHz, CDCl₃) δ -90.49 (d, J = 41.4 Hz), δ -90.62 (d, J = 41.4 Hz) ppm. **¹³C NMR** (126 MHz, CDCl₃) δ 167.0, 154.5 (dd, J = 290.2, 288.0 Hz), 134.7, 133.7 (d, J = 2.5 Hz), 131.3, 128.8, 128.5, 128.4, 127.6, 126.8, 90.0 (dd, J = 19.7, 16.3 Hz), 49.1 (t, J = 2.8 Hz), 34.5, 33.3, 31.7, 25.7, 22.6, 14.1 ppm. **HRMS** calcd. for (C₂₂H₂₆F₂NO) [M+H]⁺:

358.1977, found 358.1984. **IR (neat):** 3238, 3065, 2932, 2856, 1704, 1628, 1542, 1225, 692.




N-(1,1-difluoro-2-phenylnon-1-en-4-yl)-4-methoxybenzamide (3b) Following General Procedure A, N-hexyl-4-methoxybenzamide (**1b**) (94.1 mg, 0.40 mmol) and (3,3,3-trifluoroprop-1-en-2-yl)benzene (**2a**) (34.4 mg, 0.20 mmol) were used, affording the title compound as a white solid (75.0 mg, 96% yield) by using Hexane/EtOAc (6:1) as eluent. M.P.: 82-83 °C. **¹H NMR** (400 MHz, CDCl₃) δ 7.45 – 7.40 (m, 2H), 7.38 – 7.30 (m, 4H), 7.28 – 7.22 (m, 1H), 6.85 – 6.76 (m, 2H), 5.70 (d, *J* = 8.9 Hz, 1H), 4.25 – 4.10 (m, 1H), 3.81 (s, 3H), 2.80 – 2.54 (m, 2H), 1.65 – 1.51 (m, 1H), 1.53 – 1.40 (m, 1H), 1.37 – 1.17 (m, 6H), 0.89 – 0.80 (m, 3H) ppm. **¹⁹F NMR** (376 MHz, CDCl₃) δ -90.66 (d, *J* = 41.4 Hz), δ -90.68 (d, *J* = 41.4 Hz) ppm. **¹³C NMR** (126 MHz, CDCl₃) δ 166.5, 162.1, 154.5 (dd, *J* = 290.3, 288.0 Hz), 133.8 (d, *J* = 2.2 Hz), 128.8, 128.6, 128.5 (t, *J* = 3.0 Hz), 127.6, 127.0, 113.7, 90.0 (dd, *J* = 19.4, 16.5 Hz), 55.4, 49.0 (t, *J* = 2.7 Hz), 34.5, 33.2, 31.7, 25.7, 22.6, 14.1 ppm. **HRMS** calcd. for (C₂₃H₂₈F₂NO₂) [M+H]⁺: 388.2083, found 388.2067. **IR (neat):** 3234, 2932, 2857, 1738, 1605, 1506, 1026, 692.




N-(1,1-difluoro-2-phenylnon-1-en-4-yl)-4-fluorobenzamide (3c) Following General Procedure A, 4-fluoro-N-hexylbenzamide (**1c**) (89.3 mg, 0.40 mmol) and (3,3,3-trifluoroprop-1-en-2-yl)benzene (**2a**) (34.43 mg, 0.20 mmol) were used, affording the title compound as a white solid (50.0 mg, 67% yield) by using Hexane/EtOAc (8:1) as eluent. M.P.: 83-84 °C. **¹H NMR** (400 MHz, CDCl₃) δ 7.45 – 7.37 (m, 3H), 7.35 – 7.31 (m, 3H), 7.28 – 7.20 (m, 1H), 7.00 (t, *J* = 8.6 Hz, 2H), 5.59 (d, *J* = 8.9 Hz, 1H), 4.26 – 4.10 (m, 1H), 2.76 – 2.62 (m, 2H), 1.65 – 1.54 (m, 1H), 1.52 – 1.43 (m, 1H), 1.34 – 1.22 (m, 6H), 0.88 – 0.82 (m, 3H) ppm. **¹⁹F NMR** (376 MHz, CDCl₃) δ -90.05, -90.07, -108.30 ppm. **¹³C NMR** (126 MHz, CDCl₃) δ 166.0, 163.5, 154.5 (dd, *J* = 290.0, 288.2 Hz), 133.8 (d, *J* = 1.5 Hz), 130.7 (d, *J* = 3.1 Hz), 129.1 (d, *J* = 8.9 Hz), 128.9, 128.5 (t, *J* = 3.0 Hz), 127.7, 115.5 (d, *J* = 21.9 Hz), 89.9 (dd, *J* = 19.7, 16.3 Hz), 49.3 (t, *J* = 2.8 Hz), 34.6, 33.2,

31.75, 25.7, 22.6, 14.1. **HRMS** calcd. for (C₂₂H₂₅F₃NO) [M+H]⁺: 376.1883, found 376.1887. **IR (neat)**: 3242, 2955, 2929, 2857, 1713, 1631, 1504, 1228, 853, 692.



N-(1,1-difluoro-2-phenylnon-1-en-4-yl)-4-(trifluoromethoxy)benzamide (3d)


Following General Procedure A, N-hexyl-4-(trifluoromethoxy)benzamide (**1d**) (115.7 mg, 0.40 mmol) and (3,3,3-trifluoroprop-1-en-2-yl)benzene (**2a**) (34.4 mg, 0.20 mmol) were used, affording the title compound as white solid (70.0 mg, 79% yield) by using Hexane/EtOAc (8:1) as eluent. M.P.:70-71 °C. **¹H NMR** (400 MHz, CDCl₃) δ 7.48 – 7.43 (m, 2H), 7.36 – 7.28 (m, 4H), 7.28 – 7.20 (m, 1H), 7.18 – 7.06 (m, 2H), 5.93 (d, *J* = 8.8 Hz, 1H), 4.36 – 4.08 (m, 1H), 2.73 – 2.66 (m, 2H), 1.64 – 1.50 (m, 1H), 1.53 – 1.41 (m, 1H), 1.35 – 1.19 (m, 6H), 0.87 – 0.82 (m, 3H) ppm. **¹⁹F NMR** (376 MHz, CDCl₃) δ -57.55, -90.09 ppm. **¹³C NMR** (126 MHz, CDCl₃) δ 165.8, 154.5 (t, *J* = 289.2 Hz), 151.4 (q, *J* = 1.8 Hz), 133.8, 133.2, 128.9, 128.7, 128.4 (t, *J* = 3.0 Hz), 127.6, 120.5, 120.4 (q, *J* = 258.2 Hz), 89.9 (t, *J* = 18.1 Hz), 49.4 (t, *J* = 2.7 Hz), 34.5, 33.2, 31.7, 25.7, 22.6, 14.0 ppm. **HRMS** calcd. for (C₂₃H₂₅F₅NO₂) [M+H]⁺: 442.1800, found 442.1807. **IR (neat)**: 3265, 2933, 2860, 1735, 1637, 1548, 1240, 695.



N-(1,1-difluoro-2-phenylnon-1-en-4-yl)-4-((trifluoromethyl)thio)benzamide (3e)


Following General Procedure A, N-hexyl-4-((trifluoromethyl)thio)benzamide (**1e**) (122.1 mg, 0.40 mmol) and (3,3,3-trifluoroprop-1-en-2-yl)benzene (**2a**) (34.4 mg, 0.20 mmol) were used, affording the title compound as an oil (86.3 mg, 94% yield) by using Hexane/EtOAc (10:1) as eluent. **¹H NMR** (400 MHz, CDCl₃) δ 7.61 (d, *J* = 8.1 Hz, 2H), 7.44 – 7.39 (m, 2H), 7.36 – 7.29 (m, 4H), 7.26 – 7.21 (m, 1H), 5.61 (d, *J* = 8.9 Hz, 1H), 4.28 – 4.12 (m, 1H), 2.78 – 2.64 (m, 2H), 1.66 – 1.55 (m, 1H), 1.54 – 1.42 (m, 1H), 1.37 – 1.22 (m, 6H), 0.90 – 0.82 (m, 3H) ppm. **¹⁹F NMR** (376 MHz, CDCl₃) δ -41.89, -89.95 ppm. **¹³C NMR** (126 MHz, CDCl₃) δ 165.9, 154.5 (t, *J* = 289.3 Hz), 136.9, 136.0, 133.8, 128.9, 128.8 (q, *J* = 156.4 Hz), 128.4 (t, *J* = 3.0 Hz), 127.8, 127.7, 125.1, 89.9 (t, *J* = 18.0 Hz), 49.5, 34.5, 33.1, 31.7, 25.7, 22.6, 14.1. **HRMS** calcd. for (C₂₃H₂₅F₅NOS) [M+H]⁺:

458.1572, found 458.1567. **IR (neat):** 2930, 2860, 1727, 1637, 1231, 1111, 1015, 761, 692.




N-(1,1-difluoro-2-phenylnon-1-en-4-yl)-4-(trifluoromethyl)benzamide (3f)

Following General Procedure A, N-hexyl-4-(trifluoromethyl)benzamide (**1f**) (109.3 mg, 0.40 mmol) and (3,3,3-trifluoroprop-1-en-2-yl)benzene (**2a**) (34.4 mg, 0.20 mmol) were used, affording the title compound as a white solid (66.0 mg, 77% yield) by using Hexane/EtOAc (10:1) as eluent. M.P.: 88-89 °C. **¹H NMR** (400 MHz, CDCl₃) δ 7.57 (d, *J* = 8.1 Hz, 2H), 7.49 (d, *J* = 8.2 Hz, 2H), 7.37 – 7.29 (m, 4H), 7.29 – 7.22 (m, 1H), 5.79 (d, *J* = 8.9 Hz, 1H), 4.30 – 4.14 (m, 1H), 2.76 – 2.58 (m, 2H), 1.65 – 1.55 (m, 1H), 1.55 – 1.43 (m, 1H), 1.35 – 1.23 (m, 6H), 0.87 – 0.83 (m, 3H). **¹⁹F NMR** (376 MHz, CDCl₃) δ -63.08, -90.34. **¹³C NMR** (126 MHz, CDCl₃) δ 165.80, 154.53 (t, *J* = 289.4 Hz), 137.97, 133.83, 133.13 (q, *J* = 32.8 Hz), 128.96, 128.44 (q, *J* = 4.3, 3.6 Hz), 127.72, 127.27, 125.53 (q, *J* = 3.7 Hz), 123.79 (q, *J* = 272.5 Hz), 89.85 (t, *J* = 18.1 Hz), 49.54 (t, *J* = 2.8 Hz), 34.51, 33.14, 31.71, 25.73, 22.60, 14.07. **HRMS** calcd. for (C₂₃H₂₅F₅NO) [M+H]⁺: 426.1851, found 426.1844. **IR (neat):** 3285, 2929, 2855, 1736, 1644, 1546, 1123, 694.




methyl 4-((1,1-difluoro-2-phenylnon-1-en-4-yl)carbamoyl)benzoate (3g) Following General Procedure A, methyl 4-(hexylcarbamoyl)benzoate (**1g**) (105.3 mg, 0.40 mmol) and (3,3,3-trifluoroprop-1-en-2-yl)benzene (**2a**) (34.4 mg, 0.20 mmol) were used, affording the title compound as an amorphous white solid (72.2 mg, 87% yield) by using Hexane/EtOAc (8:1) as eluent. M.P.: 79-80 °C. **¹H NMR** (400 MHz, CDCl₃) δ 7.97 – 7.93 (m, 2H), 7.47 – 7.41 (m, 2H), 7.35 – 7.28 (m, 4H), 7.27 – 7.20 (m, 1H), 5.89 (d, *J* = 9.0 Hz, 1H), 4.27 – 4.12 (m, 1H), 3.91 (s, 3H), 2.78 – 2.53 (m, 2H), 1.64 – 1.53 (m, 1H), 1.52 – 1.44 (m, 1H), 1.34 – 1.20 (m, 6H), 0.86 – 0.81 (m, 3H). **¹⁹F NMR** (376 MHz, CDCl₃) δ -89.95 (d, *J* = 41.4 Hz), δ -90.07 (d, *J* = 41.4 Hz). **¹³C NMR** (126 MHz, CDCl₃) δ 166.40, 166.20, 154.46 (dd, *J* = 290.4, 288.4 Hz), 138.59, 133.76 (d, *J* = 2.4 Hz), 132.53, 129.69, 128.88, 128.41 (t, *J* = 3.8 Hz), 127.68, 126.83, 89.87 (dd, *J* = 19.6, 16.5 Hz), 52.42, 49.43 (t, *J* = 2.8 Hz), 34.42, 33.09, 31.68, 25.69, 22.56, 14.05. **HRMS** calcd. for

(C₂₄H₂₈F₂NO₃) [M+H]⁺: 416.2032, found 416.2034. **IR (neat)**: 2930, 2859, 1723, 1638, 1541, 1275, 1105, 696.




4-cyano-N-(1,1-difluoro-2-phenylnon-1-en-4-yl)benzamide (3h) Following General Procedure A, 4-cyano-N-hexylbenzamide (**1h**) (92.1 mg, 0.40 mmol) and (3,3,3-trifluoroprop-1-en-2-yl)benzene (**2a**) (34.4 mg, 0.20 mmol) were used, affording the title compound as a colorless oil (62.1 mg, 81% yield) by using Hexane/EtOAc (6:1) as eluent. **¹H NMR** (400 MHz, CDCl₃) δ 7.62 (d, *J* = 8.1 Hz, 2H), 7.45 (d, *J* = 8.0 Hz, 2H), 7.39 – 7.30 (m, 4H), 7.27 – 7.22 (m, 1H), 5.67 (d, *J* = 8.9 Hz, 1H), 4.22 (d, *J* = 6.5 Hz, 1H), 2.79 – 2.62 (m, 2H), 1.66 – 1.56 (m, 1H), 1.56 – 1.43 (m, 1H), 1.34 – 1.21 (m, 6H), 0.87 – 0.83 (m, 3H). **¹⁹F NMR** (376 MHz, CDCl₃) δ -89.78. **¹³C NMR** (126 MHz, CDCl₃) δ 165.15, 154.51 (dd, *J* = 289.6, 288.5 Hz), 138.57, 133.86 (d, *J* = 1.6 Hz), 132.37, 128.98, 128.43 (t, *J* = 2.9 Hz), 127.74, 127.48, 118.13, 114.96, 89.65 (dd, *J* = 19.6, 16.4 Hz), 49.70 (t, *J* = 2.7 Hz), 34.49, 33.05, 31.68, 25.71, 22.59, 14.08. **HRMS** calcd. for (C₂₃H₂₄F₂N₂NaO) [M+Na]⁺: 405.1749, found 405.1753. **IR (neat)**: 3237, 2930, 2858, 2230, 1729, 1633, 1548, 1232, 695.




N-(1,1-difluoro-2-phenylnon-1-en-4-yl)-3-fluorobenzamide (3i) Following General Procedure A, 3-fluoro-N-hexylbenzamide (**1i**) (89.3 mg, 0.40 mmol) and (3,3,3-trifluoroprop-1-en-2-yl)benzene (**2a**) (34.4 mg, 0.20 mmol) were used, affording the title compound as an amorphous white solid (62.5 mg, 83% yield) by using Hexane/EtOAc (10:1) as eluent. M.P.: 82-83 °C. **¹H NMR** (400 MHz, CDCl₃) δ 7.35 – 7.32 (m, 4H), 7.30 – 7.21 (m, 2H), 7.20 – 7.10 (m, 3H), 5.73 (d, *J* = 8.9 Hz, 1H), 4.30 – 3.77 (m, 1H), 2.86 – 2.49 (m, 2H), 1.65 – 1.54 (m, 1H), 1.53 – 1.43 (m, 1H), 1.35 – 1.21 (m, 6H), 0.87 – 0.83 (m, 3H). **¹⁹F NMR** (376 MHz, CDCl₃) δ -90.06, -111.81. **¹³C NMR** (126 MHz, CDCl₃) δ 165.73 (d, *J* = 2.5 Hz), 162.69 (d, *J* = 247.5 Hz), 154.45 (t, *J* = 289.3 Hz), 136.97 (d, *J* = 6.7 Hz), 133.73, 130.07 (d, *J* = 7.9 Hz), 128.86, 128.41 (t, *J* = 3.0 Hz), 127.70, 122.25 (d, *J* = 3.0 Hz), 118.27 (d, *J* = 21.3 Hz), 114.14 (d, *J* = 22.8 Hz), 89.90 (t,

$J = 18.1$ Hz), 49.33 (t, $J = 2.8$ Hz), 34.43, 33.11, 31.69, 25.68, 22.56, 14.04. **HRMS** calcd. for (C₂₂H₂₅F₃NO) [M+H]⁺: 376.1883, found 376.1879. **IR (neat)**: 3238, 3071, 2933, 2857, 1706, 1631, 1548, 1227, 691.




3-chloro-N-(1,1-difluoro-2-phenylnon-1-en-4-yl)benzamide (3j) Following General Procedure A, 3-chloro-N-hexylbenzamide (**1j**) (95.9 mg, 0.40 mmol) and (3,3,3-trifluoroprop-1-en-2-yl)benzene (**2a**) (34.4 mg, 0.20 mmol) were used, affording the title compound as an amorphous white solid (52.0 mg, 59% yield) by using Hexane/EtOAc (8:1) as eluent. M.P.: 85-86 °C. **¹H NMR** (400 MHz, CDCl₃) δ 7.39 – 7.33 (m, 1H), 7.31 – 7.25 (m, 6H), 7.24 – 7.19 (m, 2H), 5.67 (d, $J = 8.9$ Hz, 1H), 4.22 – 4.11 (m, 1H), 2.71 – 2.61 (m, 2H), 1.60 – 1.51 (m, 1H), 1.50 – 1.40 (m, 1H), 1.30 – 1.17 (m, 6H), 0.84 – 0.79 (m, 3H). **¹⁹F NMR** (376 MHz, CDCl₃) δ -90.36 (d, $J = 33.8$ Hz), δ -90.45 (d, $J = 33.8$ Hz). **¹³C NMR** (126 MHz, CDCl₃) δ 165.69, 154.48 (dd, $J = 290.2, 288.0$ Hz), 136.45, 134.64, 133.79 (d, $J = 2.0$ Hz), 131.40, 129.80, 128.93, 128.42 (t, $J = 3.0$ Hz), 127.82, 127.00, 124.95, 89.87 (dd, $J = 19.2, 16.9$ Hz), 49.46 (t, $J = 2.8$ Hz), 34.47, 33.08, 31.72, 25.70, 22.59, 14.08. **HRMS** calcd. for (C₂₂H₂₄ClF₂NNaO) [M+Na]⁺: 414.1407, found 414.1400. **IR (neat)**: 3065, 2929, 2858, 1723, 1636, 1541, 1236, 696.




N-(1,1-difluoro-2-phenylnon-1-en-4-yl)-2-fluorobenzamide (3k) Following General Procedure A, 2-fluoro-N-hexylbenzamide (**1k**) (89.3 mg, 0.40 mmol) and (3,3,3-trifluoroprop-1-en-2-yl)benzene (**2a**) (34.4 mg, 0.20 mmol) were used, affording the title compound as an amorphous white solid (52.0 mg, 70% yield) by using Hexane/EtOAc (10:1) as eluent. M.P.: 79-80 °C. **¹H NMR** (400 MHz, CDCl₃) δ 8.01 (td, $J = 7.8, 1.8$ Hz, 1H), 7.47 – 7.39 (m, 1H), 7.36 – 7.27 (m, 4H), 7.25 – 7.17 (m, 2H), 7.06 (dd, $J = 12.2, 8.2$ Hz, 1H), 6.34 (d, $J = 8.7$ Hz, 1H), 4.25 – 4.07 (m, 1H), 2.76 – 2.63 (m, 2H), 1.66 – 1.53 (m, 1H), 1.54 – 1.40 (m, 1H), 1.39 – 1.18 (m, 6H), 0.87 – 0.82 (m, 3H). **¹⁹F NMR** (376 MHz, CDCl₃) δ -90.52 (d, $J = 41.1$ Hz), -90.81 (dd, $J = 41.3, 3.4$ Hz), -114.08 (d, $J = 3.4$ Hz). **¹³C NMR** (126 MHz, CDCl₃) 162.91 (d, $J = 3.2$ Hz), 160.69 (d, $J = 246.8$ Hz),

154.54 (dd, $J = 290.0, 289.0$ Hz), 133.38, 133.19 (d, $J = 9.2$ Hz), 132.15 (d, $J = 2.2$ Hz), 128.67, 128.43 (t, $J = 3.1$ Hz), 127.56, 124.84 (d, $J = 3.3$ Hz), 121.25 (d, $J = 11.6$ Hz), 116.03 (d, $J = 25.0$ Hz), 90.02 (dd, $J = 21.1, 14.9$ Hz), 48.94 (t, $J = 2.9$ Hz), 34.32, 33.11, 31.71, 25.50, 22.58, 14.08. **HRMS** calcd. for (C₂₂H₂₄F₃NNaO) [M+Na]⁺: 397.1702, found 397.1688. **IR (neat)**: 3259, 3065, 2952, 2856, 1703, 1630, 1540, 1224, 757.




N-(1,1-difluoro-2-phenylnon-1-en-4-yl)thiophene-2-carboxamide (3l) Following General Procedure A, N-hexylthiophene-2-carboxamide (**1l**) (84.5 mg, 0.40 mmol) and (3,3,3-trifluoroprop-1-en-2-yl)benzene (**2a**) (34.4 mg, 0.20 mmol) were used, affording the title compound as an amorphous white solid (50.4 mg, 69% yield) by using Hexane/EtOAc (10:1) as eluent. M.P.: 123-124 °C. **¹H NMR** (400 MHz, CDCl₃) δ 7.42 (dd, $J = 5.0, 1.1$ Hz, 1H), 7.37 – 7.28 (m, 4H), 7.27 – 7.22 (m, 1H), 7.13 (dd, $J = 3.7, 1.1$ Hz, 1H), 6.99 (dd, $J = 5.0, 3.7$ Hz, 1H), 5.53 (d, $J = 8.9$ Hz, 1H), 4.38 – 3.88 (m, 1H), 2.75 – 2.56 (m, 2H), 1.64 – 1.52 (m, 1H), 1.52 – 1.42 (m, 1H), 1.36 – 1.19 (m, 6H), 0.87 – 0.82 (m, 3H). **¹⁹F NMR** (376 MHz, CDCl₃) δ -90.39 (d, $J = 41.2$ Hz), -90.58 (d, $J = 41.1$ Hz). **¹³C NMR** (126 MHz, CDCl₃) δ 161.44, 154.52 (dd, $J = 291.1, 287.3$ Hz), 139.14, 133.59 (d, $J = 6.0$ Hz), 129.84, 128.86, 128.47 (t, $J = 3.0$ Hz), 127.69, 127.54, 89.92 (dd, $J = 20.8, 15.3$ Hz), 49.15 (t, $J = 2.8$ Hz), 34.50, 33.25 (d, $J = 1.4$ Hz), 31.74, 25.64, 22.60, 14.10. **HRMS** calcd. for (C₂₀H₂₃F₂NNaOS) [M+Na]⁺: 386.1361, found 386.1345. **IR (neat)**: 3250, 3081, 2928, 2855, 1705, 1613, 1544, 1227, 693.




N-(1,1-difluoro-9-hydroxy-2-phenylnon-1-en-4-yl)benzamide (3m) Following General Procedure A, N-(6-hydroxyhexyl)benzamide (**1m**) (88.5 mg, 0.40 mmol) and (3,3,3-trifluoroprop-1-en-2-yl)benzene (**2a**) (34.4 mg, 0.20 mmol) were used, affording the title compound as a colorless oil (59.2 mg, 79% yield) by using Hexane/EtOAc (1:1) as eluent. **¹H NMR** (400 MHz, CDCl₃) δ 7.49 – 7.43 (m, 3H), 7.39 – 7.33 (m, 6H), 7.31 – 7.28 (m, 1H), 5.75 (d, $J = 9.0$ Hz, 1H), 4.31 – 4.19 (m, 1H), 3.59 (t, $J = 6.4$ Hz, 2H), 2.78 – 2.66 (m, 2H), 1.67 – 1.58 (m, 1H), 1.60 – 1.46 (m, 3H), 1.43 – 1.31 (m, 4H). **¹⁹F**

NMR (376 MHz, CDCl₃) δ -89.99 (d, J = 41.4 Hz), δ -90.12 (d, J = 41.4 Hz). **¹³C NMR** (126 MHz, CDCl₃) δ 167.15, 154.48 (dd, J = 290.2, 288.0 Hz), 134.55, 133.67 (d, J = 2.9 Hz), 131.45, 128.90, 128.54, 128.48 (t, J = 3.0 Hz), 127.69, 126.78, 89.92 (dd, J = 20.1, 16.0 Hz), 62.54, 48.79 (t, J = 2.7 Hz), 34.62, 33.39, 32.52, 29.80, 25.54. **HRMS** calcd. for (C₂₂H₂₆F₂NO₂) [M+H]⁺: 374.1926, found 374.1934. **IR (neat)**: 3308, 2927, 2857, 1736, 1635, 1541, 1233, 695.




6-benzamido-9,9-difluoro-8-phenylnon-8-en-1-yl benzoate (3n) Following General Procedure A, 6-benzamidohexyl benzoate (**1n**) (130.2 mg, 0.40 mmol) and (3,3,3-trifluoroprop-1-en-2-yl)benzene (**2a**) (34.4 mg, 0.20 mmol) were used, affording the title compound as an oil (58.0 mg, 60% yield) by using Hexane/EtOAc (6:1) as eluent. **¹H NMR** (400 MHz, CDCl₃) δ 8.05 – 7.97 (m, 2H), 7.59 – 7.50 (m, 1H), 7.49 – 7.39 (m, 5H), 7.38 – 7.29 (m, 6H), 7.27 – 7.21 (m, 1H), 5.80 (d, J = 8.8 Hz, 1H), 4.34 – 4.14 (m, 3H), 2.78 – 2.65 (m, 2H), 1.77 – 1.66 (m, 2H), 1.68 – 1.57 (m, 1H), 1.59 – 1.47 (m, 1H), 1.49 – 1.33 (m, 4H). **¹⁹F NMR** (376 MHz, CDCl₃) δ -89.95 (d, J = 41.0 Hz), -90.09 (d, J = 41.3 Hz). **¹³C NMR** (126 MHz, CDCl₃) δ 167.02, 166.74, 154.46 (dd, J = 290.7, 287.7 Hz), 134.60, 133.61 (t, J = 2.4 Hz), 132.93, 131.39, 130.50, 129.61, 128.87, 128.50, 128.45, 128.42, 127.67, 126.77, 89.92 (dd, J = 20.2, 15.9 Hz), 64.94, 48.94 (t, J = 2.8 Hz), 34.47, 33.26, 28.67, 26.00, 25.70. **HRMS** calcd. for (C₂₉H₃₀F₂NO₃) [M+H]⁺: 478.2188, found 478.2197. **IR (neat)**: 3305, 3063, 2933, 2855, 1731, 1629, 1539, 1230, 693.




N-(9-((tert-butyldimethylsilyloxy)-1,1-difluoro-2-phenylnon-1-en-4-yl)benzamide (3o) Following General Procedure A, N-(6-((tert-butyldimethylsilyloxy)hexyl)benzamide (**1o**) (134.2 mg, 0.40 mmol) and (3,3,3-trifluoroprop-1-en-2-yl)benzene (**2a**) (34.4 mg, 0.20 mmol) were used, affording the title compound as a colorless oil (49.0 mg, 50% yield) by using Hexane/EtOAc (10:1) as eluent. **¹H NMR** (400 MHz, CDCl₃) δ 7.48 – 7.42 (m, 3H), 7.39 – 7.30 (m, 6H), 7.30 – 7.21 (m, 1H), 5.67 (d, J = 8.8 Hz, 1H), 4.29 – 4.13 (m, 1H), 3.56 (t, J = 6.5 Hz, 2H), 2.77

– 2.63 (m, 2H), 1.68 – 1.56 (m, 1H), 1.54 – 1.41 (m, 3H), 1.41 – 1.28 (m, 4H), 0.88 (s, 9H), 0.03 (s, 6H). ¹⁹F NMR (376 MHz, CDCl₃) δ -90.03 (d, *J* = 41.2 Hz), -90.17 (d, *J* = 42.1 Hz). ¹³C NMR (126 MHz, CDCl₃) δ 166.98, 154.47 (dd, *J* = 290.2, 288.0 Hz), 134.68, 133.69 (d, *J* = 2.5 Hz), 131.36, 128.86, 128.49, 128.44 (t, *J* = 3.0 Hz), 127.63, 126.76, 89.94 (dd, *J* = 20.0, 16.1 Hz), 63.17, 49.06 (t, *J* = 2.8 Hz), 34.62, 33.25, 32.77, 26.06, 25.85, 25.83, 18.44, -5.19. HRMS calcd. for (C₂₈H₄₀F₂NO₂Si) [M+H]⁺: 488.2791, found 488.2779. IR (neat): 3302, 2929, 2856, 1728, 1636, 1540, 1236, 694.




N-(9-chloro-1,1-difluoro-2-phenylnon-1-en-4-yl)benzamide (3p) Following General Procedure A, N-(6-chlorohexyl)benzamide (**1p**) (95.9 mg, 0.40 mmol) and (3,3,3-trifluoroprop-1-en-2-yl)benzene (**2a**) (34.4 mg, 0.20 mmol) were used, affording the title compound as a colorless oil (41.0 mg, 52% yield) by using Hexane/EtOAc (8:1) as eluent. ¹H NMR (400 MHz, CDCl₃) δ 7.49 – 7.41 (m, 3H), 7.38 – 7.32 (m, 6H), 7.30 – 7.26 (m, 1H), 5.65 (d, *J* = 9.0 Hz, 1H), 4.29 – 4.16 (m, 1H), 3.48 (t, *J* = 6.7 Hz, 2H), 2.75 – 2.66 (m, 2H), 1.77 – 1.68 (m, 2H), 1.66 – 1.57 (m, 1H), 1.56 – 1.47 (m, 1H), 1.45 – 1.32 (m, 4H). ¹⁹F NMR (376 MHz, CDCl₃) δ -89.93 (d, *J* = 41.0 Hz), -90.10 (d, *J* = 41.0 Hz). ¹³C NMR (126 MHz, CDCl₃) δ 167.01, 154.51 (dd, *J* = 290.2, 288.0 Hz), 134.61, 133.66 (d, *J* = 2.5 Hz), 131.48, 128.95, 128.58, 128.49 (t, *J* = 2.9 Hz), 127.74, 126.77, 89.90 (dd, *J* = 20.7, 15.5 Hz), 48.94 (d, *J* = 2.8 Hz), 45.05, 34.55, 33.35, 32.52, 26.82, 25.39. HRMS calcd. for (C₂₂H₂₅ClF₂NO) [M+H]⁺: 392.1587, found 392.1593. IR (neat): 3305, 3063, 2933, 2855, 1731, 1629, 1539, 1230, 693.




N-(1,1-difluoro-2-phenylnon-1-en-4-yl)hexanamide (3q) Following General Procedure A, N-hexylhexanamide (**1q**) (79.7 mg, 0.40 mmol) and (3,3,3-trifluoroprop-1-en-2-yl)benzene (**2a**) (34.4 mg, 0.20 mmol) were used, affording the title compound as a colorless oil (67.7 mg, 96% yield) by using Hexane/EtOAc (3:1) as eluent. ¹H NMR (400 MHz, CDCl₃) δ 7.39 – 7.30 (m, 4H), 7.29 – 7.24 (m, 1H), 5.02 (d, *J* = 9.0 Hz, 1H),

4.27 – 3.74 (m, 1H), 2.83 – 2.38 (m, 2H), 1.99 – 1.90 (m, 2H), 1.56 – 1.40 (m, 3H), 1.37 – 1.16 (m, 11H), 0.91 – 0.80 (m, 6H). ^{19}F NMR (376 MHz, CDCl_3) δ -90.67 (d, J = 41.8 Hz), -90.87 (d, J = 41.6 Hz). ^{13}C NMR (126 MHz, CDCl_3) δ 172.69, 154.46 (dd, J = 290.8, 287.0 Hz), 133.70 (dd, J = 3.8, 2.3 Hz), 128.72, 128.47 (t, J = 3.0 Hz), 127.62, 90.05 (dd, J = 20.7, 15.0 Hz), 48.31 (t, J = 2.7 Hz), 36.90, 34.49, 33.34 (d, J = 1.5 Hz), 31.71, 31.53, 25.59, 25.40, 22.61, 22.50, 14.07, 14.03. **HRMS** calcd. for $(\text{C}_{21}\text{H}_{32}\text{F}_2\text{NO})$ $[\text{M}+\text{H}]^+$: 352.2446, found 352.2459. **IR (neat)**: 3276, 2929, 2859, 1736, 1642, 1543, 1223, 696.




9,9-difluoro-6-hexanamido-8-phenylnon-8-en-1-yl acetate (3r) Following General Procedure A, 6-hexanamidoheptyl acetate (**1r**) (102.9 mg, 0.40 mmol) and (3,3,3-trifluoroprop-1-en-2-yl)benzene (**2a**) (34.4 mg, 0.20 mmol) were used, affording the title compound as a colorless oil (56.0 mg, 68% yield) by using Hexane/EtOAc (3:1) as eluent. ^1H NMR (400 MHz, CDCl_3) δ 7.38 – 7.29 (m, 4H), 7.29 – 7.23 (m, 1H), 5.04 (d, J = 9.0 Hz, 1H), 4.27 – 3.80 (m, 3H), 2.68 – 2.44 (m, 2H), 2.02 (s, 3H), 1.97 – 1.92 (m, 2H), 1.60 – 1.42 (m, 5H), 1.39 – 1.17 (m, 9H), 0.87 (t, J = 7.1 Hz, 3H). ^{19}F NMR (376 MHz, CDCl_3) δ -90.56 (d, J = 41.5 Hz), -90.79 (d, J = 41.6 Hz). ^{13}C NMR (126 MHz, CDCl_3) δ 172.71, 171.28, 154.44 (dd, J = 291.1, 287.0 Hz), 133.59 (dd, J = 4.0, 2.5 Hz), 128.73, 128.43 (t, J = 3.0 Hz), 127.66, 89.98 (dd, J = 21.0, 14.9 Hz), 64.43, 48.16 (t, J = 2.8 Hz), 36.85, 34.41, 33.34 (d, J = 1.4 Hz), 31.52, 28.54, 25.80, 25.56, 25.35, 22.47, 21.08, 14.02. **HRMS** calcd. for $(\text{C}_{23}\text{H}_{33}\text{F}_2\text{NNaO}_3)$ $[\text{M}+\text{Na}]^+$: 432.2321, found 432.2321. **IR (neat)**: 3284, 2933, 2860, 1737, 1644, 1542, 1232, 697.




N-(9-((tert-butyldimethylsilyl)oxy)-1,1-difluoro-2-phenylnon-1-en-4-yl)hexanamide (3s) Following General Procedure A, N-(6-(tert-butyldimethylsilyl)hexyl)hexanamide (**1s**) (131.8 mg, 0.40 mmol) and (3,3,3-trifluoroprop-1-en-2-yl)benzene (**2a**) (34.4 mg, 0.20 mmol) were used, affording the title compound as a colorless oil (50.9 mg, 53%

yield) by using Hexane/EtOAc (3:1) as eluent. $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.39 – 7.30 (m, 4H), 7.29 – 7.24 (m, 1H), 4.98 (d, $J = 8.5$ Hz, 1H), 4.07 – 3.87 (m, 1H), 3.55 (t, $J = 6.5$ Hz, 2H), 2.65 – 2.45 (m, 2H), 1.95 (t, $J = 7.4$ Hz, 2H), 1.55 – 1.40 (m, 5H), 1.37 – 1.17 (m, 9H), 0.93 – 0.80 (m, 12H), 0.03 (s, 6H). $^{19}\text{F NMR}$ (376 MHz, CDCl_3) δ -90.22 (d, $J = 41.6$ Hz), -90.42 (d, $J = 41.8$ Hz). $^{13}\text{C NMR}$ (126 MHz, CDCl_3) δ 172.66, 154.43 (dd, $J = 290.2, 288.0$ Hz), 133.63, 128.71, 128.44 (t, $J = 3.0$ Hz), 127.61, 90.01 (dd, $J = 19.7, 16.3$ Hz), 63.18, 48.30, 36.89, 34.56, 33.33, 32.80, 31.52, 29.81, 26.07, 25.80, 25.37, 22.48, 18.45, 14.03, -5.18. **HRMS** calcd. for $(\text{C}_{27}\text{H}_{46}\text{F}_2\text{NO}_2\text{Si})$ $[\text{M}+\text{H}]^+$: 482.3260, found 482.3255. **IR (neat)**: 3283, 2928, 2857, 1729, 1642, 1548, 1235, 696.




N-(9-chloro-1,1-difluoro-2-phenylnon-1-en-4-yl)hexanamide (3t) Following General Procedure A, N-(6-chlorohexyl)hexanamide (**1ae**) (93.5 mg, 0.40 mmol) and (3,3,3-trifluoroprop-1-en-2-yl)benzene (**2a**) (34.4 mg, 0.20 mmol) were used, affording the title compound as a colorless oil (50.2 mg, 65% yield) by using Hexane/EtOAc (3:1) as eluent. $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.38 – 7.30 (m, 4H), 7.29 – 7.26 (m, 1H), 5.11 – 4.75 (m, 1H), 4.04 – 3.89 (m, 1H), 3.48 (t, $J = 6.7$ Hz, 2H), 2.59 – 2.52 (m, 2H), 2.00 – 1.93 (m, 2H), 1.76 – 1.64 (m, 2H), 1.57 – 1.49 (m, 2H), 1.48 – 1.43 (m, 3H), 1.41 – 1.19 (m, 7H), 0.88 (t, $J = 7.1$ Hz, 3H). $^{19}\text{F NMR}$ (376 MHz, CDCl_3) δ -90.12 (d, $J = 41.5$ Hz), -90.36 (d, $J = 41.5$ Hz). $^{13}\text{C NMR}$ (126 MHz, CDCl_3) δ 172.74, 154.47 (dd, $J = 291.1, 286.9$ Hz), 133.58 (d, $J = 6.6$ Hz), 128.77, 128.45 (t, $J = 3.0$ Hz), 127.70, 89.97 (dd, $J = 21.0, 14.9$ Hz), 48.18 (t, $J = 2.8$ Hz), 45.00, 36.87, 34.46, 33.40 (d, $J = 1.4$ Hz), 32.51, 31.54, 26.75, 25.38, 25.29, 22.49, 14.04. **HRMS** calcd. for $(\text{C}_{21}\text{H}_{31}\text{ClF}_2\text{NO})$ $[\text{M}+\text{H}]^+$: 386.2057, found 386.2048. **IR (neat)**: 3274, 2930, 2859, 1728, 1640, 1546, 1234, 696.




N-(1,1-difluoro-2-phenylnon-1-en-4-yl)-6-hydroxyhexanamide (3u) Following General Procedure A, N-hexyl-6-hydroxyhexanamide (**1u**) (86.1 mg, 0.40 mmol) and (3,3,3-trifluoroprop-1-en-2-yl)benzene (**2a**) (34.4 mg, 0.20 mmol) were used, affording


the title compound as a colorless oil (64.3 mg, 87% yield) by using Hexane/EtOAc (1:1) as eluent. $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.38 – 7.30 (m, 4H), 7.29 – 7.24 (m, 1H), 5.07 (d, $J = 9.0$ Hz, 1H), 4.02 – 3.90 (m, 1H), 3.62 (t, $J = 6.5$ Hz, 2H), 2.59 – 2.47 (m, 2H), 1.97 (td, $J = 7.3, 2.1$ Hz, 2H), 1.85 (s, 1H), 1.61 – 1.43 (m, 5H), 1.38 – 1.15 (m, 9H), 0.84 (t, $J = 6.8$ Hz, 3H). $^{19}\text{F NMR}$ (376 MHz, CDCl_3) δ -90.62 (d, $J = 41.5$ Hz), -90.79 (d, $J = 41.5$ Hz). $^{13}\text{C NMR}$ (126 MHz, CDCl_3) δ 172.54, 154.45 (dd, $J = 290.2, 288.0$ Hz), 133.69 (d, $J = 5.7$ Hz), 128.73, 128.45 (t, $J = 3.0$ Hz), 127.64, 90.03 (dd, $J = 20.6, 15.2$ Hz), 62.66, 48.42 (t, $J = 2.8$ Hz), 36.65, 34.46, 33.31, 32.38, 31.70, 25.60, 25.41, 25.21, 22.61, 14.09. **HRMS** calcd. for $(\text{C}_{21}\text{H}_{32}\text{F}_2\text{NO}_2)$ $[\text{M}+\text{H}]^+$: 368.2396, found 368.2404. **IR (neat)**: 3284, 2930, 2859, 1735, 1641, 1547, 1366, 1233, 696.




6-((1,1-difluoro-2-phenylnon-1-en-4-yl)amino)-6-oxohexyl benzoate (3v) Following General Procedure A, 6-(hexylamino)-6-oxohexyl benzoate (**1v**) (127.8 mg, 0.40 mmol) and (3,3,3-trifluoroprop-1-en-2-yl)benzene (**2a**) (34.4 mg, 0.20 mmol) were used, affording the title compound as a colorless oil (48.3 mg, 51% yield) by using Hexane/EtOAc (2:1) as eluent. $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 8.08 – 7.95 (m, 2H), 7.60 – 7.51 (m, 1H), 7.47 – 7.40 (m, 2H), 7.39 – 7.29 (m, 4H), 7.29 – 7.20 (m, 1H), 4.99 (d, $J = 9.0$ Hz, 1H), 4.30 (t, $J = 6.6$ Hz, 2H), 4.04 – 3.91 (m, 1H), 2.59 – 2.51 (m, 2H), 2.04 – 1.92 (m, 2H), 1.81 – 1.70 (m, 2H), 1.64 – 1.54 (m, 2H), 1.51 – 1.37 (m, 3H), 1.32 – 1.14 (m, 7H), 0.90 – 0.78 (m, 3H). $^{19}\text{F NMR}$ (376 MHz, CDCl_3) δ -90.59 (d, $J = 41.7$ Hz), -90.76 (d, $J = 41.7$ Hz). $^{13}\text{C NMR}$ (126 MHz, CDCl_3) δ 172.24, 166.77, 154.45 (dd, $J = 290.2, 288.0$ Hz), 133.70 (d, $J = 4.2$ Hz), 133.00, 130.53, 129.66, 128.73, 128.47, 128.45 (t, $J = 3.0$ Hz), 127.63, 90.02 (dd, $J = 20.4, 15.3$ Hz), 64.90, 48.41 (t, $J = 2.8$ Hz), 36.66, 34.44, 33.29, 31.68, 28.63, 25.84, 25.60, 25.29, 22.59, 14.09. **HRMS** calcd. for $(\text{C}_{28}\text{H}_{35}\text{F}_2\text{NNaO}_3)$ $[\text{M}+\text{Na}]^+$: 494.2477, found 494.2492. **IR (neat)**: 3291, 2930, 2859, 1719, 1641, 1542, 1272, 1233, 710.




6-chloro-N-(1,1-difluoro-2-phenylnon-1-en-4-yl)hexanamide (3w) Following General Procedure A, 6-chloro-N-hexylhexanamide (**1w**) (93.5 mg, 0.40 mmol) and (3,3,3-trifluoroprop-1-en-2-yl)benzene (**2a**) (34.4 mg, 0.20 mmol) were used, affording the title compound as a colorless oil (40.0 mg, 52% yield) by using Hexane/EtOAc (3:1) as eluent. $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.39 – 7.30 (m, 4H), 7.30 – 7.25 (m, 1H), 4.97 (d, $J = 9.0$ Hz, 1H), 4.04 – 3.91 (m, 1H), 3.51 (t, $J = 6.6$ Hz, 2H), 2.60 – 2.50 (m, 2H), 2.04 – 1.88 (m, 2H), 1.82 – 1.70 (m, 2H), 1.59 – 1.45 (m, 3H), 1.45 – 1.35 (m, 2H), 1.33 – 1.17 (m, 7H), 0.90 – 0.79 (m, 3H). $^{19}\text{F NMR}$ (376 MHz, CDCl_3) δ -90.59 (d, $J = 41.6$ Hz), -90.76 (d, $J = 41.6$ Hz). $^{13}\text{C NMR}$ (126 MHz, CDCl_3) δ 172.19, 154.44 (dd, $J = 290.2, 288.0$ Hz), 133.70 (t, $J = 2.8$ Hz), 128.74, 128.45 (t, $J = 3.1$ Hz), 127.64, 90.01 (dd, $J = 20.6, 15.3$ Hz), 48.44 (t, $J = 2.8$ Hz), 44.93, 36.55, 34.47, 33.30, 32.38, 31.69, 26.55, 25.61, 24.84, 22.60, 14.09. **HRMS** calcd. for ($\text{C}_{21}\text{H}_{31}\text{ClF}_2\text{NO}$) $[\text{M}+\text{H}]^+$: 386.2057, found 386.2049. **IR (neat)**: 3276, 2930, 2859, 1736, 1640, 1546, 1336, 1232, 696.




N-(1,1-difluoro-2-phenylnon-1-en-4-yl)cyclopropanecarboxamide (3x) Following General Procedure A, with double catalyst loading, N-hexylcyclopropanecarboxamide (**1x**) (67.7 mg, 0.40 mmol) and (3,3,3-trifluoroprop-1-en-2-yl)benzene (**2a**) (34.4 mg, 0.20 mmol) were used, affording the title compound as an amorphous white solid (42.0 mg, 65% yield) by using Hexane/EtOAc (3:1) as eluent. M.P.: 86-87 °C. $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.40 – 7.28 (m, 4H), 7.28 – 7.23 (m, 1H), 5.16 (d, $J = 8.9$ Hz, 1H), 4.03 – 3.88 (m, 1H), 2.66 – 2.50 (m, 2H), 1.53 – 1.43 (m, 1H), 1.39 – 1.15 (m, 7H), 1.13 – 1.02 (m, 1H), 0.90 – 0.80 (m, 5H), 0.68 – 0.59 (m, 2H). $^{19}\text{F NMR}$ (376 MHz, CDCl_3) δ -90.72 (d, $J = 41.8$ Hz), -90.88 (d, $J = 41.9$ Hz). $^{13}\text{C NMR}$ (126 MHz, CDCl_3) δ 173.04, 154.44 (dd, $J = 290.5, 287.2$ Hz), 133.69 (d, $J = 5.2$ Hz), 128.68, 128.46 (t, $J = 3.0$ Hz), 127.55, 90.05 (dd, $J = 20.6, 15.2$ Hz), 48.59, 34.33, 33.28, 31.73, 25.56, 22.59, 14.79, 14.09, 7.11, 6.93. **HRMS** calcd. for ($\text{C}_{19}\text{H}_{26}\text{F}_2\text{NO}$) $[\text{M}+\text{H}]^+$: 322.1977, found 322.1981. **IR (neat)**: 3282, 3031, 2929, 1720, 1635, 1549, 1230, 694.




N-(1,1-difluoro-2-phenylhept-1-en-4-yl)acetamide (3y) Following General Procedure A, N-butylacetamide (**1y**) (46.1 mg, 0.40 mmol) and (3,3,3-trifluoroprop-1-en-2-yl)benzene (**2a**) (34.4 mg, 0.20 mmol) were used, affording the title compound as a colorless oil (45.8 mg, 86% yield) by using Hexane/EtOAc (3:1) as eluent. **¹H NMR** (400 MHz, CDCl₃) δ 7.40 – 7.30 (m, 4H), 7.29 – 7.25 (m, 1H), 4.97 (d, *J* = 9.0 Hz, 1H), 4.09 – 3.89 (m, 1H), 2.74 – 2.45 (m, 2H), 1.75 (s, 3H), 1.52 – 1.40 (m, 1H), 1.39 – 1.21 (m, 3H), 0.85 (t, *J* = 7.2 Hz, 3H). **¹⁹F NMR** (376 MHz, CDCl₃) δ -90.26 (d, *J* = 41.4 Hz), -90.49 (d, *J* = 41.5 Hz). **¹³C NMR** (126 MHz, CDCl₃) δ 169.75, 154.47 (dd, *J* = 290.2, 288.0 Hz), 133.76 (d, *J* = 6.4 Hz), 128.74, 128.44 (t, *J* = 3.0 Hz), 127.64, 89.99 (dd, *J* = 21.0, 15.0 Hz), 48.47 (t, *J* = 2.8 Hz), 36.63, 33.20 (d, *J* = 1.5 Hz), 23.29, 19.19, 14.00. **HRMS** calcd. for (C₁₅H₂₀F₂NO) [M+H]⁺: 268.1507, found 268.1506. **IR (neat)**: 3273, 2969, 1737, 1647, 1557, 1373, 1232.



N-(1,1-difluoro-2-phenylnon-1-en-4-yl)-5-oxohexanamide (3z) Following General Procedure A, N-hexyl-5-oxohexanamide (**1z**) (89.2 mg, 0.40 mmol) and (3,3,3-trifluoroprop-1-en-2-yl)benzene (**2a**) (34.4 mg, 0.20 mmol) were used, affording the title compound as an oil (45.0 mg, 55% yield) by using Hexane/EtOAc (3:1) as eluent. **¹H NMR** (400 MHz, CDCl₃) δ 7.38 – 7.29 (m, 4H), 7.28 – 7.23 (m, 1H), 5.16 (d, *J* = 9.0 Hz, 1H), 4.02 – 3.82 (m, 1H), 2.58 – 2.51 (m, 2H), 2.44 (t, *J* = 7.0 Hz, 2H), 2.11 (s, 3H), 2.02 – 1.92 (m, 2H), 1.84 – 1.71 (m, 2H), 1.53 – 1.39 (m, 1H), 1.37 – 1.09 (m, 7H), 0.89 – 0.78 (m, 3H). **¹⁹F NMR** (376 MHz, CDCl₃) δ -90.22 (d, *J* = 41.6 Hz), -90.38 (d, *J* = 41.5 Hz). **¹³C NMR** (126 MHz, CDCl₃) δ 208.65, 171.92, 154.45 (dd, *J* = 290.2, 288.0 Hz), 133.66 (t, *J* = 3.0 Hz), 128.73, 128.44 (t, *J* = 3.0 Hz), 127.64, 90.03 (dd, *J* = 20.5, 15.3 Hz), 48.45, 42.57, 35.48, 34.43, 33.32, 31.68, 30.05, 25.62, 22.61, 19.62, 14.09. **HRMS** calcd. for (C₂₁H₃₀F₂NO₂) [M+H]⁺: 366.2239, found 366.2230. **IR (neat)**: 3291, 2929, 2858, 1718, 1643, 1543, 1366, 1233, 697.




N-(1,1-difluoro-7-methyl-2-phenyloct-1-en-4-yl)hexanamide (3aa) Following General Procedure A, N-(4-methylpentyl)hexanamide (**1aa**) (79.7 mg, 0.40 mmol) and (3,3,3-trifluoroprop-1-en-2-yl)benzene (**2a**) (34.4 mg, 0.20 mmol) were used, affording the title compound as a colorless oil (41.0 mg, 58% yield) by using Hexane/EtOAc (3:1) as eluent. $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.39 – 7.30 (m, 4H), 7.29 – 7.26 (m, 1H), 4.97 (d, $J = 9.0$ Hz, 1H), 4.03 – 3.87 (m, 1H), 2.56 (dt, $J = 6.6, 2.3$ Hz, 2H), 2.00 – 1.93 (m, 2H), 1.55 – 1.40 (m, 4H), 1.38 – 1.19 (m, 5H), 1.17 – 1.08 (m, 2H), 0.88 (t, $J = 7.1$ Hz, 3H), 0.83 (d, $J = 3.8$ Hz, 3H), 0.81 (d, $J = 3.9$ Hz, 3H). $^{19}\text{F NMR}$ (376 MHz, CDCl_3) δ -90.67 (d, $J = 41.8$ Hz), -90.85 (d, $J = 41.6$ Hz). $^{13}\text{C NMR}$ (126 MHz, CDCl_3) δ 172.66, 154.46 (dd, $J = 290.8, 286.9$ Hz), 133.69 (d, $J = 6.4$ Hz), 128.74, 128.48 (t, $J = 3.1$ Hz), 127.65, 90.06 (dd, $J = 20.9, 15.0$ Hz), 48.49, 36.92, 34.94, 33.35, 32.36, 31.55, 28.00, 25.42, 22.73, 22.52, 22.49, 14.06. **HRMS** calcd. for $(\text{C}_{21}\text{H}_{32}\text{F}_2\text{NO})$ $[\text{M}+\text{H}]^+$: 352.2446, found 352.2433. **IR (neat)**: 3277, 2955, 2870, 1729, 1639, 1548, 1236, 696.




N-(1,1-difluoro-2-phenylnon-1-en-4-yl)-4-methylpentanamide (3ab) Following General Procedure A, N-hexyl-4-methylpentanamide (**1ab**) (79.7 mg, 0.40 mmol) and (3,3,3-trifluoroprop-1-en-2-yl)benzene (**2a**) (34.4 mg, 0.20 mmol) were used, affording the title compound as a colorless oil (51.4 mg, 73% yield) by using Hexane/EtOAc (3:1) as eluent. $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.38 – 7.30 (m, 4H), 7.31 – 7.22 (m, 1H), 5.05 (d, $J = 9.0$ Hz, 1H), 4.02 – 3.91 (m, 1H), 2.55 (dt, $J = 6.5, 2.3$ Hz, 2H), 2.00 – 1.91 (m, 2H), 1.55 – 1.43 (m, 2H), 1.40 – 1.32 (m, 3H), 1.29 – 1.16 (m, 6H), 0.89 – 0.80 (m, 9H). $^{19}\text{F NMR}$ (376 MHz, CDCl_3) δ -90.31 (d, $J = 41.4$ Hz), δ -90.42 (d, $J = 41.4$ Hz). $^{13}\text{C NMR}$ (126 MHz, CDCl_3) δ 172.86, 154.45 (dd, $J = 290.2, 288.0$ Hz), 133.73, 128.74, 128.46 (t, $J = 3.0$ Hz), 127.64, 90.03 (dd, $J = 20.1, 15.7$ Hz), 48.37, 34.89, 34.52, 34.47, 33.29, 31.71, 27.88, 25.59, 22.61, 22.41, 22.37, 14.08. **HRMS** calcd. for $(\text{C}_{21}\text{H}_{32}\text{F}_2\text{NO})$


[M+H]⁺: 352.2446, found 352.2432. **IR (neat)**: 3283, 2956, 2859, 1728, 1639, 1546, 1234, 695.



(1S,2R,5S)-2-isopropyl-5-methylcyclohexyl 9,9-difluoro-8-phenyl-6-propionamidononanoate (3ac) Following General Procedure A and using 1,4-dioxane/DCM (3/1) as solvent, (1S,2R,5S)-2-isopropyl-5-methylcyclohexyl 6-propionamidohexanoate (**1ac**) (147.0 mg, 0.40 mmol) and (3,3,3-trifluoroprop-1-en-2-yl)benzene (**2a**) (34.4 mg, 0.20 mmol) were used, affording the mixture of diastereomers (dr = 1:1) as a colorless oil (55.1 mg, 53% yield) by using Hexane/EtOAc (3:1) as eluent. **¹H NMR** (400 MHz, CDCl₃) δ 7.39 – 7.30 (m, 4H), 7.30 – 7.21 (m, 1H), 5.03 (d, *J* = 8.9 Hz, 1H), 4.66 (dt, *J* = 10.9, 5.5 Hz, 1H), 3.96 (q, *J* = 7.1 Hz, 1H), 2.60 – 2.49 (m, 2H), 2.22 (t, *J* = 7.5 Hz, 2H), 2.00 – 1.89 (m, 3H), 1.87 – 1.78 (m, 1H), 1.72 – 1.60 (m, 2H), 1.58 – 1.44 (m, 6H), 1.37 – 1.20 (m, 9H), 1.09 – 0.98 (m, 1H), 0.94 – 0.82 (m, 10H), 0.77 – 0.69 (m, 3H). **¹⁹F NMR** (376 MHz, CDCl₃) δ -90.51 (d, *J* = 41.5 Hz) (*diastereomer 1*), -90.52 (d, *J* = 41.7 Hz) (*diastereomer 2*), -90.73 (d, *J* = 41.5 Hz) (*diastereomer 1*), -90.74 (d, *J* = 41.7 Hz) (*diastereomer 2*). **¹³C NMR** (126 MHz, CDCl₃) δ 173.20, 172.67, 154.44 (dd, *J* = 291.1, 286.9 Hz), 133.57 (t, *J* = 3.2 Hz), 128.73, 128.43 (t, *J* = 3.1 Hz), 127.65, 89.96 (dd, *J* = 20.9, 14.9 Hz), 74.13, 48.19, 47.12, 41.07, 36.85, 34.50, 34.37, 34.13, 33.30, 31.53, 31.49, 29.80, 26.40, 25.45, 25.33, 24.93, 23.56, 22.47, 22.12, 20.84, 16.43, 14.02. **HRMS** calcd. for (C₃₁H₄₈F₂NO₃) [M+H]⁺: 520.3597, found 520.3592. **IR (neat)**: 3284, 2928, 2867, 1729, 1642, 1543, 1223, 697.




(3S,5S,8R,9S,10S,13R,14S,17R)-10,13-dimethyl-17-((R)-6-methylheptan-2-yl)hexadecahydro-1H-cyclopenta[a]phenanthren-3-yl 9,9-difluoro-8-phenyl-6-propionamidonon-8-enoate (3ad) Following General Procedure A, (3S,5S,8R,9S,10S,13R,14S,17R)-10,13-dimethyl-17-((R)-6-methylheptan-2-yl)hexadecahydro-1H-cyclopenta[a]phenanthren-3-yl 6-propionamidohexanoate (**1ad**) (240.0 mg, 0.40 mmol) and (3,3,3-trifluoroprop-1-en-2-yl)benzene (**2a**) (34.4 mg, 0.20 mmol) were used, affording the mixture of diastereomers (dr = 1:1) as a colorless oil (77.5 mg, 52% yield) by using Hexane/EtOAc (3:1) as eluent. ¹H NMR (400 MHz, CDCl₃) δ 7.40 – 7.22 (m, 5H), 5.04 (d, *J* = 8.8 Hz, 1H), 4.85 – 4.45 (m, 1H), 4.23 – 3.73 (m, 1H), 2.60 – 2.45 (m, 2H), 2.20 (t, *J* = 7.3 Hz, 2H), 2.00 – 1.85 (m, 3H), 1.84 – 1.62 (m, 5H), 1.60 – 1.44 (m, 9H), 1.40 – 1.18 (m, 16H), 1.18 – 0.94 (m, 12H), 0.93 – 0.82 (m, 12H), 0.81 (s, 3H), 0.64 (s, 3H). ¹⁹F NMR (376 MHz, CDCl₃) δ -90.10 (d, *J* = 41.5 Hz), -90.30 (d, *J* = 41.5 Hz). ¹³C NMR (126 MHz, CDCl₃) δ 173.25, 172.81, 154.47 (dd, *J* = 291.1, 286.9 Hz), 133.56, 128.75, 128.44 (t, *J* = 3.0 Hz), 127.67, 89.95 (dd, *J* = 20.9, 14.9 Hz), 73.76, 56.54 (*diastereomer 1*), 56.39 (*diastereomer 2*), 54.35, 48.22, 44.79, 42.71, 40.11, 39.64, 36.87, 36.29, 35.92, 35.59, 34.54, 34.18, 34.13, 33.32, 32.11, 31.54, 28.74, 28.36, 28.13, 27.63, 25.44, 25.35, 24.86, 24.33, 23.96, 22.94, 22.68, 22.49, 21.32, 18.79, 14.06, 12.35, 12.19. **HRMS** calcd. for (C₄₈H₇₅F₂NNaO₃) [M+Na]⁺: 774.5607, found 774.5588 **IR (neat)**: 2930, 2866, 1730, 1449, 1379, 1173, 700.




N-(1,1-difluoro-2-(4-(trifluoromethyl)phenyl)non-1-en-4-yl)benzamide (3ae) Following General Procedure A, N-hexylbenzamide (**1a**) (82.1 mg, 0.40 mmol) and 1-(trifluoromethyl)-4-(3,3,3-trifluoroprop-1-en-2-yl)benzene (48.0 mg, 0.20 mmol) were used, affording the title compound as a white solid (82.0 mg, 96% yield) by using


Hexane/EtOAc (10:1) as eluent. M.P.: 83-84 °C. $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.58 (d, $J = 8.2$ Hz, 2H), 7.53 – 7.42 (m, 5H), 7.36 (t, $J = 7.6$ Hz, 2H), 5.61 (d, $J = 8.8$ Hz, 1H), 4.31 – 4.02 (m, 1H), 2.76 – 2.68 (m, 2H), 1.67 – 1.54 (m, 1H), 1.54 – 1.41 (m, 1H), 1.38 – 1.18 (m, 6H), 0.88 – 0.80 (m, 3H). $^{19}\text{F NMR}$ (376 MHz, CDCl_3) δ -62.80, -88.54 (d, $J = 37.2$ Hz), -88.78 (d, $J = 37.1$ Hz). $^{13}\text{C NMR}$ (126 MHz, CDCl_3) δ 167.15, 154.62 (dd, $J = 290.2, 288.0$ Hz), 137.31, 134.56, 131.61, 129.72 (d, $J = 32.3$ Hz), 128.84 (t, $J = 3.2$ Hz), 128.66, 126.64, 125.76 (q, $J = 3.7$ Hz), 124.08 (q, $J = 272.2$ Hz), 89.62 (dd, $J = 19.7, 16.3$ Hz), 49.04 (t, $J = 2.8$ Hz), 34.61, 33.31, 31.72, 25.71, 22.60, 14.08. **HRMS** calcd. for $(\text{C}_{23}\text{H}_{25}\text{F}_5\text{NO})$ $[\text{M}+\text{H}]^+$: 426.1851, found 426.1833. **IR (neat)**: 3294, 2928, 2857, 1721, 1634, 1547, 1324, 696.



N-(1,1-difluoro-2-(4-methoxyphenyl)non-1-en-4-yl)benzamide (3af) Following General Procedure A and using 2x catalyst loading, N-hexylbenzamide (**1a**) (82.1 mg, 0.40 mmol) and 1-methoxy-4-(3,3,3-trifluoroprop-1-en-2-yl)benzene (40.4 mg, 0.20 mmol) were used, affording the title compound as an amorphous white solid (41.0 mg, 53% yield) by using Hexane/EtOAc (6:1) as eluent. M.P.: 96-97 °C. $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.52 – 7.43 (m, 3H), 7.35 (t, $J = 7.5$ Hz, 2H), 7.28 (d, $J = 8.2$ Hz, 2H), 6.87 (d, $J = 8.7$ Hz, 2H), 5.65 (d, $J = 8.9$ Hz, 1H), 4.28 – 4.07 (m, 1H), 3.77 (s, 3H), 2.73 – 2.59 (m, 2H), 1.66 – 1.53 (m, 1H), 1.54 – 1.39 (m, 1H), 1.38 – 1.18 (m, 6H), 0.88 – 0.83 (m, 3H). $^{19}\text{F NMR}$ (376 MHz, CDCl_3) δ -91.32 (d, $J = 43.9$ Hz), -91.56 (d, $J = 43.8$ Hz). $^{13}\text{C NMR}$ (126 MHz, CDCl_3) δ 166.93, 159.05, 154.39 (dd, $J = 290.2, 288.0$ Hz), 134.77, 131.41, 129.65 (t, $J = 3.1$ Hz), 128.54, 126.80, 125.77, 114.36, 89.40 (dd, $J = 22.0, 15.3$ Hz), 55.39, 49.04 (t, $J = 2.8$ Hz), 34.53, 33.31, 31.78, 25.70, 22.63, 14.12. **HRMS** calcd. for $(\text{C}_{23}\text{H}_{28}\text{F}_2\text{NO}_2)$ $[\text{M}+\text{H}]^+$: 388.2083, found 388.2065. **IR (neat)**: 3331, 2928, 2857, 1735, 1631, 1513, 1223, 696.




N-(1,1-difluoro-2-(2-fluorophenyl)non-1-en-4-yl)benzamide (3ag) Following General Procedure A, N-hexylbenzamide (1a) (82.1 mg, 0.40 mmol) and 1-fluoro-2-(3,3,3-trifluoroprop-1-en-2-yl)benzene (38.0 mg, 0.20 mmol) were used, affording the title compound as an amorphous white solid (71.0 mg, 94% yield) by using Hexane/EtOAc (10:1) as eluent. M.P.: 79-80 °C. ¹H NMR (400 MHz, CDCl₃) δ 7.54 (d, *J* = 7.6 Hz, 2H), 7.46 (t, *J* = 7.3 Hz, 1H), 7.37 (t, *J* = 7.5 Hz, 2H), 7.32 – 7.20 (m, 2H), 7.10 (t, *J* = 7.5 Hz, 1H), 7.04 (dd, *J* = 10.2, 8.2 Hz, 1H), 5.74 (d, *J* = 8.8 Hz, 1H), 4.25 – 3.98 (m, 1H), 2.79 – 2.57 (m, 2H), 1.64 – 1.52 (m, 1H), 1.55 – 1.41 (m, 1H), 1.36 – 1.16 (m, 6H), 0.87 – 0.81 (m, 3H). ¹⁹F NMR (376 MHz, CDCl₃) δ -86.43 (dd, *J* = 36.5, 11.8 Hz), -90.12 (dd, *J* = 36.4, 1.9 Hz), -113.67 (dd, *J* = 11.9, 1.9 Hz). ¹³C NMR (126 MHz, CDCl₃) δ 167.02, 160.05 (d, *J* = 247.9 Hz), 154.26 (dd, *J* = 290.8, 288.2 Hz), 134.78, 131.42, 131.21, 129.85 (d, *J* = 8.3 Hz), 128.57, 126.78, 124.56 (d, *J* = 3.5 Hz), 121.36 (d, *J* = 10.1 Hz), 116.03 (d, *J* = 22.1 Hz), 84.50 (dd, *J* = 24.8, 17.1 Hz), 48.89 (t, *J* = 2.8 Hz), 34.56, 33.16, 31.72, 25.69, 22.59, 14.09. HRMS calcd. for (C₂₂H₂₅F₃NO) [M+H]⁺: 376.1883, found 376.1886. IR (neat): 3307, 2933, 2855, 1741, 1636, 1541, 1251, 693.




N-(2-(3,5-dichlorophenyl)-1,1-difluoronon-1-en-4-yl)benzamide (3ah) Following General Procedure A, N-hexylbenzamide (1a) (82.1 mg, 0.40 mmol) and 1,3-dichloro-5-(3,3,3-trifluoroprop-1-en-2-yl)benzene (48.2 mg, 0.20 mmol) were used, affording the title compound as an amorphous white solid (58.1 mg, 68% yield) by using Hexane/EtOAc (10:1) as eluent. M.P.: 89-90 °C. ¹H NMR (400 MHz, CDCl₃) δ 7.59 – 7.53 (m, 2H), 7.52 – 7.44 (m, 1H), 7.39 (t, *J* = 7.5 Hz, 2H), 7.26 – 7.21 (m, 2H), 7.19 (t, *J* = 1.8 Hz, 1H), 5.66 (d, *J* = 8.8 Hz, 1H), 4.27 – 4.09 (m, 1H), 2.73 – 2.55 (m, 2H), 1.66 – 1.55 (m, 1H), 1.54 – 1.44 (m, 1H), 1.38 – 1.23 (m, 6H), 0.93 – 0.81 (m, 3H). ¹⁹F NMR (376 MHz, CDCl₃) δ -87.15 (d, *J* = 35.4 Hz), -87.45 (d, *J* = 35.5 Hz). ¹³C NMR (126 MHz, CDCl₃) δ 167.16, 154.78 (dd, *J* = 290.2, 288.0 Hz), 136.87, 135.35, 134.49 (d, *J* = 2.5 Hz), 131.61, 128.66, 127.75, 126.92 (t, *J* = 3.3 Hz), 126.74, 88.89 (dd, *J* = 23.3, 13.8 Hz), 49.00 (t, *J* = 2.8 Hz), 34.72, 33.35, 31.72, 25.72, 22.63, 14.10. HRMS calcd. for

(C₂₂H₂₄Cl₂F₂NO) [M+H]⁺: 426.1198, found 426.1185. **IR (neat)**: 3291, 2928, 2855, 1736, 1634, 1536, 1246, 692.




N-(1,1-difluoro-2-(3-methoxyphenyl)non-1-en-4-yl)benzamide (3ai) Following General Procedure A, N-hexylbenzamide (**1a**) (82.1 mg, 0.40 mmol) and 1-methoxy-3-(3,3,3-trifluoroprop-1-en-2-yl)benzene (40.4 mg, 0.20 mmol) were used, affording the title compound as a white solid (49.4 mg, 64% yield) by using Hexane/EtOAc (6:1) as eluent. M.P.: 81-82 °C. ¹H NMR (400 MHz, CDCl₃) δ 7.49 – 7.40 (m, 3H), 7.38 – 7.31 (m, 2H), 7.25 (t, *J* = 8.0 Hz, 1H), 6.98 – 6.90 (m, 1H), 6.91 – 6.85 (m, 1H), 6.83 – 6.75 (m, 1H), 5.67 (d, *J* = 8.9 Hz, 1H), 4.30 – 4.16 (m, 1H), 3.74 (s, 3H), 2.76 – 2.61 (m, 2H), 1.65 – 1.53 (m, 1H), 1.53 – 1.43 (m, 1H), 1.39 – 1.19 (m, 6H), 0.89 – 0.81 (m, 3H). ¹⁹F NMR (376 MHz, CDCl₃) δ -89.73 (d, *J* = 40.6 Hz), -90.32 (d, *J* = 40.3 Hz). ¹³C NMR (126 MHz, CDCl₃) δ 166.93, 159.92, 154.50 (dd, *J* = 291.7, 286.9 Hz), 135.19 (dd, *J* = 4.5, 2.9 Hz), 134.75, 131.37, 129.88, 128.51, 126.77, 120.83 (t, *J* = 3.0 Hz), 114.30 (t, *J* = 3.1 Hz), 113.21, 89.95 (dd, *J* = 21.6, 14.6 Hz), 55.35, 49.16 (t, *J* = 2.8 Hz), 34.58, 33.23 (d, *J* = 1.5 Hz), 31.78, 25.70, 22.62, 14.11. **HRMS** calcd. for (C₂₃H₂₇F₂NNaO₂) [M+Na]⁺: 410.1902, found 410.1906. **IR (neat)**: 3298, 2930, 2858, 1728, 1634, 1537, 1246, 693.




N-(1,1-difluoro-2-(naphthalen-2-yl)non-1-en-4-yl)benzamide (3aj) Following General Procedure A, 2-(3,3,3-trifluoroprop-1-en-2-yl)naphthalene (82.1 mg, 0.40 mmol) and 2-(3,3,3-trifluoroprop-1-en-2-yl)naphthalene (44.4 mg, 0.20 mmol) were used, affording the title compound as an oil (76.5 mg, 94% yield) by using Hexane/EtOAc (10:1) as eluent. ¹H NMR (400 MHz, CDCl₃) δ 7.92 – 7.73 (m, 5H), 7.57 – 7.40 (m, 3H), 7.34 (t, *J* = 7.3 Hz, 1H), 7.27 (d, *J* = 7.0 Hz, 1H), 7.15 (t, *J* = 7.6 Hz, 2H), 5.63 (d, *J* = 8.8 Hz, 1H), 4.35 – 4.19 (m, 1H), 2.87 – 2.75 (m, 2H), 1.68 – 1.57 (m, 1H), 1.57 – 1.44 (m, 1H), 1.38 – 1.19 (m, 6H), 0.88 – 0.81 (m, 3H). ¹⁹F NMR (376 MHz, CDCl₃) δ -89.50 (d, *J* = 40.1 Hz), -89.71 (d, *J* = 40.1 Hz). ¹³C NMR (126 MHz, CDCl₃) δ 166.98, 154.72 (dd,

$J = 290.2, 288.0$ Hz), 134.52, 133.49, 132.69, 131.34, 131.29, 128.68, 128.38, 128.11, 127.71, 127.63 (t, $J = 3.0$ Hz), 126.62, 126.55, 126.42, 126.16 (t, $J = 2.9$ Hz), 90.05 (dd, $J = 21.2, 14.9$ Hz), 49.27 (t, $J = 2.8$ Hz), 34.56, 33.25, 31.77, 25.73, 22.62, 14.10. **HRMS** calcd. for (C₂₆H₂₈F₂NO) [M+H]⁺: 408.2133, found 408.2121. **IR (neat)**: 3298, 2928, 2858, 1726, 1635, 1537, 1228, 695.




N-(1,1-difluoro-2-(pyrimidin-5-yl)non-1-en-4-yl)benzamide (3ak) Following General Procedure A, N-hexylbenzamide (**1a**) (82.1 mg, 0.40 mmol) and N-(1,1-difluoro-2-(pyrimidin-5-yl)non-1-en-4-yl)benzamide (34.8 mg, 0.20 mmol) were used, affording the title compound as an amorphous white solid (53.2 mg, 74% yield) by using Hexane/EtOAc (5:1) as eluent. M.P.: 89-90 °C. **¹H NMR** (400 MHz, CDCl₃) δ 9.06 (s, 1H), 8.77 (s, 2H), 7.61 (d, $J = 7.2$ Hz, 2H), 7.48 (t, $J = 7.2$ Hz, 1H), 7.39 (t, $J = 7.2$ Hz, 2H), 5.88 (s, 1H), 4.29 – 3.95 (m, 1H), 2.85 – 2.51 (m, 2H), 1.69 – 1.45 (m, 2H), 1.41 – 1.17 (m, 6H), 0.89 – 0.80 (m, 3H). **¹⁹F NMR** (376 MHz, CDCl₃) δ -85.95 (d, $J = 33.6$ Hz), -86.84 (d, $J = 33.5$ Hz). **¹³C NMR** (126 MHz, CDCl₃) δ 167.39, 156.83 (d, $J = 115.0$ Hz), 155.07 (dd, $J = 290.2, 288.0$ Hz), 134.38, 131.72, 128.76, 128.10, 126.80, 85.30 (dd, $J = 24.5, 14.2$ Hz), 48.73 (t, $J = 2.8$ Hz), 34.89, 33.26, 31.65, 25.80, 22.57, 14.05. **HRMS** calcd. for (C₂₀H₂₄F₂N₃O) [M+H]⁺: 360.1882, found 360.1867. **IR (neat)**: 3295, 3062, 2927, 2857, 1706, 1637, 1538, 1253, 691.




tert-butyl 2-(4-benzamido-1,1-difluoronon-1-en-2-yl)-1H-pyrrole-1-carboxylate (3al) Following General Procedure A, N-hexylbenzamide (**1a**) (82.1 mg, 0.40 mmol) and tert-butyl 2-(3,3,3-trifluoroprop-1-en-2-yl)-1H-pyrrole-1-carboxylate (52.2 mg, 0.20 mmol) were used, affording the title compound as an amorphous white solid (50.0 mg, 56% yield) by using Hexane/EtOAc (6:1) as eluent. M.P.: 90-91 °C. **¹H NMR** (400 MHz, CDCl₃) δ 7.74 – 7.64 (m, 2H), 7.51 – 7.43 (m, 1H), 7.42 – 7.35 (m, 2H), 7.19 (dd, $J =$

3.4, 1.7 Hz, 1H), 6.32 (d, $J = 9.0$ Hz, 1H), 6.22 (dd, $J = 3.4, 1.7$ Hz, 1H), 6.15 (t, $J = 3.4$ Hz, 1H), 4.42 – 4.14 (m, 1H), 2.72 – 2.62 (m, 1H), 2.55 – 2.44 (m, 1H), 1.56 (s, 9H), 1.50 – 1.42 (m, 2H), 1.36 – 1.19 (m, 6H), 0.88 – 0.82 (m, 3H). **^{19}F NMR** (376 MHz, CDCl_3) δ -86.34 (d, $J = 35.6$ Hz), -90.66 (d, $J = 35.9$ Hz). **^{13}C NMR** (126 MHz, CDCl_3) δ 164.72, 164.60, 164.16 (dd, $J = 290.2, 288.0$ Hz), 133.96, 127.27, 126.34, 125.62, 108.60, 107.68, 100.90, 99.46, 85.83 (dd, $J = 19.7, 16.3$ Hz), 53.32, 53.14, 52.17, 30.35, 18.72, 18.68, 11.39, 11.33. **HRMS** calcd. for $(\text{C}_{25}\text{H}_{32}\text{F}_2\text{N}_2\text{NaO}_3)$ $[\text{M}+\text{Na}]^+$: 469.2273, found 469.2260. **IR (neat)**: 3343, 2970, 2929, 2857, 1739, 1637, 1370, 1146, 712.



N-(2-(dibenzo[b,d]thiophen-4-yl)-1,1-difluoronon-1-en-4-yl)benzamide (3am)


Following General Procedure A, N-hexylbenzamide (1a) (82.1 mg, 0.40 mmol) and N-(2-(dibenzo[b,d]thiophen-4-yl)-1,1-difluoronon-1-en-4-yl)benzamide (55.7 mg, 0.20 mmol) were used, affording the title compound as an oil (84.0 mg, 91% yield) by using Hexane/EtOAc (10:1) as eluent. **^1H NMR** (400 MHz, CDCl_3) δ 8.13 – 8.06 (m, 1H), 7.96 (dd, $J = 6.7, 2.1$ Hz, 1H), 7.90 – 7.81 (m, 1H), 7.51 – 7.44 (m, 2H), 7.42 – 7.36 (m, 2H), 7.28 (t, $J = 7.2$ Hz, 1H), 7.18 (d, $J = 7.6$ Hz, 2H), 7.07 (t, $J = 7.4$ Hz, 2H), 5.76 (d, $J = 8.7$ Hz, 1H), 4.33 – 4.18 (m, 1H), 3.04 – 2.88 (m, 1H), 2.87 – 2.73 (m, 1H), 1.72 – 1.55 (m, 2H), 1.39 – 1.22 (m, 6H), 0.92 – 0.81 (m, 3H). **^{19}F NMR** (376 MHz, CDCl_3) δ -84.11 (d, $J = 34.6$ Hz), -89.08 (d, $J = 34.5$ Hz). **^{13}C NMR** (126 MHz, CDCl_3) δ 166.81, 154.17 (dd, $J = 290.2, 288.0$ Hz), 139.07, 138.89, 136.27, 135.97, 134.16, 131.15, 129.10 (d, $J = 4.5$ Hz), 128.16, 127.83 (d, $J = 3.1$ Hz), 127.16, 126.45, 125.31, 124.75, 122.89, 121.93, 121.10, 88.78 (dd, $J = 23.1, 16.9$ Hz), 49.40 (t, $J = 2.7$ Hz), 34.36, 32.86, 31.74, 25.85, 22.60, 14.09. **HRMS** calcd. for $(\text{C}_{28}\text{H}_{28}\text{F}_2\text{NOS})$ $[\text{M}+\text{H}]^+$: 464.1854, found 464.1838. **IR (neat)**: 3307, 2928, 2857, 1729, 1635, 1537, 1246, 694.




N-(4-ethyl-7,7-difluoro-6-phenylhept-6-en-1-yl)-2,2,2-trifluoroacetamide (6a)

Following General Procedure B, 2,2,2-trifluoro-N-hexylacetamide (5a) (77.08 mg, 0.40 mmol) and (3,3,3-trifluoroprop-1-en-2-yl)benzene (2a) (34.4 mg, 0.20 mmol) were used,

affording the title compound as a colorless oil (54.6 mg, 78% yield) by using Hexane/EtOAc (20:1) as eluent. $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.38 – 7.33 (m, 2H), 7.31 – 7.24 (m, 3H), 6.29 (s, 1H), 3.44 – 3.13 (m, 2H), 2.45 – 2.34 (m, 1H), 2.34 – 2.26 (m, 1H), 1.55 – 1.42 (m, 2H), 1.35 – 1.23 (m, 5H), 0.82 (t, $J = 7.2$ Hz, 3H). $^{19}\text{F NMR}$ (376 MHz, CDCl_3) δ -75.69, -91.09 (d, $J = 44.2$ Hz), -91.27 (d, $J = 44.3$ Hz). $^{13}\text{C NMR}$ (126 MHz, CDCl_3) δ 157.29 (q, $J = 36.8$ Hz), 154.06 (dd, $J = 289.9, 286.5$ Hz), 133.78 (dd, $J = 3.7, 2.1$ Hz), 128.63, 128.37 (t, $J = 3.0$ Hz), 127.49, 115.99 (q, $J = 287.8$ Hz), 91.43 (dd, $J = 20.7, 14.1$ Hz), 40.32, 36.70 (t, $J = 2.3$ Hz), 31.54, 29.32, 25.81, 25.35, 10.53. **HRMS** calcd. for ($\text{C}_{17}\text{H}_{20}\text{F}_5\text{NNaO}$) $[\text{M}+\text{Na}]^+$: 372.1357, found 372.1346. **IR (neat)**: 3308, 2969, 1702, 1558, 1367, 1161, 697.




N-(7,7-difluoro-4-(2-hydroxyethyl)-6-phenylhept-6-en-1-yl)-2,2,2-trifluoroacetamide (6b) Following General Procedure B and using toluene/1,4-dioxane (4/1) as solvent, 2,2,2-trifluoro-N-(6-hydroxyhexyl)acetamide (**5b**) (85.3 mg, 0.40 mmol) and (3,3,3-trifluoroprop-1-en-2-yl)benzene (**2a**) (34.4 mg, 0.20 mmol) were used, affording the title compound as a colorless oil (61.0 mg, 83% yield) by using Hexane/EtOAc (3:1) as eluent. $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.39 – 7.33 (m, 2H), 7.31 – 7.25 (m, 3H), 6.61 (s, 1H), 3.67 – 3.58 (m, 2H), 3.30 – 3.19 (m, 2H), 2.43 – 2.34 (m, 2H), 1.56 – 1.44 (m, 5H), 1.36 – 1.28 (m, 2H). $^{19}\text{F NMR}$ (376 MHz, CDCl_3) δ -75.91, -90.99 (d, $J = 43.8$ Hz), -91.18 (d, $J = 42.9$ Hz). $^{13}\text{C NMR}$ (126 MHz, CDCl_3) δ 157.40 (q, $J = 36.7$ Hz), 154.12 (dd, $J = 290.6, 286.5$ Hz), 133.56 (dd, $J = 4.1, 2.4$ Hz), 128.72, 128.34 (t, $J = 3.0$ Hz), 127.62, 115.99 (q, $J = 288.0$ Hz), 91.19 (dd, $J = 21.1, 13.8$ Hz), 60.72, 40.04, 35.76, 32.48, 32.20, 29.86, 25.37. **HRMS** calcd. for ($\text{C}_{17}\text{H}_{20}\text{F}_5\text{NNaO}_2$) $[\text{M}+\text{Na}]^+$: 388.1306, found 388.1290. **IR (neat)**: 3301, 2942, 1704, 1560, 1367, 1153, 699.




6,6-difluoro-5-phenyl-3-(3-(2,2,2-trifluoroacetamido)propyl)hex-5-en-1-yl 4-methylbenzenesulfonate (6c) Following General Procedure B, 6-(2,2,2-


trifluoroacetamido)hexyl 4-methylbenzenesulfonate (**5c**) (147.0 mg, 0.40 mmol) and (3,3,3-trifluoroprop-1-en-2-yl)benzene (**2a**) (34.4 mg, 0.20 mmol) were used, affording the title compound as a colorless oil (54.6 mg, 53% yield) by using Hexane/EtOAc (3:1) as eluent. $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.73 – 7.69 (m, 2H), 7.39 – 7.31 (m, 4H), 7.30 – 7.26 (m, 1H), 7.25 – 7.20 (m, 2H), 6.51 (s, 1H), 3.99 (t, $J = 6.3$ Hz, 2H), 3.28 – 3.11 (m, 2H), 2.45 (s, 3H), 2.39 – 2.28 (m, 2H), 1.70 – 1.60 (m, 1H), 1.59 – 1.41 (m, 4H), 1.28 – 1.19 (m, 2H). $^{19}\text{F NMR}$ (376 MHz, CDCl_3) δ -75.87, -90.63 (d, $J = 42.7$ Hz), -90.90 (d, $J = 42.4$ Hz). $^{13}\text{C NMR}$ (126 MHz, CDCl_3) δ 157.39 (q, $J = 36.8$ Hz), 154.09 (dd, $J = 291.0, 286.7$ Hz), 145.10, 133.17 (d, $J = 3.1$ Hz), 132.99, 130.03, 128.78, 128.31 (t, $J = 3.0$ Hz), 127.91, 127.73, 115.97 (q, $J = 287.9$ Hz), 90.79 (dd, $J = 21.2, 13.9$ Hz), 68.44, 32.37, 32.13, 31.73, 29.64, 25.49, 21.73. **HRMS** calcd. for $(\text{C}_{24}\text{H}_{26}\text{F}_2\text{NNaO}_4\text{S})$ $[\text{M}+\text{Na}]^+$: 542.1395, found 542.1376. **IR (neat)**: 3346, 2944, 1722, 1556, 1356, 1171, 694.



N-(7,7-difluoro-6-phenyl-4-(2-(phenylsulfonyl)ethyl)hept-6-en-1-yl)-2,2,2-trifluoroacetamide (6d) Following General Procedure B, 2,2,2-trifluoro-N-(6-(phenylsulfonyl)hexyl)acetamide (**5d**) (134.94 mg, 0.40 mmol) and (3,3,3-trifluoroprop-1-en-2-yl)benzene (**2a**) (34.4 mg, 0.20 mmol) were used, affording the title compound as a colorless oil (61.0 mg, 62% yield) by using Hexane/EtOAc (3:1) as eluent. $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.88 – 7.80 (m, 2H), 7.75 – 7.66 (m, 1H), 7.64 – 7.55 (m, 2H), 7.37 – 7.30 (m, 2H), 7.29 – 7.26 (m, 1H), 7.19 – 7.11 (m, 2H), 6.44 (s, 1H), 3.29 – 3.17 (m, 2H), 3.03 – 2.92 (m, 2H), 2.41 – 2.33 (m, 1H), 2.30 – 2.21 (m, 1H), 1.75 – 1.65 (m, 1H), 1.66 – 1.58 (m, 1H), 1.54 – 1.42 (m, 3H), 1.28 – 1.21 (m, 2H). $^{19}\text{F NMR}$ (376 MHz, CDCl_3) δ -75.86, -90.40 (d, $J = 42.5$ Hz), -90.64 (d, $J = 42.3$ Hz). $^{13}\text{C NMR}$ (126 MHz, CDCl_3) δ $^{13}\text{C NMR}$ (126 MHz, Chloroform-*d*) δ 157.38 (q, $J = 37.0$ Hz), 154.02 (dd, $J = 291.5, 286.7$ Hz), 138.96, 133.97, 132.96 (d, $J = 3.7$ Hz), 129.51, 128.84, 128.24 (t, $J = 2.9$ Hz), 128.14, 127.83, 115.95 (q, $J = 287.8$ Hz), 90.58 (dd, $J = 21.2, 14.2$ Hz), 53.29, 39.81, 34.30 (t, $J = 2.6$ Hz), 31.54, 29.43, 25.63, 25.39. **HRMS** calcd. for $(\text{C}_{23}\text{H}_{24}\text{F}_5\text{NNaO}_3\text{S})$ $[\text{M}+\text{Na}]^+$: 512.1295, found 512.1282. **IR (neat)**: 3325, 2940, 1718, 1558, 1447, 1304, 1141, 689.




N-(4-(2-(1,3-dioxoisindolin-2-yl)ethyl)-7,7-difluoro-6-phenylhept-6-en-1-yl)-2,2,2-trifluoroacetamide (6e) Following General Procedure B, N-(6-(1,3-dioxoisindolin-2-yl)hexyl)-2,2,2-trifluoroacetamide (**5e**) (136.9 mg, 0.40 mmol) and (3,3,3-trifluoroprop-1-en-2-yl)benzene (**2a**) (34.4 mg, 0.20 mmol) were used, affording the title compound as a colorless oil (56.0 mg, 57% yield) by using Hexane/EtOAc (3:1) as eluent. $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.80 – 7.75 (m, 2H), 7.76 – 7.69 (m, 2H), 7.15 – 7.09 (m, 2H), 7.10 – 7.03 (m, 2H), 7.01 – 6.93 (m, 2H), 3.62 (dd, $J = 8.0, 5.5$ Hz, 2H), 3.40 (dt, $J = 12.3, 6.2$ Hz, 1H), 3.14 (dt, $J = 13.1, 6.4$ Hz, 1H), 2.51 – 2.42 (m, 1H), 2.32 – 2.23 (m, 1H), 1.81 – 1.72 (m, 1H), 1.72 – 1.66 (m, 1H), 1.62 – 1.58 (m, 1H), 1.57 – 1.50 (m, 1H), 1.48 – 1.41 (m, 1H), 1.31 – 1.24 (m, 2H). $^{19}\text{F NMR}$ (376 MHz, CDCl_3) δ -75.85, -90.76 (d, $J = 43.1$ Hz), -91.29 (d, $J = 43.4$ Hz). $^{13}\text{C NMR}$ (126 MHz, CDCl_3) δ 168.60, 157.52 (d, $J = 36.6$ Hz), 154.13 (dd, $J = 290.2, 288.0$ Hz), 134.10, 133.01 (dd, $J = 4.5, 2.9$ Hz), 132.05, 128.47, 128.14 (t, $J = 2.9$ Hz), 127.28, 123.38, 116.08 (q, $J = 288.1$ Hz), 90.80 (dd, $J = 21.6, 13.9$ Hz), 39.30, 35.36, 31.95, 31.81 (t, $J = 2.3$ Hz), 31.40, 29.10, 25.19. **HRMS** calcd. for ($\text{C}_{25}\text{H}_{23}\text{F}_5\text{N}_2\text{NaO}_3$) $[\text{M}+\text{Na}]^+$: 517.1521, found 517.1525. **IR (neat)**: 3334, 2943, 1703, 1397, 1372, 1153, 719, 696.




N-(7,7-difluoro-4,6-diphenylhept-6-en-1-yl)-2,2,2-trifluoroacetamide (6f) Following General Procedure B, 2,2,2-trifluoro-N-(4-phenylbutyl)acetamide (**5f**) (98.0 mg, 0.40 mmol) and (3,3,3-trifluoroprop-1-en-2-yl)benzene (**2a**) (34.4 mg, 0.20 mmol) were used, affording the title compound as a colorless oil (45.3 mg, 57% yield) by using Hexane/EtOAc (15:1) as eluent. $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.39 – 7.32 (m, 2H), 7.31 – 7.25 (m, 3H), 7.24 – 7.15 (m, 2H), 7.08 – 7.00 (m, 3H), 6.05 (s, 1H), 3.30 – 3.08 (m, 2H), 2.73 – 2.65 (m, 2H), 2.56 – 2.46 (m, 1H), 1.76 – 1.65 (m, 1H), 1.64 – 1.57 (m, 1H), 1.41 – 1.28 (m, 2H). $^{19}\text{F NMR}$ (376 MHz, CDCl_3) δ -76.07, -91.05 (d, $J = 42.0$ Hz), -

91.69 (d, $J = 42.0$ Hz). ^{13}C NMR (126 MHz, CDCl_3) δ 157.19 (q, $J = 36.1$ Hz), 154.08 (dd, $J = 290.6, 286.5$ Hz), 143.39, 133.40 (d, $J = 4.3$ Hz), 128.67, 128.64, 128.48 (t, $J = 3.0$ Hz), 127.68, 127.55, 126.85, 115.92 (q, $J = 289.8$ Hz), 91.07 (dd, $J = 21.6, 13.9$ Hz), 43.48, 39.89, 35.15, 32.58, 27.06. **HRMS** calcd. for $(\text{C}_{21}\text{H}_{20}\text{F}_5\text{NNaO})$ $[\text{M}+\text{Na}]^+$: 420.1357, found 420.1343. **IR (neat)**: 3310, 3028, 2942, 1703, 1557, 1367, 1161, 697.



N-(4-benzyl-7,7-difluoro-6-phenylhept-6-en-1-yl)-2,2,2-trifluoroacetamide (6g)


Following General Procedure B, 2,2,2-trifluoro-N-(5-phenylpentyl)acetamide (**5g**) (103.7 mg, 0.40 mmol) and (3,3,3-trifluoroprop-1-en-2-yl)benzene (**2a**) (34.4 mg, 0.20 mmol) were used, affording the title compound as a colorless oil (51.1 mg, 62% yield) by using Hexane/EtOAc (15:1) as eluent. ^1H NMR (400 MHz, CDCl_3) δ 7.37 – 7.31 (m, 2H), 7.30 – 7.22 (m, 3H), 7.22 – 7.15 (m, 3H), 7.04 – 6.97 (m, 2H), 6.06 (s, 1H), 3.34 – 3.02 (m, 2H), 2.59 (dd, $J = 13.7, 6.8$ Hz, 1H), 2.48 (dd, $J = 13.7, 7.8$ Hz, 1H), 2.38 (dt, $J = 7.2, 2.4$ Hz, 2H), 1.71 – 1.59 (m, 1H), 1.55 – 1.42 (m, 2H), 1.32 – 1.21 (m, 2H). ^{19}F NMR (376 MHz, CDCl_3) δ -76.04, -90.95 (d, $J = 43.2$ Hz), -91.12 (d, $J = 43.2$ Hz). ^{13}C NMR (126 MHz, CDCl_3) δ 157.05 (q, $J = 36.1$ Hz), 154.04 (dd, $J = 290.6, 286.5$ Hz), 140.39, 133.35, 129.11, 128.68, 128.50, 128.33 (t, $J = 3.1$ Hz), 127.58, 126.25, 117.36 (q, $J = 289.8$ Hz), 91.36 (dd, $J = 21.6, 13.9$ Hz), 40.14, 40.08, 37.53 (d, $J = 2.5$ Hz), 31.76, 29.65, 25.77. **HRMS** calcd. for $(\text{C}_{22}\text{H}_{22}\text{F}_5\text{NNaO})$ $[\text{M}+\text{Na}]^+$: 434.1514, found 434.1512. **IR (neat)**: 3306, 3027, 2927, 1702, 1557, 1367, 1160, 697.



N-(7,7-difluoro-4-isopropyl-6-phenylhept-6-en-1-yl)-2,2,2-trifluoroacetamide (6h)


Following General Procedure B, 2,2,2-trifluoro-N-(5-methylhexyl)acetamide (**5h**) (84.5 mg, 0.40 mmol) and (3,3,3-trifluoroprop-1-en-2-yl)benzene (**2a**) (34.4 mg, 0.20 mmol) were used, affording the title compound as a colorless oil (41.0 mg, 56% yield) by using Hexane/EtOAc (20:1) as eluent. ^1H NMR (400 MHz, CDCl_3) δ 7.39 – 7.31 (m, 2H), 7.30 – 7.24 (m, 3H), 6.27 (s, 1H), 3.31 – 3.16 (m, 2H), 2.49 – 2.38 (m, 1H), 2.30 – 2.19 (m, 1H), 1.77 – 1.64 (m, 1H), 1.54 – 1.42 (m, 2H), 1.33 – 1.14 (m, 3H), 0.84 (d, $J = 7.3$ Hz,

3H), 0.79 (d, $J = 13.6$ Hz, 3H). ^{19}F NMR (376 MHz, CDCl_3) δ -75.69, -90.92 (d, $J = 43.3$ Hz), -91.48 (dt, $J = 44.2, 2.8$ Hz). ^{13}C NMR (126 MHz, CDCl_3) δ 157.13 (q, $J = 36.8$ Hz), 153.86 (dd, $J = 290.3, 285.9$ Hz), 133.48 (d, $J = 7.4$ Hz), 128.51, 128.24 (t, $J = 3.0$ Hz), 127.37, 115.85 (q, $J = 288.0$ Hz), 91.54 (dd, $J = 21.5, 13.2$ Hz), 40.91 (t, $J = 2.3$ Hz), 40.16, 28.56, 28.43, 26.64, 26.55, 18.76, 18.68. HRMS calcd. for $(\text{C}_{18}\text{H}_{22}\text{F}_5\text{NNaO})$ $[\text{M}+\text{Na}]^+$: 386.1514, found 386.1501. IR (neat): 3309, 2957, 1703, 1558, 1369, 1208, 1168, 697.



N-(2-((4,4-difluoro-3-phenylbut-3-en-1-yl)oxy)ethyl)-2,2,2-trifluoroacetamide (6i)


Following General Procedure B and doubling the catalyst loading, 2,2,2-trifluoro-N-(2-methoxyethyl)acetamide (**5i**) (68.4 mg, 0.40 mmol) and (3,3,3-trifluoroprop-1-en-2-yl)benzene (**2a**) (34.4 mg, 0.20 mmol) were used, affording the title compound as a colorless oil (38.1 mg, 59% yield) by using Hexane/EtOAc (10:1) as eluent. ^1H NMR (400 MHz, CDCl_3) δ 7.40 – 7.34 (m, 2H), 7.33 – 7.27 (m, 3H), 6.54 (s, 1H), 3.52 – 3.44 (m, 6H), 2.73 – 2.63 (m, 2H). ^{19}F NMR (376 MHz, CDCl_3) δ -75.69, -89.82 (d, $J = 41.2$ Hz), -90.46 (d, $J = 41.2$ Hz). ^{13}C NMR (126 MHz, CDCl_3) δ 157.08 (q, $J = 36.7$ Hz), 151.37 (dd, $J = 290.6, 286.5$ Hz), 133.37, 128.70, 128.31 (t, $J = 3.3$ Hz), 127.68, 117.39 (q, $J = 288.1$ Hz), 89.70 (dd, $J = 21.6, 13.9$ Hz), 68.85, 68.26, 39.76, 28.40. HRMS calcd. for $(\text{C}_{14}\text{H}_{14}\text{F}_5\text{NNaO}_2)$ $[\text{M}+\text{Na}]^+$: 346.0837, found 346.0829. IR (neat): 3317, 2970, 1736, 1558, 1446, 1365, 1216.




N-((2S)-8,8-difluoro-5-methyl-7-phenyloct-7-en-2-yl)-2,2,2-trifluoroacetamide (6j)

Following General Procedure B, (S)-2,2,2-trifluoro-N-(hexan-2-yl)acetamide (**5j**) (78.9 mg, 0.40 mmol) and (3,3,3-trifluoroprop-1-en-2-yl)benzene (**2a**) (34.4 mg, 0.20 mmol) were used, affording the mixture of diastereomers (dr = 1:1) as a colorless oil (47.8 mg, 68% yield) by using Hexane/EtOAc (20:1) as eluent. ^1H NMR (400 MHz, CDCl_3) δ 7.36 – 7.30 (m, 2H), 7.29 – 7.22 (m, 3H), 5.96 (s, 1H), 4.06 – 3.59 (m, 1H), 2.40 – 2.29 (m, 1H), 2.28 – 2.17 (m, 1H), 1.50 – 1.36 (m, 3H), 1.35 – 1.27 (m, 1H), 1.17 – 1.07 (m,

4H), 0.90 – 0.80 (m, 3H). ¹⁹F NMR (376 MHz, CDCl₃) δ -76.09 (*diastereomer 1*), -76.10 (*diastereomer 2*), -91.43 (d, *J* = 43.5 Hz) (*diastereomer 1*), -91.47 (d, *J* = 42.8 Hz) (*diastereomer 2*), -91.70 (d, *J* = 43.7 Hz). ¹³C NMR (126 MHz, CDCl₃) δ 156.75 (q, *J* = 32.4 Hz), 154.19 (dd, *J* = 290.3, 285.9 Hz), 133.90, 128.63, 128.41 (t, *J* = 3.2 Hz), 127.47, 116.03 (q, *J* = 288.0 Hz), 91.46 (dd, *J* = 21.5, 13.2 Hz) (*diastereomer 1*), 91.29 (dd, *J* = 21.5, 13.2 Hz) (*diastereomer 2*), 46.87 (*diastereomer 1*), 46.82 (*diastereomer 2*), 34.94 (*diastereomer 1*), 34.82 (*diastereomer 2*), 33.75 (*diastereomer 1*), 33.60 (*diastereomer 2*), 32.39 (*diastereomer 1*), 32.36 (*diastereomer 2*), 31.17 (t, *J* = 2.4 Hz) (*diastereomer 1*), 31.12 (d, *J* = 2.5 Hz) (*diastereomer 2*), 20.50 (*diastereomer 1*), 20.29 (*diastereomer 2*), 19.14 (*diastereomer 1*), 19.12 (*diastereomer 2*). HRMS calcd. for (C₁₇H₂₀F₅NNaO) [M+Na]⁺: 372.1357, found 372.1352. IR (neat): 3298, 2935, 1698, 1557, 1372, 1185, 698.




N-(2-((1R,2R)-2-(3,3-difluoro-2-phenylallyl)cyclopentyl)ethyl)-2,2,2-trifluoroacetamide (6k) Following General Procedure A, N-(2-cyclopentylethyl)-2,2,2-trifluoroacetamide (**5k**) (83.7 mg, 0.40 mmol) and (3,3,3-trifluoroprop-1-en-2-yl)benzene (**2a**) (34.4 mg, 0.20 mmol) were used, affording the mixture of diastereomers (dr = 13:1) as a colorless oil as a colorless oil (45.0 mg, 62% yield) by using Hexane/EtOAc (20:1) as eluent. The major was interred to be a *trans* product according to a reported literature.² ¹H NMR (400 MHz, CDCl₃) δ 7.39 – 7.33 (m, 2H), 7.32 – 7.25 (m, 3H), 6.25 (s, 1H), 3.58 – 3.14 (m, 2H), 2.59 – 2.45 (m, 1H), 2.37 – 2.24 (m, 1H), 1.93 – 1.80 (m, 1H), 1.77 – 1.63 (m, 2H), 1.64 – 1.48 (m, 2H), 1.49 – 1.39 (m, 2H), 1.35 – 1.12 (m, 3H). ¹⁹F NMR (376 MHz, CDCl₃) δ -75.65 (*diastereomer 1, minor*), -75.67 (*diastereomer 2, major*), -91.30 (d, *J* = 44.1 Hz), -91.49 (d, *J* = 45.3 Hz) (*diastereomer 1, minor*), -91.58 (d, *J* = 44.1 Hz) (*diastereomer 2, major*), -91.86 (d, *J* = 45.3 Hz) (*diastereomer 1, minor*). ¹³C NMR (126 MHz, CDCl₃) δ 157.25 (q, *J* = 36.8 Hz), 154.07 (dd, *J* = 290.3, 286.2 Hz), 133.87 (d, *J* = 3.8 Hz), 128.63, 128.38 (t, *J* = 3.1 Hz), 127.47, 115.99 (q, *J* = 288.0 Hz), 91.94 (dd, *J* = 21.3, 13.2 Hz), 44.11 (t, *J* = 2.3 Hz), 42.90, 39.28, 34.26, 32.67, 32.05, 31.69, 23.65. HRMS calcd. for (C₁₈H₂₀F₅NNaO) [M+Na]⁺: 384.1357, found 384.1346. IR (neat): 3308, 2947, 2869, 1702, 1559, 1156, 697.




N-(8,8-difluoro-5,5-dimethyl-7-phenyloct-7-en-2-yl)-2,2,2-trifluoroacetamide (6l)

Following General Procedure B, 2,2,2-trifluoro-N-(5-methylhexan-2-yl)acetamide (**5l**) (84.5 mg, 0.40 mmol) and (3,3,3-trifluoroprop-1-en-2-yl)benzene (**2a**) (34.4 mg, 0.20 mmol) were used, affording the title compound as a colorless oil (69.0 mg, 95% yield) by using Hexane/EtOAc (20:1) as eluent. ¹H NMR (400 MHz, CDCl₃) δ 7.39 – 7.27 (m, 3H), 7.29 – 7.23 (m, 2H), 5.83 (s, 1H), 3.84 – 3.59 (m, 1H), 2.33 (dd, *J* = 2.8, 2.0 Hz, 2H), 1.36 – 1.25 (m, 2H), 1.10 – 1.06 (m, 2H), 1.04 (d, *J* = 6.6 Hz, 3H), 0.79 (s, 6H). ¹⁹F NMR (376 MHz, CDCl₃) δ -75.60, -89.27 (d, *J* = 40.7 Hz), -91.53 (d, *J* = 40.6 Hz). ¹³C NMR (126 MHz, CDCl₃) δ 156.54 (q, *J* = 36.6 Hz), 154.53 (dd, *J* = 290.3, 286.2 Hz), 135.55 (dd, *J* = 4.9, 2.5 Hz), 128.69 (t, *J* = 2.7 Hz), 128.51, 127.36, 115.99 (q, *J* = 288.2 Hz), 90.71 (dd, *J* = 21.4, 13.7 Hz), 47.12, 39.25, 37.83, 35.05 (d, *J* = 2.6 Hz), 30.79, 27.52, 27.44, 20.38. HRMS calcd. for (C₁₈H₂₂F₅NNaO) [M+Na]⁺: 386.1510, found 386.1514. IR (neat): 3300, 2969, 1722, 1698, 1557, 1368, 1159, 698.




N-(4-(3,3-difluoro-2-(p-tolyl)allyl)decyl)-2,2,2-trifluoroacetamide (6m) Following General Procedure B, N-decyl-2,2,2-trifluoroacetamide (101.3 mg, 0.40 mmol) and 1-methyl-4-(3,3,3-trifluoroprop-1-en-2-yl)benzene (37.2 mg, 0.20 mmol) were used, affording the title compound as a colorless oil (58.9 mg, 70% yield) by using Hexane/EtOAc (20:1) as eluent. ¹H NMR (400 MHz, CDCl₃) δ 7.25 – 7.10 (m, 4H), 6.39 (s, 1H), 3.42 – 3.08 (m, 2H), 2.46 – 2.16 (m, 5H), 1.63 – 1.44 (m, 2H), 1.35 – 1.15 (m, 13H), 0.88 (t, *J* = 7.0 Hz, 3H). ¹⁹F NMR (376 MHz, CDCl₃) δ -76.10, -91.91 (d, *J* = 45.4 Hz), -92.15 (d, *J* = 45.4 Hz). ¹³C NMR (126 MHz, CDCl₃) δ 157.30 (q, *J* = 36.8 Hz), 153.98 (dd, *J* = 289.6, 285.9 Hz), 137.23, 130.69 (dd, *J* = 4.1, 2.4 Hz), 129.32, 128.20 (t, *J* = 3.1 Hz), 116.00 (q, *J* = 287.9 Hz), 91.26 (dd, *J* = 21.0, 13.7 Hz), 40.34, 35.30 (t, *J* = 2.3 Hz), 32.98, 31.90 (d, *J* = 1.9 Hz), 29.86, 29.66, 26.30, 25.74, 22.74, 21.21, 14.16. HRMS calcd. for (C₂₂H₃₀F₅NNaO) [M+Na]⁺: 442.2140, found 442.2132. IR (neat): 3308, 2927, 2858, 1703, 1559, 1377, 1164.



N-(4-(3,3-difluoro-2-(4-methoxyphenyl)allyl)decyl)-2,2,2-trifluoroacetamide (6n)


Following General Procedure B, N-decyl-2,2,2-trifluoroacetamide (101.3 mg, 0.40 mmol) and 1-methoxy-4-(3,3,3-trifluoroprop-1-en-2-yl)benzene (40.4 mg, 0.20 mmol) were used, affording the title compound as a colorless oil (53.5 mg, 61% yield) by using Hexane/EtOAc (10:1) as eluent. $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.23 – 7.17 (m, 2H), 6.93 – 6.84 (m, 2H), 6.29 (s, 1H), 3.81 (s, 3H), 3.37 – 3.18 (m, 2H), 2.40 – 2.29 (m, 1H), 2.31 – 2.19 (m, 1H), 1.57 – 1.44 (m, 2H), 1.38 – 1.14 (m, 13H), 0.87 (t, $J = 6.9$ Hz, 3H). $^{19}\text{F NMR}$ (376 MHz, CDCl_3) δ -76.08, -92.37 (d, $J = 46.5$ Hz), -92.57 (d, $J = 46.6$ Hz). $^{13}\text{C NMR}$ (126 MHz, CDCl_3) δ 158.84, 157.29 (q, $J = 36.7$ Hz), 153.94 (dd, $J = 288.9, 285.7$ Hz), 129.45 (t, $J = 3.1$ Hz), 125.82 (dd, $J = 3.9, 2.2$ Hz), 116.00 (q, $J = 287.8$ Hz), 114.06, 90.90 (dd, $J = 20.9, 14.2$ Hz), 55.33, 40.34, 35.27 (t, $J = 2.3$ Hz), 32.97, 32.00, 31.89, 29.86, 29.66, 26.31, 25.77, 22.74, 14.17. **HRMS** calcd. for $(\text{C}_{22}\text{H}_{30}\text{F}_5\text{NNaO}_2)$ $[\text{M}+\text{Na}]^+$: 458.2089, found 458.2085. **IR (neat)**: 3309, 2928, 2857, 1725, 1611, 1514, 1208, 832.



N-(4-(3,3-difluoro-2-(4-(trifluoromethyl)phenyl)allyl)decyl)-2,2,2-


trifluoroacetamide (6o) Following General Procedure B, N-decyl-2,2,2-trifluoroacetamide (101.3 mg, 0.40 mmol) and 1-(trifluoromethyl)-4-(3,3,3-trifluoroprop-1-en-2-yl)benzene (48.0 mg, 0.20 mmol) were used, affording the title compound as a colorless oil (68.2 mg, 72% yield) by using Hexane/EtOAc (20:1) as eluent. $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.62 (d, $J = 7.9$ Hz, 2H), 7.41 (d, $J = 8.0$ Hz, 2H), 6.25 (s, 1H), 3.44 – 3.07 (m, 2H), 2.64 – 2.21 (m, 2H), 1.64 – 1.43 (m, 2H), 1.35 – 1.12 (m, 13H), 0.86 (t, $J = 6.8$ Hz, 3H). $^{19}\text{F NMR}$ (376 MHz, CDCl_3) δ -62.80, -76.08, -89.38 (d, $J = 39.6$ Hz), -89.65 (d, $J = 39.5$ Hz). $^{13}\text{C NMR}$ (126 MHz, CDCl_3) 157.13 (q, $J = 36.7$ Hz), 154.75 (dd, $J = 288.9, 285.7$ Hz), 137.27, 129.56 (d, $J = 14.9$ Hz), 128.70 (t, $J = 3.3$ Hz), 125.89 (q, $J = 287.9$ Hz), 125.61 (t, $J = 3.9$ Hz), 115.85 (q, $J = 317.3$ Hz), 90.90 (dd, $J = 20.9, 14.2$ Hz), 40.34, 35.48, 32.88, 31.87, 31.80, 29.97, 29.64, 26.25,

25.95, 22.73, 14.15. **HRMS** calcd. for (C₂₂H₂₇F₈NNaO) [M+Na]⁺: 496.1857, found 496.1867. **IR (neat)**: 3310, 2929, 2859, 1704, 1619, 1559, 1325, 1161, 722.



N-(4-(3,3-difluoro-2-(4-formylphenyl)allyl)decyl)-2,2,2-trifluoroacetamide (6p)


Following General Procedure B, N-decyl-2,2,2-trifluoroacetamide (93.5 mg, 0.40 mmol) and 4-(3,3,3-trifluoroprop-1-en-2-yl)benzaldehyde (40.0 mg, 0.20 mmol) were used, affording the title compound as a colorless oil (64.2 mg, 74% yield) by using Hexane/EtOAc (10:1) as eluent. **¹H NMR** (400 MHz, CDCl₃) δ 10.01 (s, 1H), 7.88 (d, *J* = 7.9 Hz, 2H), 7.47 (d, *J* = 7.8 Hz, 2H), 6.25 (s, 1H), 3.28 (q, *J* = 6.8 Hz, 2H), 2.49 – 2.23 (m, 2H), 1.59 – 1.43 (m, 2H), 1.36 – 1.14 (m, 13H), 0.86 (t, *J* = 6.9 Hz, 3H). **¹⁹F NMR** (376 MHz, CDCl₃) δ -76.04, -88.37 (d, *J* = 37.2 Hz), -88.60 (d, *J* = 37.2 Hz). **¹³C NMR** (126 MHz, CDCl₃) δ 191.70, 157.28 (q, *J* = 36.7 Hz), 154.43 (dd, *J* = 288.9, 285.7 Hz), 140.36, 135.40, 130.01, 128.95 (t, *J* = 3.3 Hz), 117.41 (q, *J* = 287.8 Hz), 91.17 (dd, *J* = 20.9, 14.2 Hz), 40.32, 35.60, 32.92, 31.87, 31.70, 29.97, 29.63, 26.28, 25.97, 22.73, 14.18. **HRMS** calcd. for (C₂₂H₂₈F₅NNaO₂) [M+Na]⁺: 456.1932, found 456.1942. **IR (neat)**: 3312, 2928, 2857, 1704, 1606, 1560, 1456, 1215, 831.



N-(4-(3,3-difluoro-2-(3-methoxyphenyl)allyl)decyl)-2,2,2-trifluoroacetamide (6q)


Following General Procedure B, N-decyl-2,2,2-trifluoroacetamide (101.35 mg, 0.40 mmol) and 1-methoxy-3-(3,3,3-trifluoroprop-1-en-2-yl)benzene (40.4 mg, 0.20 mmol) were used, affording the title compound as a colorless oil (70.2 mg, 81% yield) by using Hexane/EtOAc (10:1) as eluent. **¹H NMR** (400 MHz, CDCl₃) δ 7.30 – 7.23 (m, 1H), 6.91 – 6.77 (m, 3H), 6.23 (s, 1H), 3.81 (s, 3H), 3.34 – 3.17 (m, 2H), 2.41 – 2.22 (m, 2H), 1.54 – 1.45 (m, 2H), 1.38 – 1.17 (m, 13H), 0.87 (t, *J* = 6.9 Hz, 3H). **¹⁹F NMR** (376 MHz, CDCl₃) δ -76.08, -90.72 (d, *J* = 43.5 Hz), -91.32 (d, *J* = 43.3 Hz). **¹³C NMR** (126 MHz, CDCl₃) δ 159.75, 157.26 (q, *J* = 36.8 Hz), 154.65 (dd, *J* = 292.7, 288.3 Hz), 135.21, 129.61, 120.84 (t, *J* = 3.1 Hz), 117.43 (q, *J* = 287.8 Hz), 114.51 (t, *J* = 3.2 Hz), 112.62,

91.43 (dd, $J = 21.9, 12.9$ Hz), 55.37, 40.35, 35.40 (t, $J = 2.3$ Hz), 33.04, 31.98, 31.92, 29.92, 29.68, 26.35, 25.84, 22.76, 14.19. **HRMS** calcd. for (C₂₂H₃₀F₅NNaO₂) [M+Na]⁺: 458.2089, found 458.2102. **IR (neat)**: 3309, 2927, 2857, 1703, 1579, 1456, 1247, 1160, 720.



N-(4-(2-(3-acetylphenyl)-3,3-difluoroallyl)decyl)-2,2,2-trifluoroacetamide (6r)


Following General Procedure B, N-decyl-2,2,2-trifluoroacetamide (101.3 mg, 0.40 mmol) and 1-(3-(3,3,3-trifluoroprop-1-en-2-yl)phenyl)ethan-1-one (42.8 mg, 0.20 mmol) were used, affording the title compound as a colorless oil (80.1 mg, 89% yield) by using Hexane/EtOAc (8:1) as eluent. **¹H NMR** (400 MHz, CDCl₃) δ 7.93 – 7.82 (m, 2H), 7.57 – 7.42 (m, 2H), 6.47 (s, 1H), 3.38 – 3.15 (m, 2H), 2.61 (s, 3H), 2.43 – 2.32 (m, 2H), 1.57 – 1.46 (m, 2H), 1.35 – 1.13 (m, 13H), 0.85 (t, $J = 6.9$ Hz, 3H). **¹⁹F NMR** (376 MHz, CDCl₃) δ -76.06, -90.15 (d, $J = 41.5$ Hz), -90.30 (d, $J = 41.4$ Hz). **¹³C NMR** (126 MHz, CDCl₃) δ 198.13, 157.33 (q, $J = 36.4$ Hz), 154.30 (dd, $J = 290.2, 288.0$ Hz), 137.51, 134.46, 133.10 (t, $J = 3.3$ Hz), 129.00, 127.83 (t, $J = 3.1$ Hz), 127.59, 116.00 (q, $J = 287.9$ Hz), 91.00 (dd, $J = 21.0, 14.1$ Hz), 40.28, 35.39 (t, $J = 2.4$ Hz), 33.03, 31.87, 31.77, 29.95, 29.62, 26.77, 26.29, 25.90, 22.73, 14.16. **HRMS** calcd. for (C₂₃H₃₀F₅NNaO₂) [M+Na]⁺: 470.2089, found 470.2099. **IR (neat)**: 3317, 2928, 2858, 1719, 1558, 1363, 1208, 1156, 702.



N-(4-(2-(3-cyanophenyl)-3,3-difluoroallyl)decyl)-2,2,2-trifluoroacetamide (6s)


Following General Procedure B, N-decyl-2,2,2-trifluoroacetamide (101.3 mg, 0.40 mmol) and 3-(3,3,3-trifluoroprop-1-en-2-yl)benzotrile (39.4 mg, 0.20 mmol) were used, affording the title compound as a colorless oil (60.5 mg, 70% yield) by using Hexane/EtOAc (6:1) as eluent. **¹H NMR** (400 MHz, CDCl₃) δ 7.60 – 7.52 (m, 3H), 7.53 – 7.43 (m, 1H), 6.43 (s, 1H), 3.28 (q, $J = 6.9$ Hz, 2H), 2.39 – 2.30 (m, 2H), 1.58 – 1.45 (m, 2H), 1.31 – 1.13 (m, 13H), 0.86 (t, $J = 7.0$ Hz, 3H). **¹⁹F NMR** (376 MHz, CDCl₃) δ -

76.06, -88.90 (d, $J = 38.9$ Hz), -89.38 (d, $J = 38.7$ Hz). ^{13}C NMR (126 MHz, CDCl_3) δ 157.34 (q, $J = 36.9$ Hz), 154.39 (dd, $J = 292.4, 288.3$ Hz), 135.33 (dd, $J = 5.1, 3.1$ Hz), 132.76, 131.83, 131.04, 129.61, 118.59, 115.98 (q, $J = 287.8$ Hz), 113.00, 90.35 (dd, $J = 23.4, 12.4$ Hz), 40.26, 35.43 (t, $J = 2.4$ Hz), 32.75, 31.84, 31.67, 29.89, 29.61, 26.16, 25.87, 22.71, 14.15. **HRMS** calcd. for $(\text{C}_{22}\text{H}_{27}\text{F}_5\text{N}_2\text{NaO})$ $[\text{M}+\text{Na}]^+$: 453.1936, found 453.1943. **IR (neat)**: 3317, 2928, 2858, 2232, 1719, 1558, 1456, 1160, 772.



N-(4-(2-(3,5-dichlorophenyl)-3,3-difluoroallyl)decyl)-2,2,2-trifluoroacetamide (6t)


Following General Procedure B, N-decyl-2,2,2-trifluoroacetamide (101.3 mg, 0.40 mmol) and 1,3-dichloro-5-(3,3,3-trifluoroprop-1-en-2-yl)benzene (48.2 mg, 0.20 mmol) were used, affording the title compound as a colorless oil (77.2 mg, 81% yield) by using Hexane/EtOAc (20:1) as eluent. ^1H NMR (400 MHz, CDCl_3) δ 7.28 (t, $J = 1.9$ Hz, 1H), 7.17 – 7.16 (m, 2H), 6.35 (s, 1H), 3.38 – 3.21 (m, 2H), 2.38 – 2.22 (m, 2H), 1.58 – 1.43 (m, 2H), 1.37 – 1.13 (m, 13H), 0.87 (t, $J = 7.0$ Hz, 3H). ^{19}F NMR (376 MHz, CDCl_3) δ -76.08, -88.44 (d, $J = 37.9$ Hz), -88.70 (d, $J = 37.7$ Hz). ^{13}C NMR (126 MHz, CDCl_3) δ 157.36 (q, $J = 36.8$ Hz), 154.38 (dd, $J = 292.7, 288.3$ Hz), 136.92 (dd, $J = 4.8, 3.0$ Hz), 135.26, 127.68, 126.80 (t, $J = 3.4$ Hz), 115.99 (q, $J = 287.8$ Hz), 90.21 (dd, $J = 23.3, 12.7$ Hz), 40.33, 35.42, 32.74, 31.88, 31.66, 29.94, 29.61, 26.16, 25.87, 22.74, 14.17. **HRMS** calcd. for $(\text{C}_{21}\text{H}_{26}\text{Cl}_2\text{F}_5\text{NNaO})$ $[\text{M}+\text{Na}]^+$: 496.1204, found 496.1228. **IR (neat)**: 3308, 2927, 2857, 1702, 1559, 1457, 1161, 803.




N-(4-(3,3-difluoro-2-(2-fluorophenyl)allyl)decyl)-2,2,2-trifluoroacetamide (6u)

Following General Procedure B, N-decyl-2,2,2-trifluoroacetamide (101.3 mg, 0.40 mmol) and 1-fluoro-2-(3,3,3-trifluoroprop-1-en-2-yl)benzene (38.0 mg, 0.20 mmol) were used, affording the title compound as a colorless oil (72.3 mg, 85% yield) by using Hexane/EtOAc (20:1) as eluent. ^1H NMR (400 MHz, CDCl_3) δ 7.33 – 7.26 (m, 1H),

7.21 (td, $J = 7.5, 2.0$ Hz, 1H), 7.14 (td, $J = 7.5, 1.2$ Hz, 1H), 7.08 (ddd, $J = 9.7, 8.2, 1.2$ Hz, 1H), 6.28 (s, 1H), 3.55 – 3.01 (m, 2H), 2.39 – 2.24 (m, 2H), 1.55 – 1.40 (m, 2H), 1.33 – 1.15 (m, 13H), 0.86 (t, $J = 7.0$ Hz, 3H). ^{19}F NMR (376 MHz, CDCl_3) δ -76.11, -87.73 (dd, $J = 39.2, 12.9$ Hz), -91.64 (dd, $J = 39.1, 2.1$ Hz), -114.15 (d, $J = 12.8$ Hz). ^{13}C NMR (126 MHz, CDCl_3) δ 160.29 (d, $J = 247.5$ Hz), 157.30 (q, $J = 36.8$ Hz), 153.76 (dd, $J = 288.9, 285.7$ Hz), 130.80, 129.71 (d, $J = 8.3$ Hz), 124.31 (d, $J = 3.5$ Hz), 121.51 (d, $J = 15.2$ Hz), 116.05 (d, $J = 22.4$ Hz), 116.01 (q, $J = 288.0$ Hz), 86.07 (dd, $J = 25.2, 15.7$ Hz), 40.29, 35.64, 32.99, 32.07, 31.88, 29.85, 29.60, 26.32, 25.87, 22.74, 14.18. **HRMS** calcd. for $(\text{C}_{21}\text{H}_{27}\text{F}_6\text{NNaO})$ $[\text{M}+\text{Na}]^+$: 446.1889, found 446.1907. **IR (neat)**: 3307, 2928, 2857, 1702, 1559, 1454, 1161, 757.




N-(4-(2-(benzo[d][1,3]dioxol-5-yl)-3,3-difluoroallyl)decyl)-2,2,2-trifluoroacetamide (6v) Following General Procedure B, N-decyl-2,2,2-trifluoroacetamide (101.3 mg, 0.40 mmol) and 5-(3,3,3-trifluoroprop-1-en-2-yl)benzo[d][1,3]dioxole (43.2 mg, 0.20 mmol) were used, affording the title compound as a colorless oil (55.2 mg, 61% yield) by using Hexane/EtOAc (10:1) as eluent. ^1H NMR (400 MHz, CDCl_3) δ 6.84 – 6.60 (m, 3H), 6.31 (s, 1H), 5.96 (s, 2H), 3.27 (q, $J = 7.2$ Hz, 2H), 2.39 – 2.14 (m, 2H), 1.61 – 1.43 (m, 2H), 1.43 – 1.07 (m, 13H), 0.87 (t, $J = 6.9$ Hz, 3H). ^{19}F NMR (376 MHz, CDCl_3) δ -75.69, -91.24 (d, $J = 45.4$ Hz), -91.79 (d, $J = 45.4$ Hz). ^{13}C NMR (126 MHz, CDCl_3) δ 157.29 (q, $J = 36.7$ Hz), 154.00 (dd, $J = 289.5, 285.8$ Hz), 147.90, 146.90, 127.34 (d, $J = 7.3$ Hz), 121.89 (t, $J = 3.0$ Hz), 115.99 (q, $J = 288.0$ Hz), 108.81 (t, $J = 3.2$ Hz), 108.45, 101.29, 91.20 (dd, $J = 22.1, 13.2$ Hz), 40.37, 35.26, 32.91, 32.22, 31.88, 29.88, 29.66, 26.27, 25.82, 22.73, 14.15. **HRMS** calcd. for $(\text{C}_{22}\text{H}_{28}\text{F}_5\text{NNaO}_3)$ $[\text{M}+\text{Na}]^+$: 472.1882, found 472.1878. **IR (neat)**: 3310, 2928, 2857, 1703, 1558, 1492, 1239, 1161, 1040.




tert-butyl 2-(1,1-difluoro-4-(3-(2,2,2-trifluoroacetamido)propyl)dec-1-en-2-yl)-1H-pyrrole-1-carboxylate (6w) Following General Procedure B, N-decyl-2,2,2-

trifluoroacetamide (101.3 mg, 0.40 mmol) and *tert*-butyl 2-(3,3,3-trifluoroprop-1-en-2-yl)-1H-pyrrole-1-carboxylate (52.1 mg, 0.20 mmol) were used, affording the title compound as a colorless oil (64.9 mg, 66% yield) by using Hexane/EtOAc (15:1) as eluent. ¹H NMR (400 MHz, CDCl₃) δ 7.27 (dd, *J* = 3.5, 1.9 Hz, 1H), 6.40 (s, 1H), 6.15 (t, *J* = 3.3 Hz, 1H), 6.08 (dd, *J* = 3.3, 1.8 Hz, 1H), 3.44 – 3.14 (m, 2H), 2.29 – 2.02 (m, 2H), 1.57 (s, 9H), 1.55 – 1.40 (m, 2H), 1.37 – 1.15 (m, 13H), 0.87 (t, *J* = 6.9 Hz, 3H). ¹⁹F NMR (376 MHz, CDCl₃) δ -76.06, -87.66 (d, *J* = 39.4 Hz), -92.09 (d, *J* = 39.2 Hz). ¹³C NMR (126 MHz, CDCl₃) δ 157.31 (q, *J* = 36.6 Hz), 154.23 (dd, *J* = 289.5, 285.8 Hz), 148.88, 125.83 (d, *J* = 6.9 Hz), 122.65, 116.06 (q, *J* = 288.0 Hz), 115.36 (t, *J* = 2.1 Hz), 110.58, 85.34 (dd, *J* = 27.9, 15.0 Hz), 84.08, 40.32, 35.64 (t, *J* = 2.4 Hz), 33.16, 32.60, 31.94, 29.95, 29.67, 28.00, 26.50, 25.78, 22.75, 14.18. HRMS calcd. for (C₂₄H₃₅F₅N₂NaO₃) [M+Na]⁺: 517.2460, found 517.2450. IR (neat): 3225, 2928, 2857, 1704, 1650, 1558, 1455, 1154, 726.




N-(4-(3,3-difluoro-2-(pyrimidin-5-yl)allyl)decyl)-2,2,2-trifluoroacetamide (6x)

Following General Procedure B, N-decyl-2,2,2-trifluoroacetamide (101.3 mg, 0.40 mmol) and 5-(3,3,3-trifluoroprop-1-en-2-yl)pyrimidine (34.8 mg, 0.20 mmol) were used, affording the title compound as a colorless oil (57.2 mg, 70% yield) by using Hexane/EtOAc (3:1) as eluent. ¹H NMR (400 MHz, CDCl₃) δ 9.11 (s, 1H), 8.69 (d, *J* = 1.2 Hz, 2H), 6.48 (s, 1H), 3.30 (q, *J* = 6.9 Hz, 2H), 2.47 – 2.22 (m, 2H), 1.60 – 1.46 (m, 2H), 1.38 – 1.09 (m, 13H), 0.85 (t, *J* = 6.9 Hz, 3H). ¹⁹F NMR (376 MHz, CDCl₃) δ -76.05, -86.57 (d, *J* = 35.1 Hz), -87.66 (d, *J* = 35.3 Hz). ¹³C NMR (126 MHz, CDCl₃) δ 157.56 (q, *J* = 36.6 Hz), 157.39, 155.94, 154.67 (dd, *J* = 289.5, 285.8 Hz), 128.25, 115.98 (q, *J* = 287.9 Hz), 86.35 (dd, *J* = 25.0, 12.8 Hz), 40.25, 35.63 (t, *J* = 2.3 Hz), 32.78, 31.83, 31.02, 29.93, 29.62, 26.22, 25.98, 22.69, 14.14. HRMS calcd. for (C₁₉H₂₇F₅N₃O) [M+H]⁺: 408.2069, found 408.2062. IR (neat): 3299, 2928, 2858, 1709, 1558, 1420, 1372, 1156, 732.



N-(4-(2-(benzo[b]thiophen-3-yl)-3,3-difluoroallyl)decyl)-2,2,2-trifluoroacetamide


(6y) Following General Procedure B, N-decyl-2,2,2-trifluoroacetamide (101.3 mg, 0.40 mmol) and 3-(3,3,3-trifluoroprop-1-en-2-yl)benzo[b]thiophene (45.6 mg, 0.20 mmol) were used, affording the title compound as a colorless oil (56.1 mg, 61% yield) by using Hexane/EtOAc (20:1) as eluent. $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.93 – 7.80 (m, 1H), 7.74 – 7.61 (m, 1H), 7.48 – 7.34 (m, 2H), 7.28 (s, 1H), 6.20 (s, 1H), 3.28 – 3.10 (m, 2H), 2.49 – 2.30 (m, 2H), 1.49 – 1.38 (m, 2H), 1.35 – 1.13 (m, 13H), 0.85 (t, $J = 7.0$ Hz, 3H). $^{19}\text{F NMR}$ (376 MHz, CDCl_3) δ -75.66, -85.66 (d, $J = 39.9$ Hz), -90.77 (d, $J = 39.8$ Hz). $^{13}\text{C NMR}$ (126 MHz, CDCl_3) δ 157.06 (q, $J = 36.4$ Hz), 152.67 (dd, $J = 289.5, 285.8$ Hz), 140.10, 137.83, 129.32, 126.76, 125.13, 124.61 (d, $J = 23.8$ Hz), 123.07, 122.58 (d, $J = 2.3$ Hz), 115.97 (q, $J = 288.3$ Hz), 86.06 (dd, $J = 24.4, 15.9$ Hz), 40.32, 35.83, 33.02, 32.90, 31.87, 30.05, 29.64, 26.31, 25.92, 22.72, 14.17. **HRMS** calcd. for $(\text{C}_{23}\text{H}_{28}\text{F}_5\text{NNaOS})$ $[\text{M}+\text{Na}]^+$: 484.1704, found 484.1694 **IR (neat)**: 3306, 2926, 2856, 1703, 1558, 1457, 1367, 1272, 1160, 733.




N-(4-(2-(dibenzo[b,d]thiophen-4-yl)-3,3-difluoroallyl)decyl)-2,2,2-

trifluoroacetamide (6z) Following General Procedure B, N-decyl-2,2,2-trifluoroacetamide (101.3 mg, 0.40 mmol) and 4-(3,3,3-trifluoroprop-1-en-2-yl)dibenzo[b,d]thiophene (55.6 mg, 0.20 mmol) were used, affording the title compound as a colorless oil (55.7 mg, 96% yield) by using Hexane/EtOAc (20:1) as eluent. $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 8.18 – 8.09 (m, 2H), 7.90 – 7.81 (m, 1H), 7.52 – 7.42 (m, 3H), 7.32 (dd, $J = 7.4, 1.1$ Hz, 1H), 6.30 (s, 1H), 3.36 – 2.95 (m, 2H), 2.76 – 2.29 (m, 2H), 1.51 – 1.15 (m, 15H), 0.84 (t, $J = 6.8$ Hz, 3H). $^{19}\text{F NMR}$ (376 MHz, CDCl_3) δ -75.62, -85.43 (d, $J = 38.4$ Hz), -90.87 (d, $J = 38.5$ Hz). $^{13}\text{C NMR}$ (126 MHz, CDCl_3) δ 157.24 (q, $J = 36.4$ Hz), 153.68 (dd, $J = 289.5, 285.8$ Hz), 139.68, 139.15, 136.22, 135.77, 128.96 (d, $J = 4.2$ Hz), 127.46 (d, $J = 2.9$ Hz), 127.17, 124.85, 124.67, 122.84, 121.88,

121.16, 115.98 (q, $J = 288.0$ Hz), 90.63 (dd, $J = 23.3, 15.3$ Hz), 40.34, 35.82 (t, $J = 2.4$ Hz), 33.03, 32.16, 31.85, 30.08, 29.60, 26.28, 25.87, 22.70, 14.14. **HRMS** calcd. for (C₂₇H₃₀F₅NNaOS) [M+Na]⁺: 534.1860, found 534.1856. **IR (neat)**: 3311, 2927, 2856, 1726, 1558, 1206, 1160, 750.




Methyl (S)-8,8-difluoro-5,5-dimethyl-7-phenyl-3-((2,2,2-trifluoroacetamido)methyl)oct-7-enoate (6aa) Following General Procedure B, methyl (S)-5-methyl-3-((2,2,2-trifluoroacetamido)methyl)hexanoate (**5aa**) (107.7 mg, 0.40 mmol) and (3,3,3-trifluoroprop-1-en-2-yl)benzene (**2a**) (34.4 mg, 0.20 mmol) were used, affording the title compound as a colorless oil (80.1 mg, 95% yield) by using Hexane/EtOAc (10:1) as eluent. **¹H NMR** (400 MHz, CDCl₃) δ 7.38 – 7.21 (m, 5H), 7.03 (s, 1H), 3.67 (s, 3H), 3.28 – 3.09 (m, 2H), 2.36 (t, $J = 2.4$ Hz, 2H), 2.33 – 2.16 (m, 2H), 2.16 – 2.06 (m, 1H), 1.13 (d, $J = 4.9$ Hz, 2H), 0.81 (s, 6H). **¹⁹F NMR** (376 MHz, CDCl₃) δ -76.08, -89.19 (d, $J = 39.6$ Hz), -91.59 (d, $J = 39.6$ Hz). **¹³C NMR** (126 MHz, CDCl₃) δ 173.91, 157.54 (q, $J = 36.1$ Hz), 154.59 (dd, $J = 290.6, 286.5$ Hz), 135.38 (d, $J = 4.4$ Hz), 128.60, 128.57, 127.40, 116.00 (q, $J = 287.7$ Hz), 90.46 (dd, $J = 21.2, 13.8$ Hz), 52.06, 45.67, 44.33, 40.42, 39.56, 36.00 (t, $J = 2.6$ Hz), 30.60, 27.11 (d, $J = 3.5$ Hz). **HRMS** calcd. for (C₂₀H₂₄F₅NNaO) [M+Na]⁺: 444.1569, found 444.1559. **IR (neat)**: 3325, 2957, 1718, 1556, 1440, 1153, 698.




N-(((1S,2R,5R)-2-(5,5-difluoro-2-methyl-4-phenylpent-4-en-2-yl)-5-methylcyclohexyl)methyl)-2,2,2-trifluoroacetamide (6ab) Following General Procedure B, 2,2,2-trifluoro-N-(((1S,2S,5R)-2-isopropyl-5-methylcyclohexyl)methyl)acetamide (**5ab**) (106.1 mg, 0.40 mmol) and (3,3,3-trifluoroprop-1-en-2-yl)benzene (**2a**) (34.4 mg, 0.20 mmol) were used, affording the title compound as a colorless oil (53.0 mg, 64% yield) by using Hexane/EtOAc (20:1) as eluent. **¹H NMR** (400 MHz, CDCl₃) δ 7.39 – 7.18 (m, 5H), 6.24 (s, 1H), 3.71 – 3.26 (m,

2H), 2.58 – 2.23 (m, 2H), 2.07 (d, $J = 11.5$ Hz, 1H), 1.74 – 1.64 (m, 1H), 1.60 – 1.48 (m, 3H), 1.33 – 1.19 (m, 3H), 0.99 – 0.70 (m, 9H). ^{19}F NMR (376 MHz, CDCl_3) δ -71.56 – -81.16 (m), -89.13 (d, $J = 40.2$ Hz), -91.23 (d, $J = 40.2$ Hz). ^{13}C NMR (126 MHz, CDCl_3) δ 157.38 (q, $J = 36.6$ Hz), 154.64 (dd, $J = 290.6, 286.5$ Hz), 135.68 (d, $J = 3.2$ Hz), 128.60 (t, $J = 2.8$ Hz), 128.53, 127.24, 116.04 (q, $J = 288.2$ Hz), 90.87 (dd, $J = 21.2, 13.6$ Hz), 47.77, 39.28, 38.35, 37.76, 37.71, 35.73, 35.66, 29.84, 26.50, 25.97, 25.40, 22.58. HRMS calcd. for $(\text{C}_{22}\text{H}_{28}\text{F}_5\text{NNaO})$ $[\text{M}+\text{Na}]^+$: 440.1983, found 440.1969. IR (neat): 3264, 2924, 2855, 1722, 1698, 1373, 1156, 697.




methyl 2-((tert-butoxycarbonyl)amino)-6,6-difluoro-5-phenyl-3-(3-(2,2,2-trifluoroacetamido)propyl)hex-5-enoate (6ac) Following General Procedure B, methyl N2-(tert-butoxycarbonyl)-N6-(2,2,2-trifluoroacetyl)lysinate (**5ac**) (142.5 mg, 0.40 mmol) and (3,3,3-trifluoroprop-1-en-2-yl)benzene (**2a**) (34.4 mg, 0.20 mmol) were used, affording the mixture of diastereomers (dr = 2/1) as a colorless oil (54.1 mg, 53% yield) by using Hexane/EtOAc (5:1) as eluent. ^1H NMR (400 MHz, CDCl_3) δ 7.39 – 7.33 (m, 2H), 7.32 – 7.27 (m, 1H), 7.24 – 7.12 (m, 2H), 7.02 (s, 1H), 5.23 (d, $J = 8.5$ Hz, 1H), 4.43 (dd, $J = 8.7, 2.6$ Hz, 1H), 3.64 (s, 3H), 3.44 – 3.32 (m, 1H), 3.29 – 3.14 (m, 1H), 2.34 – 2.19 (m, 2H), 1.84 – 1.69 (m, 2H), 1.61 – 1.52 (m, 1H), 1.45 (s, 9H), 1.42 – 1.32 (m, 2H). (*diastereomer 1*) ^1H NMR (400 MHz, CDCl_3) δ 7.39 – 7.33 (m, 2H), 7.32 – 7.25 (m, 3H), 6.47 (s, 1H), 5.08 (d, $J = 8.7$ Hz, 1H), 4.36 (d, $J = 6.2$ Hz, 1H), 3.71 (s, 3H), 3.32 (dd, $J = 13.5, 6.8$ Hz, 1H), 3.17 (dd, $J = 13.9, 7.0$ Hz, 1H), 2.50 (dd, $J = 13.6, 6.2$ Hz, 1H), 2.41 – 2.28 (m, 1H), 1.90 (d, $J = 4.4$ Hz, 1H), 1.59 (t, $J = 7.5$ Hz, 2H), 1.42 (s, 9H), 1.37 – 1.24 (m, 2H). (*diastereomer 2*) ^{19}F NMR (376 MHz, CDCl_3) δ -75.65, -89.79 (d, $J = 41.2$ Hz), -90.07 (d, $J = 41.1$ Hz). (*diastereomer 1*) ^{19}F NMR (376 MHz, CDCl_3) δ -75.97, -89.82 (d, $J = 40.7$ Hz), -90.11 (d, $J = 40.6$ Hz). (*diastereomer 2*) ^{13}C NMR (126 MHz, CDCl_3) δ 172.55, 157.52 (q, $J = 36.9$ Hz), 156.46, 153.96 (dd, $J = 290.6, 286.5$ Hz), 132.72 (t, $J = 3.5$ Hz), 128.61, 128.03 (t, $J = 3.1$ Hz), 127.70, 115.88 (q, $J = 287.7$ Hz), 90.13 (dd, $J = 21.1, 14.6$ Hz), 80.65, 54.37, 52.41, 39.93, 39.87, 28.14, 28.01, 27.49, 25.82. HRMS calcd. for $(\text{C}_{23}\text{H}_{29}\text{F}_5\text{N}_2\text{NaO}_5)$ $[\text{M}+\text{Na}]^+$: 531.1889, found 531.1871. IR (neat): 3325, 2970, 1720, 1500, 1367, 1155, 699.



N-(6-(4-acetylphenyl)-4-((3R,5R,8R,9S,10S,13S,14S,17S)-3-((tert-butyl dimethylsilyl)oxy)-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)-7,7-difluoro-4-methylhept-6-en-1-yl)-2,2,2-trifluoroacetamide (6ad) Following General Procedure B, *N*-((*R*)-4-((3R,5R,8R,9S,10S,13R,14S,17S)-3-((tert-butyl dimethylsilyl)oxy)-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentyl)-2,2,2-trifluoroacetamide (**5ad**) (229.0 mg, 0.40 mmol) and 1-(3-(3,3,3-trifluoroprop-1-en-2-yl)phenyl)ethan-1-one (42.8 mg, 0.20 mmol) were used, affording the mixture of diastereomers (dr = 1/1) as a colorless oil (130.2 mg, 85% yield) by using Hexane/EtOAc (8:1) as eluent. ¹H NMR (400 MHz, CDCl₃) δ 7.89 (d, *J* = 5.6 Hz, 1H), 7.83 (d, *J* = 7.4 Hz, 1H), 7.59 – 7.41 (m, 2H), 6.20 – 6.08 (m, 1H), 3.64 – 3.51 (m, 1H), 3.02 – 2.88 (m, 1H), 2.87 – 2.75 (m, 0.52H) (*diastereomer 1*), 2.77 – 2.69 (m, 0.48H) (*diastereomer 2*), 2.62 (s, 3H), 2.59 – 2.54 (m, 1H), 2.42 (d, *J* = 14.0 Hz, 1H), 2.05 – 1.99 (m, 0.52H) (*diastereomer 1*), 1.87 – 1.67 (m, 3.48H), 1.62 – 1.52 (m, 3H), 1.45 – 1.32 (m, 10H), 1.28 – 1.19 (m, 3H), 1.14 – 0.96 (m, 7H), 0.93 – 0.88 (m, 12H), 0.86 – 0.80 (m, 2H), 0.78 – 0.74 (m, 4H), 0.05 (s, 6H). ¹⁹F NMR (376 MHz, CDCl₃) δ -76.04 (*diastereomer 1*), -76.05 (*diastereomer 2*), -88.27 (d, *J* = 38.6 Hz) (*diastereomer 1*), -88.34 (d, *J* = 38.4 Hz) (*diastereomer 2*), -90.04 (d, *J* = 38.6 Hz) (*diastereomer 1*), -90.50 (d, *J* = 38.4 Hz) (*diastereomer 2*). ¹³C NMR (126 MHz, CDCl₃) δ 198.44, 198.34, 157.03 (q, *J* = 36.8 Hz), 154.58 (dd, *J* = 290.6, 286.5 Hz), 137.49 (d, *J* = 6.0 Hz), 136.50, 133.51, 128.91, 127.89, 127.51 (d, *J* = 4.5 Hz), 115.96 (q, *J* = 288.2 Hz), 90.44 (dd, *J* = 21.6, 13.9 Hz), 72.84, 72.82, 56.79, 56.77, 56.64, 44.10, 43.97, 42.31, 41.67, 41.52, 41.38, 41.07, 40.46, 40.34, 40.31, 37.04, 36.53, 36.30, 35.94, 35.79, 35.66, 35.44, 34.67, 31.15, 27.37, 26.84, 26.35, 26.09, 23.90, 23.81, 23.75, 23.68, 23.48, 23.45, 22.94, 22.70, 20.90, 20.76, 18.42,

15.19, 15.15, -4.46, -4.48. **HRMS** calcd. for (C₄₃H₆₄F₅NNaO₃Si) [M+Na]⁺: 788.4468, found 788.4440. **IR (neat)**: 3325, 2929, 2859, 1722, 1557, 1361, 1218, 776.

Transformation of 3a



Procedure: A mixture of Pd/C (10 mg, 0.01 mmol) and **3a** (35.7mg, 0.1 mmol) in 2 ml of EtOAc was stirred under 1 atm H₂ atmosphere at room temperature for 30 h. The reaction mixture was filtered and the filtrate was concentrated. The residue was purified with silica gel chromatography (Pentane/EtOAc = 10/1) to give a mixture of diastereomers (dr = 1.5/1) as a colorless oil (30.6 mg, 85% yield).

N-(1,1-difluoro-2-phenylnonan-4-yl)benzamide (12) ¹H NMR (400 MHz, CDCl₃) δ 7.67 – 7.60 (m, 2H), 7.56 – 7.48 (m, 1H), 7.47 – 7.39 (m, 2H), 7.41 – 7.34 (m, 2H), 7.35 – 7.30 (m, 3H), 6.06 – 5.73 (m, 1H), 5.73 – 5.55 (m, 1H), 4.27 – 3.98 (m, 1H), 3.32 – 3.02 (m, 1H), 2.26 – 1.94 (m, 2H), 1.71 – 1.45 (m, 2H), 1.34 – 1.24 (m, 6H), 0.86 (t, *J* = 6.9 Hz, 3H).


¹⁹F NMR (376 MHz, CDCl₃) δ -117.59 (d, *J* = 276.4 Hz) (*diastereomer 1*), -119.51 (d, *J* = 276.0 Hz) (*diastereomer 2*), -123.26 (d, *J* = 276.0 Hz) (*diastereomer 2*), -123.32 (d, *J* = 276.4 Hz) (*diastereomer 1*).

¹³C NMR (126 MHz, CDCl₃) δ 167.10, 136.95, 134.84, 134.64, 131.55, 131.44, 129.18, 129.10, 129.01, 128.94, 128.68, 128.51, 128.03, 127.81, 126.89, 126.80, 117.92 (t, *J* = 244.6 Hz), 68.31, 48.95, 47.62, 35.86, 35.38, 31.75 (d, *J* = 2.6 Hz), 29.84, 25.68, 25.41, 22.62, 14.11.


Mechanistic Studies

Mechanistic experiments for the α sp^3 C–H defluorinative alkylation


1. KIE Experiment



An oven-dried 8 mL Schlenk tube containing a stirring bar was charged with **1a** (20.5 mg, 0.10 mmol, 1.0 equiv), **1a-d₂** (20.7 mg, 0.10 mmol, 1.0 equiv), (Ir[dF(CF₃)ppy]₂(dtbpy))PF₆ (1.1 mg, 0.01 equiv), 5,5'-dimethyl-2,2'-dipyridyl (1.1 mg, 0.06 equiv), and NiBr₂·diglyme (1.8 mg, 0.05 equiv). The tube was then introduced in the nitrogen-filled glovebox where K₃PO₄ (32 mg, 0.15 mmol, 1.5 equiv) was added followed by 0.5 mL 1,4-dioxane. Then the tube was brought outside the glovebox, and **2a** (0.10 mmol, 1 equiv) was added to the reaction mixture under N₂ atmosphere. Then the tube was stirred at 15 °C under blue LED irradiation with a cooling system for 2 hours. The reaction was quenched by addition of EtOAc (5 mL), and the reaction mixture was concentrated under vacuum. The product was purified by flash column chromatography by using hexane/ethyl acetate (8/1) as eluent, affording the mixture as a white solid (3.9 mg, 11% yield). The K_H/K_D was calculated directly from ¹H NMR spectroscopy.




2. Crossover Experiment



An oven-dried 8 mL Schlenk tube containing a stirring bar was charged with **1a-d₂** (20.7 mg, 0.10 mmol, 1.0 equiv), **1f** (27.3 mg, 0.10 mmol, 1.0 equiv), (Ir[dF(CF₃)ppy]₂(dtbpy))PF₆ (1.1 mg, 0.01 equiv), 5,5'-dimethyl-2,2'-dipyridyl (1.1 mg, 0.06 equiv), and NiBr₂·diglyme (1.8 mg, 0.05 equiv). The tube was then introduced in the nitrogen-filled glovebox where K₃PO₄ (32 mg, 0.15 mmol, 1.5 equiv) was added followed by 0.5 mL 1,4-dioxane. Then the tube was brought outside the glovebox, and **2a** (0.10 mmol, 1 equiv) was added to the reaction mixture under N₂ atmosphere. Then the tube was stirred at 15 °C under blue LED irradiation with a cooling system for 24 hours. The reaction was quenched by addition of EtOAc (5 mL) and the reaction mixture was concentrated under vacuum. The product was directly purified by flash column chromatography by using hexane/ethyl acetate (8/1) as eluent, affording **3f** as a white solid (3.1 mg, 7% yield) and **3a-d₁** as a white solid (3.0 mg, 8% yield). No deuterium exchange was observed.


3. Arguing against the involvement of Ni chain-walking scenarios



An oven-dried 8 mL Schlenk tube containing a stirring bar was charged with **8** (65.3 mg, 0.40 mmol, 2.0 equiv), (Ir[dF(CF₃)ppy]₂(dtbpy))PF₆ (1.1 mg, 0.01 equiv), 5,5'-dimethyl-2,2'-dipyridyl (2.2 mg, 0.06 equiv), and NiBr₂·diglyme (3.6 mg, 0.05 equiv). The tube

was then introduced in the nitrogen-filled glovebox where K_3PO_4 (64 mg, 0.30 mmol, 1.5 equiv) was added followed by 1 mL 1,4-dioxane. Then the tube was brought outside the glovebox, and **2a** (0.20 mmol, 1 equiv) was added to the reaction mixture under N_2 atmosphere. Then the tube was stirred at 15 °C under blue LED irradiation with a cooling system for 48 hours. The reaction was quenched by addition of EtOAc (5 mL) and the reaction mixture was concentrated under vacuum. The product was directly purified by flash column chromatography by using hexane/ethyl acetate (8/1) as eluent, affording **8a** as an amorphous solid (48.3 mg, 76% yield). M.P.: 81-82 °C. $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.51 – 7.41 (m, 3H), 7.39 – 7.31 (m, 6H), 7.29 – 7.25 (m, 1H), 5.68 (d, J = 8.8 Hz, 1H), 4.31 – 3.88 (m, 1H), 2.90 – 2.43 (m, 2H), 1.75 – 1.60 (m, 1H), 1.58 – 1.44 (m, 1H), 0.94 (t, J = 7.4 Hz, 3H). $^{19}\text{F NMR}$ (376 MHz, CDCl_3) δ -90.04 (d, J = 41.3 Hz), -90.19 (d, J = 41.2 Hz). $^{13}\text{C NMR}$ (126 MHz, CDCl_3) δ 167.12, 154.51 (dd, J = 289.2, 287.5 Hz), 134.76, 133.73, 131.41, 128.91, 128.55, 128.50 (t, J = 3.1 Hz), 127.69, 126.78, 89.96 (dd, J = 20.4, 15.6 Hz), 50.44 (t, J = 2.8 Hz), 32.92, 27.50, 10.44. **HRMS** calcd. for ($\text{C}_{19}\text{H}_{20}\text{F}_2\text{NO}$) $[\text{M}+\text{H}]^+$: 316.1507, found 316.1508. **IR (neat)**: 3265, 3062, 2961, 1736, 1636, 1539, 1233, 696.

4. Control Experiments



To an 8 mL vial equipped with a stirring bar was added **1a** (0.20 mmol, 2.0 equiv), $(\text{Ir}[\text{dF}(\text{CF}_3)\text{ppy}]_2(\text{dtbpy}))\text{PF}_6$ (1.1 mg, 0.01 equiv). The vial was then introduced in the nitrogen-filled glovebox where K_3PO_4 (64 mg, 0.30 mmol, 3.0 equiv) was added followed by 0.5 mL toluene. Then the tube was brought outside the glovebox, and **2a** (0.20 mmol, 1 equiv) was added to the reaction mixture under N_2 atmosphere. The reaction was stirred and irradiated using 451 nm Kessil light (40 W), equipped with a fan cooling system for 72 hours. The reaction was quenched by the addition of EtOAc (5 mL). The mixture was filtered through a silica plug, the filtrate was then removed under vacuum and nitromethane (5.4 μL , 0.10 mmol) was added as internal standard. The reaction mixture was analyzed by $^1\text{H NMR}$, showing that no reaction occurred.

5. Interactions of Ni(II) with the secondary amide by ^1H NMR

Two experiments were conducted to test whether a ^1H NMR chemical shift occurs by interaction of Ni(II) and the secondary amide. **(a)** In a glovebox, *N*-hexylbenzamide **1a** (4.8 mg, 0.02 mmol) and TMB (2.1 mg) were added to a 3 mL vial and dissolved in 1 mL THF- d_8 . This solution was transferred to a J. Young NMR tube, and the chemical shifts were measured by ^1H -NMR. The solution was then brought back into the glovebox and added to NiBr₂diglyme (8.2 mg, 0.02 mmol). This solution was transferred into the J. Young NMR tube and measured by ^1H and paramagnetic ^1H NMR. **(b)** An analogous procedure was used by adding **1a** (1.3 mg, 0.01 mmol) at the very end. The ^1H and paramagnetic ^1H NMR of a mixture containing NiBr₂diglyme (8.2 mg, 0.02 mmol), 5,5-dimethyl-2,2-bipyridine (3.7 mg, 0.02 mmol), *N*-hexylbenzamide **1a** (4.8 mg, 0.02 mmol) and TMB (2.1 mg) was also measured, and the spectrum recorded was identical to that shown by mixing the amide with TMB, likely due to the insolubility of the formed Ni(II)-**L1** complex. *Conclusion*; A significant chemical shift is evident by looking at the diamagnetic ^1H NMR spectra, thus suggesting a molecular interaction between Ni(II) and *N*-hexylbenzamide **1a**.




Figure SI ^1H spectra (THF- d_8 , 400 MHz) of the *N*-hexylbenzamide (blue) and NiBr₂diglyme (red) (internal standard = TMB (green)).

6. Interactions of Ni(II) with the secondary amide by UV-VIS

Two additional experiments were conducted to identify interactions between Ni species and the corresponding secondary amide. **(a)** To a quartz cuvette containing (dtbbpy)Ni^ICl (0.2 mM) in THF was added a solution of *N*-hexylbenzamide **1a** (Figure S2). **(b)** To a quartz cuvette containing (dtbbpy)Ni^{II}Cl₂ (1.2 mM) in THF was added a solution of *N*-hexylbenzamide **1a** (Figure S3.). *Conclusion*; A significant decrease in the corresponding UV absorption by addition of the secondary amide suggests an interaction between amide and Ni.




Figure S2 Monitoring UV-VIS of (dtbbpy)Ni^ICl with addition of *N*-hexylbenzamide




Figure S3. Monitoring UV-VIS of (dtbbpy)Ni^{II}Cl₂ with addition of *N*-hexylbenzamide

7. Quenching Experiments of Ir-1 with Ni Species or the Secondary Amide

Two experiments were conducted to identify whether quenching of the photocatalyst occurred with either the Ni species or the secondary amide. **(a)** To a quartz cuvette containing **Ir-1** (0.18 mM) in THF was added a solution of NiBr₂glyme and the emission spectra was recorded. (Figure S4); **(b)** Plot of the quenching experiment of **Ir-1** with NiBr₂glyme in the absence of the secondary amide; **(c)** To a quartz cuvette containing **Ir-1** (0.18 mM) and *N*-hexylbenzamide (17.1 mM, 95 eq) in THF was added a solution of NiBr₂glyme (Figure S4.). **(d)** Plot of the quenching experiment of **Ir-1** with NiBr₂glyme in the presence of the secondary amide. **(e)** Overlaid graphs of (b) and (c) showing no significant difference. We also tried to run an otherwise similar experiment to (a) and (c) with a solution of NiBr₂glyme and 5,5-dimethyl-2,2-bipyridine. Unfortunately, the Ni(II)-**L1** complex was rather insoluble, thus now allowing to obtain conclusive evidence about the role exerted for understanding the potential interaction with the Ni(II)-**L1** complex. *Conclusion:* the addition of secondary amide does not promote the quenching of **Ir-1** with NiBr₂glyme.




Figure S4 Quenching experiments aimed at identifying whether the presence of secondary amide promotes the quenching of Ir-1 with the Ni complex.

8. Quenching experiments of Ir-1 with both Ni species and Secondary Amide

Experiments were conducted to identify whether quenching of the photocatalyst occurred with both Ni species and the secondary amide. **(a)** To a quartz cuvette containing **Ir-1** (0.18 mM) and NiBr₂·glyme (0.18mM) in THF was added a solution of **1a** and the emission spectra was recorded (Figure S5); **(b)** Plot of the quenching experiment of **Ir-1** with NiBr₂glyme and increased concentrations of secondary amide; **(c)** To a quartz cuvette containing **Ir-1** (0.18 mM) in THF was added a solution of **1a**. **(d)** Plot of the quenching experiment of **Ir-1** with increased concentrations of secondary amide in the absence of Ni catalyst. **(e)** To a quartz cuvette containing **Ir-1** (0.0125 mM), NiBr₂·glyme (0.0125mM) in THF was added a solution of **1a** and the emission spectra was recorded (Figure S5); **(f)** Plot of the quenching experiment of **Ir-1** (0.0125 mM) with NiBr₂glyme (0.0125 mM) and increased concentrations of secondary amide; **(g)** To a quartz cuvette containing **Ir-1** (0.0125 mM), NiBr₂·glyme (0.0125mM) and 5,5-dimethyl-2,2-bipyridine (0.0125mM) in THF was added a solution of **1a** and the emission spectra was recorded (Figure S5). **(h)** Plot of the quenching experiment of **Ir-1** (0.0125 mM), NiBr₂glyme (0.0125 mM) with 5,5-dimethyl-2,2-bipyridine (0.0125mM) and increased concentrations of secondary amide. *Conclusion:* the presence of Ni salts slightly improve the ability of the secondary amide to promote the quenching of **Ir-1** and the presence of Ni with ligand can further improve the ability of the secondary amide to promote the quenching of **Ir-1**.




Figure S5. Quenching experiments of **Ir-1** by varying the concentration of the secondary amide **1a**.

9. Cyclic voltammogram of 1a





Figure S6 Cyclic voltammogram of **1a**. Voltammograms were taken using a glassy carbon working electrode in a 0.1 M [$n\text{Bu}_4\text{N}$][PF_6] supporting electrolyte THF solution with a 100 mV/s scan rate and 0.01 M of sample referenced to Fc (+380 vs SCE, external). Scans were started at the open-circuit potential and scanned in the cathod direction first; the second cycle is shown here. E_p values for *N*-hexylbenzamide are 1.43 V.


10. Proposed catalytic cycle for α sp^3 C–H defluorinative alkylation.



At present, it is unclear whether the reaction operates via beta-F elimination at Ni(III) or Ni(II) (for an elegant disclosure, see Norton, J. et al., *J. Am. Chem. Soc.* **2020**, *142*, 4793).


Mechanistic experiments for the δ sp^3 C–H defluorinative alkylation

1. Control Experiments




An oven-dried 8 mL Schlenk tube containing a stirring bar was charged with **5a** (0.20 mmol, 2 equiv), **Ir-1** (1.1 mg, 0.01 equiv), 5,5'-dimethyl-2,2'-dipyridyl (1.1 mg, 0.06 equiv), and NiBr₂·diglyme (1.8 mg, 0.05 equiv). The tube was introduced in the nitrogen-filled glovebox where K₃PO₄ (32 mg, 0.15 mmol, 1.5 equiv) was added followed by 0.5 mL 1,4-dioxane. Then the tube was brought outside the glovebox, and **2a** (0.10 mmol, 1 equiv) was added to the mixture under N₂ atmosphere. Then, the tube was stirred at 15 °C under blue LED irradiation with a cooling system for 72 hours. The reaction was quenched by addition of EtOAc (5 mL) and the mixture was filtered through a silica plug. The filtrate was removed under vacuum and MeNO₃ (5.4 μ L, 0.10 mmol) was added as standard. The mixture was analyzed by ¹H NMR, showing that no reaction occurred.

2. Control experiments with secondary amides possessing a pending olefin



To an 8 mL vial equipped with a stirring bar was added **10** (0.40 mmol, 2.0 equiv) and **Ir-1** (2.2 mg, 0.01 equiv). The vial was then introduced in the nitrogen-filled glovebox where K_3PO_4 (128 mg, 0.60 mmol, 3.0 equiv) was added followed by 1.0 mL toluene. Then the tube was brought outside the glovebox, and **2a** (0.20 mmol, 1 equiv) was added to the reaction mixture under N_2 atmosphere. The reaction was stirred and irradiated using 451 nm Kessil light (40 W), equipped with a fan cooling system for 72 hours. The reaction was quenched by the addition of EtOAc (5 mL), and the reaction was quenched by addition of EtOAc (5 mL). The reaction mixture was concentrated under vacuum and purified by flash chromatography column on silica gel (Hexane/EA = 15: 1) to give a mixture of **11a** and **11b** (50.1 mg, 75% yield, **11a/11b** = 8.3/1).



1H NMR (400 MHz, $CDCl_3$) δ 7.40 – 7.33 (m, $2H_{major+minor}$), 7.33 – 7.26 (m, $3H_{major+minor}$), 4.43 – 4.27 (m, $0.11H_{minor}$), 4.24 – 4.03 (m, $0.90H_{major}$), 3.90 – 3.78 (m, $0.11H_{minor}$), 3.73 – 3.51 (m, $1.80H_{major}$), 3.53 – 3.38 (m, $0.11H_{minor}$), 2.85 – 2.67 (m, $0.11H_{minor}$), 2.61 – 2.27 (m, $2.0H_{major+minor}$), 2.10 – 1.85 (m, $4H_{major+minor}$), 1.81 – 1.67 (m, $1H_{major+minor}$), 1.48 – 1.32 (m, $1H_{major+minor}$).

^{19}F NMR (376 MHz, $CDCl_3$) δ -70.94 (s, $0.33F_{minor}$), -72.54 (s, $2.67F_{major}$), -90.82 (d, $j = 45.1$ Hz, $0.33F_{minor}$), -90.92 (d, $j = 45.1$ Hz, $0.33F_{minor}$), -91.26 (d, $j = 41.4$ Hz, $1.78F_{major}$), -91.28 (d, $j = 41.4$ Hz, $1.78F_{major}$).

^{13}C NMR (126 MHz, $CDCl_3$) δ 156.59, 153.67, 133.35, 128.71, 128.32 (t, $J = 3.3$ Hz), 127.59, 116.45 (q, $J = 287.9$ Hz), 91.98 (dd, $J = 20.1, 15.8$ Hz), 58.94, 46.68 (d, $J = 3.5$ Hz), 31.01, 28.88, 24.82, 24.48.

HRMS calcd. for $(C_{16}H_{16}F_5NNaO)$ $[M+Na]^+$: 356.1044, found 356.1052.

IR (neat): 2970, 1738, 1688, 1366, 1232, 1204, 1142, 698.

3. Identification of interactions between secondary amide and base via ^1H NMR

Two experiments were conducted to test whether a ^1H NMR chemical shift occurs between CF_3 -amides and K_3PO_4 . **(a)** N-decyl-2,2,2-trifluoroacetamide (9.7 mg, 0.04 mmol) and TMB (2.1 mg) were added to a 3 mL vial and dissolved in 1 mL $\text{THF-}d_8$. This solution was then transferred to an NMR tube, and the chemical shifts were measured by ^1H NMR. This solution was then added to K_3PO_4 (12.3 mg, 0.06 mmol) and stirred for 20 min, filtered through a celite plug and measured again by ^1H NMR. This solution was added to K_3PO_4 (155 mg, 0.73 mmol) and stirred for 20 min, filtered through celite and measured again by ^1H NMR. **(b)** An analogous procedure was used with **1a** (10.5 mg, 0.05 mmol) and TMB (3.0 mg). *Conclusion*; A minor chemical shift changes upon reaction of N-decyl-2,2,2-trifluoroacetamide with K_3PO_4 , suggesting an interaction of these species, an observation that is in contrast with the analogous experiment using **1a**.




Figure S7. Interactions of the corresponding secondary amides with the base

4. Quenching of Ir-1 with both N-decyl-2,2,2-trifluoroacetamide and deprotonated N-decyl-2,2,2-trifluoroacetamide

Two experiments were conducted to test whether quenching of the photoexcited state of **Ir-1** was observed by the secondary amide or its deprotonated form. **(a)** To a quartz cuvette containing **Ir-1** (0.18 mM) in THF was added a solution of N-decyl-2,2,2-trifluoroacetamide and the emission spectra was recorded. (Figure S8) **(b)** Plot of the quenching of **Ir-1** with the secondary amide, indicating a virtually inexistent quenching. **(c)** To a quartz cuvette containing **Ir-1** (0.18 mM) in THF was added a solution of the Li salt of N-decyl-2,2,2-trifluoroacetamide (Figure S8). **(d)** Plot of the quenching of **Ir-1** with the secondary amide, indicating significant quenching of **Ir-1** (ca. 2000x more than just the amide) *Conclusion*; Deprotonation of the secondary amide causes a significant quenching of the photoexcited state of **Ir-1**.




Figure S8. Quenching experiment of **Ir-1** with CF₃-amide and its Li salt.

5. Cyclic voltammogram of N-decyl-2,2,2-trifluoroacetamide and Deprotonated N-decyl-2,2,2-trifluoroacetamide




Figure S9. Cyclic voltammogram of N-decyl-2,2,2-trifluoroacetamide. Voltammograms were taken using a glassy carbon working electrode in a 0.1 M [$n\text{Bu}_4\text{N}$][PF_6] supporting electrolyte THF solution with a 50 mV/s scan rate and 0.01 M of sample referenced to Fc (+380 vs SCE, external). Scans were started at the open-circuit potential and scanned in the cathod direction first; the second cycle is shown here. E_p values for N-decyl-2,2,2-trifluoroacetamide are 1.46 V.





Figure S10. Cyclic voltammogram of deprotonated N-decyl-2,2,2-trifluoroacetamide. Voltammograms were taken using a glassy carbon working electrode in a 0.1 M $[\text{nBu}_4\text{N}][\text{PF}_6]$ supporting electrolyte THF solution with a 100 mV/s scan rate and 0.01 M of sample referenced to Fc (+380 vs SCE, external). Scans were started at the open-circuit potential and scanned in the cathod direction first; the second cycle is shown here. E_p values for deprotonated N-decyl-2,2,2-trifluoroacetamide are 0.95 V.


6. Proposed mechanistic rationale for the δ sp^3 C–H defluorinative alkylation




References

1. Choi, G. J.; Zhu, Q.; Miller, D. C.; Gu, C. J.; Knowles, R. R. *Nature* **2016**, *539*, 268.
2. Thullen, S. M.; Treacy, S. M.; Rovis, T. *J. Am. Chem. Soc.* **2019**, *141*, 14062.
3. Ichitsuka, T.; Fujita, T.; Ichikawa, J. *ACS Catal.* **2015**, *5*, 5947.
4. This complex was prepared according to M. Mohadjer Beromi, G. W. Brudvig, N. Hazari, H. M. C. Lant, B. Q. Mercado, *Angew. Chem. Int. Ed.* **2019**, *58*, 6094.


^1H NMR, ^{19}F NMR & ^{13}C NMR spectra




^1H NMR spectrum (400 MHz, CDCl_3) of **1r**




^{13}C NMR spectrum (101 MHz, CDCl_3) of **1r**




¹H NMR spectrum (400 MHz, CDCl₃) of **1s**




¹³C NMR spectrum (101 MHz, CDCl₃) of **1s**




¹H NMR spectrum (400 MHz, CDCl₃) of **1z**




¹³C NMR spectrum (101 MHz, CDCl₃) of **1z**




¹H NMR spectrum (400 MHz, CDCl₃) of **1w**




^{13}C NMR spectrum (101 MHz, CDCl_3) of **1w**




^1H NMR spectrum (400 MHz, CDCl_3) of **5d**




¹⁹F NMR spectrum (376 MHz, CDCl₃) of **5d**




¹³C NMR spectrum (101 MHz, CDCl₃) of **5d**




^1H NMR spectrum (400 MHz, CDCl_3) of **5e**




^{19}F NMR spectrum (376 MHz, CDCl_3) of **5e**




¹³C NMR spectrum (101 MHz, CDCl₃) of **5e**




¹H NMR spectrum (400 MHz, CDCl₃) of **1ac**




^{13}C NMR spectrum (101 MHz, CDCl_3) of **1ac**




^1H NMR spectrum (400 MHz, CDCl_3) of **1ad**




¹³C NMR spectrum (101 MHz, CDCl₃) of **1ad**




¹H NMR spectrum (400 MHz, CDCl₃) of **8a**




^{19}F NMR spectrum (376 MHz, CDCl_3) of **8a**




¹³C NMR spectrum (101 MHz, CDCl₃) of **8a**




¹H NMR spectrum (400 MHz, CDCl₃) of **11a** and **11b**




¹⁹F NMR spectrum (376 MHz, CDCl₃) of **11a** and **11b**




¹³C NMR spectrum (101 MHz, CDCl₃) of **11a** and **11b**




¹H NMR spectrum (400 MHz, CDCl₃) of 3a




¹⁹F NMR spectrum (376 MHz, CDCl₃) of **3a**




¹³C NMR spectrum (101 MHz, CDCl₃) of **3a**




^1H NMR spectrum (400 MHz, CDCl_3) of **3b**




^{19}F NMR spectrum (376 MHz, CDCl_3) of **3b**




^{13}C NMR spectrum (101 MHz, CDCl_3) of **3b**




^1H NMR spectrum (400 MHz, CDCl_3) of **3c**




^{19}F NMR spectrum (376 MHz, CDCl_3) of **3c**




^{13}C NMR spectrum (101 MHz, CDCl_3) of **3c**




^1H NMR spectrum (400 MHz, CDCl_3) of **3d**




¹⁹F NMR spectrum (376 MHz, CDCl₃) of **3d**




^{13}C NMR spectrum (101 MHz, CDCl_3) of **3d**




^1H NMR spectrum (400 MHz, CDCl_3) of **3e**




^{19}F NMR spectrum (376 MHz, CDCl_3) of **3e**




^{13}C NMR spectrum (101 MHz, CDCl_3) of **3e**




^1H NMR spectrum (400 MHz, CDCl_3) of **3f**




^{19}F NMR spectrum (376 MHz, CDCl_3) of **3f**




¹³C NMR spectrum (101 MHz, CDCl₃) of **3f**




¹H NMR spectrum (400 MHz, CDCl₃) of **3g**




89.89
90.00
90.01
90.12




^{19}F NMR spectrum (376 MHz, CDCl_3) of **3g**




166.40
166.26
166.20
157.33
154.47
154.45
151.58
138.59
138.34
133.77
133.75
132.53
129.69
128.88
128.44
128.41
128.38
127.68
126.86
126.83
90.05
89.89
89.86
89.69
77.16 CDCl_3
52.42
49.45
49.43
49.40
34.42
33.09
31.68
25.69
22.56
22.55
14.05




^{13}C NMR spectrum (101 MHz, CDCl_3) of **3g**




¹H NMR spectrum (400 MHz, CDCl₃) of **3h**




¹⁹F NMR spectrum (376 MHz, CDCl₃) of **3h**




¹³C NMR spectrum (101 MHz, CDCl₃) of **3h**




¹H NMR spectrum (400 MHz, CDCl₃) of **3i**




^{19}F NMR spectrum (376 MHz, CDCl_3) of **3i**




^{13}C NMR spectrum (101 MHz, CDCl_3) of **3i**




¹H NMR spectrum (400 MHz, CDCl₃) of **3j**




¹⁹F NMR spectrum (376 MHz, CDCl₃) of **3j**




¹³C NMR spectrum (101 MHz, CDCl₃) of **3j**




¹H NMR spectrum (400 MHz, CDCl₃) of **3k**




¹⁹F NMR spectrum (376 MHz, CDCl₃) of **3k**




¹³C NMR spectrum (101 MHz, CDCl₃) of **3k**




¹H NMR spectrum (400 MHz, CDCl₃) of **31**




¹⁹F NMR spectrum (376 MHz, CDCl₃) of **31**




¹³C NMR spectrum (101 MHz, CDCl₃) of **31**




¹H NMR spectrum (400 MHz, CDCl₃) of **3m**




^{19}F NMR spectrum (376 MHz, CDCl_3) of **3m**




¹³C NMR spectrum (101 MHz, CDCl₃) of **3m**




¹H NMR spectrum (400 MHz, CDCl₃) of **3n**




¹⁹F NMR spectrum (376 MHz, CDCl₃) of **3n**




¹³C NMR spectrum (101 MHz, CDCl₃) of **3n**




^1H NMR spectrum (400 MHz, CDCl_3) of **3o**




^{19}F NMR spectrum (376 MHz, CDCl_3) of **3o**




^{13}C NMR spectrum (101 MHz, CDCl_3) of **3o**



^1H NMR spectrum (400 MHz, CDCl_3) of **3p**




^{19}F NMR spectrum (376 MHz, CDCl_3) of **3p**




^{13}C NMR spectrum (101 MHz, CDCl_3) of **3p**


^{19}F NMR spectrum (376 MHz, CDCl_3) of **3q**




^{13}C NMR spectrum (101 MHz, CDCl_3) of **3q**




^1H NMR spectrum (400 MHz, CDCl_3) of **3r**




^{19}F NMR spectrum (376 MHz, CDCl_3) of **3r**




^{13}C NMR spectrum (101 MHz, CDCl_3) of **3r**




^1H NMR spectrum (400 MHz, CDCl_3) of **3s**




¹⁹F NMR spectrum (376 MHz, CDCl₃) of **3s**




¹³C NMR spectrum (101 MHz, CDCl₃) of **3s**




^1H NMR spectrum (400 MHz, CDCl_3) of **3t**




^{19}F NMR spectrum (376 MHz, CDCl_3) of **3t**




^{13}C NMR spectrum (101 MHz, CDCl_3) of **3t**




¹H NMR spectrum (400 MHz, CDCl₃) of **3u**




¹⁹F NMR spectrum (376 MHz, CDCl₃) of **3u**




¹³C NMR spectrum (101 MHz, CDCl₃) of **3u**




¹H NMR spectrum (400 MHz, CDCl₃) of **3v**




¹⁹F NMR spectrum (376 MHz, CDCl₃) of **3v**




¹³C NMR spectrum (101 MHz, CDCl₃) of **3v**




¹³C NMR spectrum (101 MHz, CDCl₃) of **3w**




¹H NMR spectrum (400 MHz, CDCl₃) of **3x**




^{19}F NMR spectrum (376 MHz, CDCl_3) of **3x**




^{13}C NMR spectrum (101 MHz, CDCl_3) of **3x**




¹H NMR spectrum (400 MHz, CDCl₃) of **3y**




¹⁹F NMR spectrum (376 MHz, CDCl₃) of **3y**




¹³C NMR spectrum (101 MHz, CDCl₃) of **3y**




¹H NMR spectrum (400 MHz, CDCl₃) of **3z**




^{19}F NMR spectrum (376 MHz, CDCl_3) of **3z**




^{13}C NMR spectrum (101 MHz, CDCl_3) of **3z**




¹H NMR spectrum (400 MHz, CDCl₃) of **3aa**



¹⁹F NMR spectrum (376 MHz, CDCl₃) of **3aa**




¹³C NMR spectrum (101 MHz, CDCl₃) of **3aa**




¹H NMR spectrum (400 MHz, CDCl₃) of **3ab**




^{19}F NMR spectrum (376 MHz, CDCl_3) of **3ab**




^{13}C NMR spectrum (101 MHz, CDCl_3) of **3ab**




¹H NMR spectrum (400 MHz, CDCl₃) of **3ac**




¹⁹F NMR spectrum (376 MHz, CDCl₃) of **3ac**




^{13}C NMR spectrum (101 MHz, CDCl_3) of **3ac**




^1H NMR spectrum (400 MHz, CDCl_3) of **3ad**




^{19}F NMR spectrum (376 MHz, CDCl_3) of **3ad**




^{13}C NMR spectrum (101 MHz, CDCl_3) of **3ad**




^1H NMR spectrum (400 MHz, CDCl_3) of **3ae**




^{19}F NMR spectrum (376 MHz, CDCl_3) of **3ae**




¹³C NMR spectrum (101 MHz, CDCl₃) of 3ae




^1H NMR spectrum (400 MHz, CDCl_3) of **3af**




^{19}F NMR spectrum (376 MHz, CDCl_3) of **3af**




¹³C NMR spectrum (101 MHz, CDCl₃) of **3af**




¹H NMR spectrum (400 MHz, CDCl₃) of **3ag**




¹⁹F NMR spectrum (376 MHz, CDCl₃) of **3ag**




¹³C NMR spectrum (101 MHz, CDCl₃) of **3ag**




¹H NMR spectrum (400 MHz, CDCl_3) of **3ah**




¹⁹F NMR spectrum (376 MHz, CDCl_3) of **3ah**




¹³C NMR spectrum (101 MHz, CDCl₃) of **3ah**




¹H NMR spectrum (400 MHz, CDCl₃) of **3ai**




¹⁹F NMR spectrum (376 MHz, CDCl₃) of **3ai**




¹³C NMR spectrum (101 MHz, CDCl₃) of **3ai**




¹H NMR spectrum (400 MHz, CDCl₃) of **3aj**




¹⁹F NMR spectrum (376 MHz, CDCl₃) of **3aj**




¹³C NMR spectrum (101 MHz, CDCl₃) of **3aj**




^1H NMR spectrum (400 MHz, CDCl_3) of **3ak**




^{19}F NMR spectrum (376 MHz, CDCl_3) of **3ak**




¹³C NMR spectrum (101 MHz, CDCl₃) of **3ak**




¹H NMR spectrum (400 MHz, CDCl₃) of **3al**




^{19}F NMR spectrum (376 MHz, CDCl_3) of **3al**




^{13}C NMR spectrum (101 MHz, CDCl_3) of **3al**




¹H NMR spectrum (400 MHz, CDCl₃) of **3am**




¹⁹F NMR spectrum (376 MHz, CDCl₃) of **3am**




¹³C NMR spectrum (101 MHz, CDCl₃) of **3am**




¹H NMR spectrum (400 MHz, CDCl₃) of **6a**




¹⁹F NMR spectrum (376 MHz, CDCl₃) of **6a**




¹³C NMR spectrum (101 MHz, CDCl₃) of **6a**




¹H NMR spectrum (400 MHz, CDCl₃) of **6b**




¹⁹F NMR spectrum (376 MHz, CDCl₃) of **6b**




¹³C NMR spectrum (101 MHz, CDCl₃) of **6b**




¹H NMR spectrum (400 MHz, CDCl₃) of **6c**




¹⁹F NMR spectrum (376 MHz, CDCl₃) of **6c**




¹³C NMR spectrum (101 MHz, CDCl₃) of **6c**




¹H NMR spectrum (400 MHz, CDCl₃) of **6d**




¹⁹F NMR spectrum (376 MHz, CDCl₃) of **6d**




¹³C NMR spectrum (101 MHz, CDCl₃) of **6d**




¹H NMR spectrum (400 MHz, CDCl₃) of **6e**




^{19}F NMR spectrum (376 MHz, CDCl_3) of **6e**




^{13}C NMR spectrum (101 MHz, CDCl_3) of **6e**




¹H NMR spectrum (400 MHz, CDCl₃) of **6f**




¹⁹F NMR spectrum (376 MHz, CDCl₃) of **6f**




¹³C NMR spectrum (101 MHz, CDCl₃) of **6f**





¹H NMR spectrum (400 MHz, CDCl₃) of **6g**




^{19}F NMR spectrum (376 MHz, CDCl_3) of **6g**




^{13}C NMR spectrum (101 MHz, CDCl_3) of **6g**







¹³C NMR spectrum (101 MHz, CDCl₃) of **6h**




¹H NMR spectrum (400 MHz, CDCl₃) of **6i**




^{19}F NMR spectrum (376 MHz, CDCl_3) of **6i**




^{13}C NMR spectrum (101 MHz, CDCl_3) of **6i**




¹H NMR spectrum (400 MHz, CDCl₃) of **6j**




¹⁹F NMR spectrum (376 MHz, CDCl₃) of **6j**




¹³C NMR spectrum (101 MHz, CDCl₃) of **6j**




¹H NMR spectrum (400 MHz, CDCl₃) of **6k**




^{19}F NMR spectrum (376 MHz, CDCl_3) of **6k**




¹⁹F NMR spectrum (376 MHz, CDCl₃) of **61**




¹³C NMR spectrum (101 MHz, CDCl₃) of **61**




¹H NMR spectrum (400 MHz, CDCl₃) of **6m**




¹⁹F NMR spectrum (376 MHz, CDCl₃) of **6m**




¹³C NMR spectrum (101 MHz, CDCl₃) of **6m**




^1H NMR spectrum (400 MHz, CDCl_3) of **6n**




^{19}F NMR spectrum (376 MHz, CDCl_3) of **6n**




^{13}C NMR spectrum (101 MHz, CDCl_3) of **6n**




^1H NMR spectrum (400 MHz, CDCl_3) of **6o**




¹⁹F NMR spectrum (376 MHz, CDCl₃) of **60**




¹³C NMR spectrum (101 MHz, CDCl₃) of **60**




^1H NMR spectrum (400 MHz, CDCl_3) of **6p**




^{19}F NMR spectrum (376 MHz, CDCl_3) of **6p**




¹³C NMR spectrum (101 MHz, CDCl₃) of **6p**




¹H NMR spectrum (400 MHz, CDCl₃) of **6q**




^{19}F NMR spectrum (376 MHz, CDCl_3) of **6q**



^{13}C NMR spectrum (101 MHz, CDCl_3) of **6q**




¹H NMR spectrum (400 MHz, CDCl₃) of **6r**




¹⁹F NMR spectrum (376 MHz, CDCl₃) of **6r**


¹H NMR spectrum (400 MHz, CDCl₃) of **6s**




¹⁹F NMR spectrum (376 MHz, CDCl₃) of **6s**




^{13}C NMR spectrum (101 MHz, CDCl_3) of **6s**




^1H NMR spectrum (400 MHz, CDCl_3) of **6t**




^{19}F NMR spectrum (376 MHz, CDCl_3) of **6t**




¹³C NMR spectrum (101 MHz, CDCl₃) of **6t**





¹H NMR spectrum (400 MHz, CDCl₃) of **6u**




¹⁹F NMR spectrum (376 MHz, CDCl₃) of **6u**




^{13}C NMR spectrum (101 MHz, CDCl_3) of **6u**




^1H NMR spectrum (400 MHz, CDCl_3) of **6v**




¹⁹F NMR spectrum (376 MHz, CDCl₃) of **6v**



¹³C NMR spectrum (101 MHz, CDCl₃) of **6v**




¹³C NMR spectrum (101 MHz, CDCl₃) of **6w**




^1H NMR spectrum (400 MHz, CDCl_3) of **6x**




^{19}F NMR spectrum (376 MHz, CDCl_3) of **6x**




¹³C NMR spectrum (101 MHz, CDCl₃) of **6x**




¹H NMR spectrum (400 MHz, CDCl₃) of **6y**




^{19}F NMR spectrum (376 MHz, CDCl_3) of **6y**




^{13}C NMR spectrum (101 MHz, CDCl_3) of **6y**




^1H NMR spectrum (400 MHz, CDCl_3) of **6z**




^{19}F NMR spectrum (376 MHz, CDCl_3) of **6z**




^{13}C NMR spectrum (101 MHz, CDCl_3) of **6z**




¹H NMR spectrum (400 MHz, CDCl₃) of 6aa




¹⁹F NMR spectrum (376 MHz, CDCl₃) of 6aa




^{13}C NMR spectrum (101 MHz, CDCl_3) of **6aa**




^1H NMR spectrum (400 MHz, CDCl_3) of **6ab**




^{19}F NMR spectrum (376 MHz, CDCl_3) of **6ab**




^{13}C NMR spectrum (101 MHz, CDCl_3) of **6ab**




¹H NMR spectrum (400 MHz, CDCl₃) of **6ac** (diastereomer 1)




¹H NMR spectrum (400 MHz, CDCl₃) of **6ac** (diastereomer 2)




^{19}F NMR spectrum (376 MHz, CDCl_3) of **6ac**




^{13}C NMR spectrum (101 MHz, CDCl_3) of **6ac**




¹³C NMR spectrum (101 MHz, CDCl₃) of **6ad**



¹H NMR spectrum (400 MHz, CDCl₃) of **12**



¹⁹F NMR spectrum (376 MHz, CDCl₃) of **12**



¹³C NMR spectrum (101 MHz, CDCl₃) of **12**